<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">106601</article-id><article-id pub-id-type="doi">10.7554/eLife.106601</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.106601.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>The denitrosylase SCoR2 controls cardioprotective metabolic reprogramming</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Grimmett</surname><given-names>Zachary W</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3820-2049</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Rongli</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Hua-Lin</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="pa1">†</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Qiuying</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5909-3959</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Miller</surname><given-names>Dawson</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Qian</surname><given-names>Zhaoxia</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Justin</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Kalra</surname><given-names>Riti</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" deceased="yes"><name><surname>Gross</surname><given-names>Steven S</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="fn1"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Koch</surname><given-names>Walter J</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Premont</surname><given-names>Richard T</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8053-5026</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Stamler</surname><given-names>Jonathan S</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6866-1572</contrib-id><email>jss156@case.edu</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/051fd9666</institution-id><institution>Medical Scientist Training Program, Case Western Reserve University School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/051fd9666</institution-id><institution>Institute for Transformative Molecular Medicine, Department of Medicine, Case Western Reserve University School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/051fd9666</institution-id><institution>Cardiovascular Research Institute, Case Western Reserve University School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02r109517</institution-id><institution>Department of Pharmacology, Weill Cornell Medicine</institution></institution-wrap><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00py81415</institution-id><institution>Department of Surgery, Duke University School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Durham</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00py81415</institution-id><institution>Department of Medicine, Duke University School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Durham</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01gc0wp38</institution-id><institution>Harrington Discovery Institute, University Hospitals Cleveland Medical Center</institution></institution-wrap><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Emoto</surname><given-names>Noriaki</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00088z429</institution-id><institution>Kobe Pharmaceutical University</institution></institution-wrap><country>Japan</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Barton</surname><given-names>Matthias</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02crff812</institution-id><institution>University of Zurich</institution></institution-wrap><country>Switzerland</country></aff></contrib></contrib-group><author-notes><fn fn-type="present-address" id="pa1"><label>†</label><p>Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, United States</p></fn><fn fn-type="fn" id="fn1"><label>‡</label><p>Deceased</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>17</day><month>11</month><year>2025</year></pub-date><volume>14</volume><elocation-id>RP106601</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2025-03-12"><day>12</day><month>03</month><year>2025</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2025-03-14"><day>14</day><month>03</month><year>2025</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2025.03.12.642752"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-06-05"><day>05</day><month>06</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.106601.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-09-02"><day>02</day><month>09</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.106601.2"/></event></pub-history><permissions><copyright-statement>© 2025, Grimmett et al</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Grimmett et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-106601-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-106601-figures-v1.pdf"/><abstract><p>Acute myocardial infarction (MI) is a leading cause of morbidity and mortality, and therapeutic options remain limited. Endogenously generated nitric oxide (NO) is highly cardioprotective, but protection is not replicated by nitroso-vasodilators (e.g., nitrates, nitroprusside) used in clinical practice, highlighting specificity in NO-based signaling and untapped therapeutic potential. Signaling by NO is mediated largely by <italic>S</italic>-nitrosylation, entailing specific enzymes that form and degrade <italic>S</italic>-nitrosothiols in proteins (SNO-proteins), termed nitrosylases and denitrosylases, respectively. SNO-CoA Reductase 2 (SCoR2; product of the <italic>Akr1a1</italic> gene) is a recently discovered protein denitrosylase. Genetic variants in SCoR2 have been associated with cardiovascular disease, but its function is unknown. Here, we show that mice lacking SCoR2/AKR1A1 exhibit robust protection in an animal model of MI. SCoR2 regulates ketolytic energy availability, antioxidant levels, and polyol homeostasis via <italic>S</italic>-nitrosylation of key metabolic effectors. Human cardiomyopathy shows reduced SCoR2 expression and an <italic>S</italic>-nitrosylation signature of metabolic reprogramming, mirroring SCoR2<sup>−/−</sup> mice. Deletion of SCoR2 thus coordinately reprograms multiple metabolic pathways—ketone body utilization, glycolysis, pentose phosphate shunt, and polyol metabolism—to limit infarct size, establishing SCoR2 as a novel regulator in the injured myocardium and a potential drug target.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd><italic>S</italic>-nitrosylation</kwd><kwd>denitrosylase</kwd><kwd>myocardial infarction</kwd><kwd>metabolic reprogramming</kwd><kwd>ischemia–reperfusion</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/012pb6c26</institution-id><institution>National Heart Lung and Blood Institute</institution></institution-wrap></funding-source><award-id>HL158507</award-id><principal-award-recipient><name><surname>Stamler</surname><given-names>Jonathan S</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/012pb6c26</institution-id><institution>National Heart Lung and Blood Institute</institution></institution-wrap></funding-source><award-id>HL126900</award-id><principal-award-recipient><name><surname>Stamler</surname><given-names>Jonathan S</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/012pb6c26</institution-id><institution>National Heart Lung and Blood Institute</institution></institution-wrap></funding-source><award-id>HL157151</award-id><principal-award-recipient><name><surname>Koch</surname><given-names>Walter J</given-names></name><name><surname>Stamler</surname><given-names>Jonathan S</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00adh9b73</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>DK119506</award-id><principal-award-recipient><name><surname>Stamler</surname><given-names>Jonathan S</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00adh9b73</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>DK128347</award-id><principal-award-recipient><name><surname>Stamler</surname><given-names>Jonathan S</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/013kjyp64</institution-id><institution>American Heart Association</institution></institution-wrap></funding-source><award-id>19PABH134580006</award-id><principal-award-recipient><name><surname>Stamler</surname><given-names>Jonathan S</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/006zn3t30</institution-id><institution>National Institute of Arthritis and Musculoskeletal and Skin Diseases</institution></institution-wrap></funding-source><award-id>AR076029</award-id><principal-award-recipient><name><surname>Chen</surname><given-names>Qiuying</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01s5ya894</institution-id><institution>National Institute of Neurological Disorders and Stroke</institution></institution-wrap></funding-source><award-id>NS131322</award-id><principal-award-recipient><name><surname>Gross</surname><given-names>Steven S</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04q48ey07</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>GM007250-44</award-id><principal-award-recipient><name><surname>Grimmett</surname><given-names>Zachary W</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Mice lacking the denitrosylase enzyme SCoR2 demonstrate robust cardioprotection resulting from coordinate reprogramming of multiple metabolic pathways.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Cardiovascular disease resulting in myocardial infarction (MI) is the leading cause of death in the U.S. (<xref ref-type="bibr" rid="bib87">Tsao et al., 2023</xref>). In the setting of an acute MI, preservation of even an additional 5% of myocardial tissue can reduce mortality and progression to heart failure (<xref ref-type="bibr" rid="bib81">Stone et al., 2016</xref>). However, despite decades of research, no FDA-approved drug can reduce infarct size, and post-MI morbidity/mortality remains high (<xref ref-type="bibr" rid="bib46">Johansson et al., 2017</xref>). Targeting well-described mediators of myocardial ischemia–reperfusion (I/R) injury, such as intracellular Ca<sup>2+</sup> overload, pH imbalance, oxidative stress, or inflammation, has thus far been unsuccessful in mitigating lethal cardiac injury in humans (<xref ref-type="bibr" rid="bib30">Hausenloy and Yellon, 2013</xref>; <xref ref-type="bibr" rid="bib33">Heusch, 2017</xref>; <xref ref-type="bibr" rid="bib55">Lefer and Marbán, 2017</xref>).</p><p>An extensive literature spanning over three decades details the protective effects of nitric oxide (NO) in myocardial ischemia (<xref ref-type="bibr" rid="bib5">Bolli, 2001</xref>; <xref ref-type="bibr" rid="bib70">Schulz et al., 2004</xref>; <xref ref-type="bibr" rid="bib45">Janssens et al., 2004</xref>; <xref ref-type="bibr" rid="bib56">Lima et al., 2009</xref>; <xref ref-type="bibr" rid="bib24">Gonzalez et al., 2008</xref>; <xref ref-type="bibr" rid="bib17">Dezfulian et al., 2009</xref>; <xref ref-type="bibr" rid="bib18">Duranski et al., 2005</xref>; <xref ref-type="bibr" rid="bib82">Sun et al., 2007</xref>), including regulation of mitochondrial energetics, Ca<sup>2+</sup> transport, HIF-1α-mediated hypoxia response, and cell death. It is increasingly appreciated that NO signals largely through protein <italic>S</italic>-nitrosylation (<xref ref-type="bibr" rid="bib72">Seth et al., 2018</xref>), a ubiquitous post-translational modification that regulates protein activity with manifold functional consequences. <italic>S</italic>-nitrosylation has been convincingly demonstrated to exert a broadly protective role in myocardial I/R injury (<xref ref-type="bibr" rid="bib56">Lima et al., 2009</xref>; <xref ref-type="bibr" rid="bib82">Sun et al., 2007</xref>). Accumulating evidence implicates specific enzymes that attach (nitrosylases) and remove (denitrosylases) NO groups at target Cys residues (<xref ref-type="bibr" rid="bib72">Seth et al., 2018</xref>; <xref ref-type="bibr" rid="bib103">Zhou et al., 2023a</xref>; <xref ref-type="bibr" rid="bib80">Stomberski et al., 2022</xref>), by direct analogy to kinases and phosphatases that add and remove phosphate groups (i.e., phosphorylation). Studies of the founding member of the denitrosylase family, <italic>S</italic>-nitrosoglutathione (GSNO) reductase (GSNOR), have demonstrated important roles in I/R and transverse aortic constriction models of cardiac injury in mice, and in cardiac arrest in humans (<xref ref-type="bibr" rid="bib31">Hayashida et al., 2019</xref>). Targets of GSNOR include SNO-HIF-1α (<xref ref-type="bibr" rid="bib56">Lima et al., 2009</xref>), SNO-ANT1 (<xref ref-type="bibr" rid="bib83">Tang et al., 2023</xref>), and SNO-GRK2 (<xref ref-type="bibr" rid="bib96">Whalen et al., 2007</xref>; <xref ref-type="bibr" rid="bib41">Huang et al., 2013</xref>), suggesting GSNOR confers protection through multiple synergistic mechanisms.</p><p>SCoR2 (also known as AKR1A1) is a newly identified protein denitrosylase with distinct cellular distribution, substrates, and purview (<xref ref-type="bibr" rid="bib1">Anand et al., 2014</xref>; <xref ref-type="bibr" rid="bib79">Stomberski et al., 2019</xref>); it is mechanistically and functionally homologous to yeast SCoR1/Adh6 (<xref ref-type="bibr" rid="bib1">Anand et al., 2014</xref>). SCoR2 is highly expressed in kidney proximal tubules, but also found in other tissues including the heart (<xref ref-type="bibr" rid="bib102">Zhou et al., 2019</xref>). Inhibition of SCoR2 by genetic knockout or drug treatment protects mice from acute kidney injury (<xref ref-type="bibr" rid="bib102">Zhou et al., 2019</xref>; <xref ref-type="bibr" rid="bib104">Zhou et al., 2023b</xref>) and lowers cholesterol by inhibiting liver PCSK9 secretion (<xref ref-type="bibr" rid="bib80">Stomberski et al., 2022</xref>). SCoR2 acts on seemingly distinct sets of SNO-protein substrates in the kidney and liver, suggesting that its broader role in biology remains to be understood. Genetic variants in SCoR2/<italic>AKR1A1</italic> are associated with heart failure (<xref ref-type="bibr" rid="bib94">Watanabe, 2019a</xref>; <xref ref-type="bibr" rid="bib95">Watanabe et al., 2019b</xref>; <xref ref-type="bibr" rid="bib2">Aragam et al., 2019</xref>) and cardiovascular function in humans (<xref ref-type="bibr" rid="bib9">Cardiovascular Disease Knowledge Portal, 2022</xref>; <xref ref-type="bibr" rid="bib14">Costanzo et al., 2023</xref>); however, the role and function of SCoR2 in the cardiovascular system remains unexplored. We therefore assessed cardiac protection in mice lacking SCoR2 and employed a multi-omic approach to define SCoR2-dependent protective changes following cardiac ischemia/reperfusion injury.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Cardiovascular physiology of SCoR2</title><p>Measures of cardiac function by echocardiography were unchanged at baseline in naive SCoR2<sup>−/−</sup> mice (identical to previously described global <italic>Akr1a1</italic><sup>−/−</sup> mice; <xref ref-type="bibr" rid="bib102">Zhou et al., 2019</xref>) relative to SCoR2<sup>+/+</sup>, including ejection fraction, fractional shortening, left ventricular internal diameter at end-systole (LVID-s), and ventricular pressures (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A–F</xref>). SCoR2<sup>−/−</sup> mice also did not differ in blood pressure (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1G, H</xref>), heart rate (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1I</xref>), body weight (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1J</xref>), or heart/lung weight (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1K</xref>). Thus, knockout of SCoR2 has no major effect on baseline cardiac function.</p></sec><sec id="s2-2"><title>SCoR2<sup>−/−</sup>-mediated cardioprotection in an animal model of MI</title><p>We employed a model of acute MI, in which the mouse left anterior descending (LAD) artery is ligated for 30 min, followed by 1–24 hr of reperfusion. LAD ligation induced ST-elevation, confirmed by electrocardiography (ECG), characteristic of acute myocardial ischemia. Mice lacking SCoR2 exhibited markedly reduced infarct size after I/R injury, as measured by differential Evans blue/TTC staining of left ventricle (LV) cross-sections distal to the ligation (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Area of necrosis as a percentage of total LV area and as a percentage of area at risk (AAR) was also decreased in SCoR2<sup>−/−</sup> mice relative to SCoR2<sup>+/+</sup> mice, though AAR/LV was not different (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Thus, SCoR2 deletion is protective in I/R injury, implying that its denitrosylated substrates contribute to tissue damage.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Knockout of SCoR2 protects from myocardial injury.</title><p>(<bold>A</bold>) Representative myocardial infarct staining after ischemia–reperfusion (I/R) in SCoR2<sup>+/+</sup> (+/+) and SCoR2<sup>-/-</sup> (-/-) mice, taken from the same anatomical plane. Infarcted necrotic tissue is white, the area at risk is red, and tissue with normal perfusion is dark blue. (<bold>B</bold>) Quantification of the myocardial infarct size after I/R injury (24 hr reperfusion). AON (area of necrosis) is expressed as a percentage of the LV (left ventricle) and AAR (area at risk). (<bold>C</bold>) Quantification of left ventricular function after I/R injury (24 hr reperfusion). Ejection fraction (EF) and fractional shortening (FS) were determined by echocardiography. (<bold>D</bold>) Left ventricular internal diameter at end systole (LVID-s) was measured in SCoR2<sup>+/+</sup> and SCoR2<sup>-/-</sup> mice after I/R injury (24 hr reperfusion). (<bold>A–D</bold>) <italic>N</italic> = 5 +/+, 6 -/- mice. (<bold>E</bold>) Serum troponin-1 concentration in +/+ and -/- mice after I/R injury (4 hr reperfusion); <italic>N</italic> = 3–4 mice/condition. (<bold>F</bold>) Serum lactate dehydrogenase (LDH) concentration in +/+ and -/- mice after I/R injury (4 hr reperfusion) normalized to +/+ sham; N=4–5 mice/condition. (<bold>G</bold>) Quantification of post-MI survival at 4 hr post-reperfusion in -/- (<italic>N</italic> = 27) and +/+ (<italic>N</italic> = 30) mice. 12/30 +/+ mice and 5/27 -/- mice did not survive at 4 hr post-reperfusion. (<bold>H, I</bold>) Quantification of TUNEL<sup>+</sup> (apoptotic) nuclei in post-MI +/+ versus -/- myocardium at 4 hr post-reperfusion (<italic>N</italic> = 3 each), with representative images in (<bold>I</bold>). Red asterisks indicate TUNEL<sup>+</sup> nuclei; scale bar = 50 µm. Significance in (<bold>B–D</bold>) assessed by two-tailed Student’s <italic>t</italic>-test, in (<bold>E</bold>) by one-tailed Mann–Whitney test, in (<bold>F</bold>) by one-tailed Student’s <italic>t</italic>-test, in (<bold>G</bold>) by one-sided chi-squared test, and in (<bold>H</bold>) by two-tailed Student’s <italic>t</italic>-test; *p &lt; 0.05, **p &lt; 0.01, ****p&lt;0.0001, ns = not significant.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106601-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Characterization of SCoR2<sup>-/-</sup> mice at baseline and 24 hr post-MI.</title><p>Quantification of left ventricular contractile function (<bold>A–F</bold>), blood pressure (<bold>G, H</bold>), heart rate (<bold>I</bold>), and weight (<bold>J, K</bold>) in uninjured SCoR2<sup>+/+</sup> (+/+) and SCoR2<sup>-/-</sup> (-/-) mice at baseline. Ejection fraction (EF (<bold>A</bold>)), fractional shortening (FS (<bold>B</bold>)), left ventricular diameter at end systole (LVID-s (<bold>C</bold>)), maximum LV pressure (<bold>D</bold>), left ventricular end diastolic pressure (LV EDP (<bold>E</bold>)), maximum change in LV pressure over time (LV d<italic>P</italic>/d<italic>t</italic> (<bold>F</bold>)), systolic blood pressure (SBP (<bold>G</bold>)), diastolic blood pressure (DBP (<bold>H</bold>)) and heart rate (HR (<bold>I</bold>)) were determined by echocardiography in <italic>N</italic> = 3–7 uninjured +/+ and -/- mice. Body weight and ratio of left ventricle (LV), right ventricle (RV), and lung dry weight to body weight were quantified in <italic>N</italic> = 4–5 +/+ and -/- mice in (<bold>J</bold>) and (<bold>K</bold>), respectively. At 24 hr post-MI, heart rate (HR (<bold>L</bold>)) and left ventricular parameters (stroke volume (SV (<bold>M</bold>)), cardiac output (CO (<bold>N</bold>)), left ventricular posterior wall at end systole/diastole (LVPW-s (<bold>O</bold>), LVPW-d (<bold>P</bold>)) and interventricular septal at end systole/diastole (IVS-s (<bold>Q</bold>), IVS-d (<bold>R</bold>))) were determined by echocardiography in <italic>N</italic> = 5–6 +/+ and -/- mice. Statistical significance in (<bold>A–R</bold>) was determined by two-tailed Mann–Whitney test; ns = not significant.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106601-fig1-figsupp1-v1.tif"/></fig></fig-group><p>Cardiac function was assessed by transthoracic echocardiography 24 hr after I/R injury. Ejection fraction (EF) and fractional shortening (FS) were both better maintained in SCoR2<sup>-/-</sup> mice relative to SCoR2<sup>+/+</sup> (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). LVID-s was reduced in SCoR2<sup>-/-</sup> hearts versus SCoR2<sup>+/+</sup> (<xref ref-type="fig" rid="fig1">Figure 1D</xref>), consistent with preserved LV function. Heart rate, stroke volume, and cardiac output remained unchanged in SCoR2<sup>-/-</sup> mice relative to SCoR2<sup>+/+</sup> (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1L–N</xref>), and markers of cardiac hypertrophy (LV posterior wall (LVPW) and interventricular septum (IVS) thickness) were also unchanged (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1O–R</xref>). Cardiac troponin-1 released into the bloodstream at 4 hr after LAD ligation was reduced by SCoR2 deletion (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). Likewise, lactate dehydrogenase (LDH) levels in plasma were lower in injured SCoR2<sup>-/-</sup> mice compared to SCoR2<sup>+/+</sup> at 4 hr post-reperfusion (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). Notably, SCoR2<sup>-/-</sup> mice demonstrated improved post-MI survival (12/30; 40%) relative to SCoR2<sup>+/+</sup> mice (5/27; 19%) at 4 hr post-reperfusion, supportive of an acute cardioprotective phenotype (<xref ref-type="fig" rid="fig1">Figure 1G</xref>). Fewer TUNEL<sup>+</sup> nuclei were observed in the myocardium of SCoR2<sup>-/-</sup> mice at 4 hr post-MI, indicating reduced apoptotic cell death (<xref ref-type="fig" rid="fig1">Figure 1H, I</xref>).</p></sec><sec id="s2-3"><title>SCoR2 mediates denitrosylation of cardiac SNO-proteins</title><p>The canonical NO-stimulated cGMP/protein kinase G pathway protects against cardiac injury (<xref ref-type="bibr" rid="bib50">Kukreja et al., 2012</xref>), but cGMP levels after I/R were no different in SCoR2<sup>+/+</sup> versus SCoR2<sup>-/-</sup> mice (<xref ref-type="fig" rid="fig2">Figure 2A</xref>), suggesting protection mediated by protein <italic>S</italic>-nitrosylation (<xref ref-type="bibr" rid="bib102">Zhou et al., 2019</xref>; <xref ref-type="bibr" rid="bib80">Stomberski et al., 2022</xref>; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). Indeed, while SCoR2 expression was verified in WT heart (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>), its activity was eliminated in hearts from SCoR2<sup>-/-</sup> mice (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>) and protein <italic>S</italic>-nitrosylation was elevated at baseline (i.e., in the uninjured SCoR2<sup>-/-</sup> mouse heart) (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D, E</xref>). Further, in SCoR2<sup>+/+</sup> heart lysates at baseline, addition of SNO-CoA (SCoR2 substrate and NO donor) (<xref ref-type="bibr" rid="bib103">Zhou et al., 2023a</xref>) alone increased protein <italic>S</italic>-nitrosylation (<xref ref-type="fig" rid="fig2">Figure 2B</xref>), whereas co-administration of NADPH (the electron donor used by SCoR2 during denitrosylation) led to a decrease in cardiac SNO-proteins (<xref ref-type="fig" rid="fig2">Figure 2C, D</xref>). Although other denitrosylase enzymes are present in the heart, SCoR2 is responsible for approximately 65% of NADPH-dependent denitrosylase activity (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>); thus, SCoR2 regulates protein <italic>S</italic>-nitrosylation in the heart. Conversely, while SCoR2/AKR1A1 is required for vitamin C synthesis (<xref ref-type="bibr" rid="bib51">Lai et al., 2017</xref>), mice were supplemented with vitamin C, and other putative carbohydrate substrates for SCoR2’s aldo-keto reductase activity were undetectable (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>SCoR2 regulates protein <italic>S</italic>-nitrosylation in the mouse heart.</title><p>(<bold>A</bold>) cGMP (pmol/mg total protein) in SCoR2<sup>+/+</sup> (+/+) and SCoR2<sup>-/-</sup> (-/-) mouse heart lysate post-I/R (1 hr reperfusion) as assessed by ELISA; <italic>N</italic> = 3 mouse hearts per group. (<bold>B</bold>) SNO-CoA (60 μM) added to +/+ mouse heart lysate (1 mg/ml) for 10 min increases protein <italic>S</italic>-nitrosylation as assessed by SNORAC and Coomassie blue staining, shown as fold increase relative to control after normalization to total protein; <italic>N</italic> = 10 +/+ mouse hearts per group. (<bold>C</bold>) In the presence of 100 μM NADPH (required for SCoR2 activity), cardiac protein <italic>S</italic>-nitrosylation is reduced, shown as fold decrease relative to SNO-CoA normalized to total protein; <italic>N</italic> = 10 +/+ mouse hearts per group. (<bold>D</bold>) Representative Coomassie-stained SDS/PAGE gel displaying SNO-proteins isolated by SNORAC following incubation of mouse heart extract with SNO-CoA alone or in combination with NADPH, as quantified in (<bold>B</bold>) and (<bold>C</bold>). Significance in (<bold>A</bold>) assessed by two-tailed Mann–Whitney test, and in (<bold>B, C</bold>) by ratio paired one-tailed Student’s <italic>t</italic>-test. **p ≤ 0.01, ****p ≤ 0.0001.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig2">Figure 2D</xref>, indicating the relevant bands and treatments.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106601-fig2-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig2">Figure 2D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106601-fig2-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106601-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Characterization of SCoR2 and protein <italic>S</italic>-nitrosylation in SCoR2<sup>-/-</sup> mice.</title><p>(<bold>A</bold>) Protein <italic>S</italic>-nitrosylation is regulated by four distinct classes of enzymes: NOS enzymes synthesize NO from <sc>l</sc>-arginine (<xref ref-type="bibr" rid="bib87">Tsao et al., 2023</xref>), SNO synthase enzymes produce <italic>S</italic>-nitrosothiols (SNOs) from NO (<xref ref-type="bibr" rid="bib81">Stone et al., 2016</xref>), <italic>S</italic>-nitrosylase (aka transnitrosylase) enzymes transfer SNO to target proteins to regulate activity, interactions, localization or stability (<xref ref-type="bibr" rid="bib46">Johansson et al., 2017</xref>), denitrosylase enzymes (such as SCoR2) remove SNO from substrate proteins (<xref ref-type="bibr" rid="bib30">Hausenloy and Yellon, 2013</xref>). This panel was created using <ext-link ext-link-type="uri" xlink:href="https://biorender.com/htrukr3">Biorender.com</ext-link>. (<bold>B</bold>) Representative western blot showing expression of SCoR2 in hearts of +/+ and –/– mice after sham or ischemia–reperfusion (I/R) surgery. <italic>N</italic> = 4 mice per genotype. (<bold>C</bold>) NADPH-dependent SNO-CoA reductase activity measured in heart extracts from healthy untreated +/+ and -/- mice; <italic>N</italic> = 4 mice per genotype. (<bold>D, E</bold>) SNO-proteins identified via SNORAC from heart tissue isolated from healthy untreated +/+ (<italic>N</italic> = 3) and -/- (<italic>N</italic> = 4) mice. SNO-proteins shown in +Asc gel (<bold>D</bold>), total protein identified via Coomassie staining in input gel (<bold>E</bold>). Statistical significance in (<bold>C</bold>) determined by two-tailed Mann–Whitney test; *p ≤ 0.05.</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>JPEG file containing original western blots for <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>, indicating the relevant bands and treatments.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106601-fig2-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2s1sdata2"><label>Figure 2—figure supplement 1—source data 2.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106601-fig2-figsupp1-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2s1sdata3"><label>Figure 2—figure supplement 1—source data 3.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref>, indicating the relevant bands and treatments.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106601-fig2-figsupp1-data3-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2s1sdata4"><label>Figure 2—figure supplement 1—source data 4.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106601-fig2-figsupp1-data4-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2s1sdata5"><label>Figure 2—figure supplement 1—source data 5.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref>, indicating the relevant bands and treatments.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106601-fig2-figsupp1-data5-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2s1sdata6"><label>Figure 2—figure supplement 1—source data 6.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref><xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106601-fig2-figsupp1-data6-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106601-fig2-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-4"><title>Multi-omic analysis identifies SCoR2-regulated cardioprotective pathways</title><p>To identify proteins whose <italic>S</italic>-nitrosylation was regulated by SCoR2 following cardiac injury, heart lysates from SCoR2<sup>+/+</sup> versus SCoR2<sup>-/-</sup> mice at 4 hr post-I/R (vs. sham) were subjected to <italic>S</italic>-nitrosothiol resin assisted capture (SNORAC) and visualized by staining with Coomassie blue (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). To elucidate mechanisms of SCoR2 deficiency-dependent cardioprotection and identify sites of regulation, we subjected post-I/R SCoR2<sup>+/+</sup> and SCoR2<sup>-/-</sup> mouse hearts to three complementary unbiased screens (done in triplicate): (1) SCoR2-dependent nitrosoproteome; (2) SCoR2 interactome; and (3) SCoR2-dependent metabolome (in heart and plasma) (<xref ref-type="fig" rid="fig3">Figure 3B</xref>).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>A combined multi-omics approach identifies SCoR2-regulated SNO-proteins and metabolic pathways responsible for widespread metabolic reprogramming.</title><p>(<bold>A</bold>) <italic>S</italic>-Nitrosylated proteins in heart of SCoR2<sup>+/+</sup> (+/+) and SCoR2<sup>-/-</sup> (-/-) mice post-I/R versus sham. Representative Coomassie-stained SDS/PAGE gel displaying SNO-proteins isolated by SNORAC using hearts of +/+ and -/- mice subjected to either sham operation or I/R (4 hr reperfusion). Ascorbate was omitted from the SNORAC assay (-Asc) as a specificity control. (<bold>B</bold>) Three coordinated screens in +/+ versus -/- mouse heart tissue, that is (1) SNORAC/MS (SCoR2-dependent <italic>S</italic>-nitrosoproteome 4 hr after I/R, elevated &gt;1.2-fold in -/- vs. +/+) (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>; <italic>N</italic> = 3), (2) SCoR2 co-IP interactome (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>; <italic>N</italic> = 4), and (3) untargeted metabolomic screening in heart and plasma (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>; <italic>N</italic> = 5 per condition), converge on the proteins BDH1 and PKM2 as SCoR2 substrate SNO-proteins in the heart which alter relevant cardioprotective metabolic pathways. (<bold>C</bold>) Full list of 31 overlapping proteins identified in both screens (1) and (2), that is, the cardiac SCoR2-dependent <italic>S</italic>-nitrosoproteome and the cardiac SCoR2 interactome. Panels B and C were created using <ext-link ext-link-type="uri" xlink:href="https://biorender.com/8bscxsc">Biorender.com</ext-link>.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig3">Figure 3A</xref>, indicating the relevant bands.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106601-fig3-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata2"><label>Figure 3—source data 2.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig3">Figure 3A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106601-fig3-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106601-fig3-v1.tif"/></fig><p>LC–MS/MS of SNORAC samples from 4 hr post-I/R SCoR2<sup>+/+</sup> and SCoR2<sup>-/-</sup> mouse heart identified nearly 2000 unique SNO-proteins. Of these, 158 proteins showed increased <italic>S</italic>-nitrosylation (&gt;1.2-fold) in post-I/R SCoR2<sup>-/-</sup> hearts relative to post-I/R SCoR2<sup>+/+</sup>, comprising the SCoR2-dependent nitrosoproteome (<xref ref-type="fig" rid="fig3">Figure 3B</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Notably, metabolic proteins were heavily represented in the cardiac SCoR2-dependent nitrosoproteome (35/158 proteins; <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>), similar to wild-type hearts (<xref ref-type="bibr" rid="bib53">Lau et al., 2021</xref>).</p><p>Co-immunoprecipitation using anti-SCoR2 antibody in untreated SCoR2<sup>+/+</sup> heart lysate coupled with LC–MS/MS identified 515 SCoR2-associated proteins (SCoR2-dependent interactome) (<xref ref-type="fig" rid="fig3">Figure 3B</xref>; <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>), of which 31 overlapped the SCoR2-dependent nitrosoproteome (<xref ref-type="fig" rid="fig3">Figure 3B, C</xref>). Since these 31 SNO-proteins both associated with SCoR2 and displayed SCoR2-dependent <italic>S</italic>-nitrosylation, they represent candidate SCoR2 denitrosylation substrates.</p><p>Untargeted metabolite profiling (using an LC/MS metabolomic platform) was performed in parallel using heart lysate and blood plasma from 4 hr post-I/R SCoR2<sup>+/+</sup> and SCoR2<sup>-/-</sup> mice to identify metabolites regulated by SCoR2-dependent SNO-proteins (SCoR2-dependent metabolome) (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). These metabolite studies identified three metabolic pathways that were significantly perturbed by SCoR2 deletion: ketone body oxidation, pentose phosphate pathway (PPP), and polyol metabolism.</p><p>Finally, multi-omic analysis by integration of all this data identified two specific SCoR2-substrate SNO-proteins, β-hydroxybutyrate dehydrogenase (BDH1) and pyruvate kinase M2 (PKM2) (<xref ref-type="fig" rid="fig3">Figure 3B, C</xref>). This unbiased analysis suggests that these two enzymes are likely to be key contributors to metabolic reprogramming after cardiac I/R, identifying specific targets for SCoR2 in its regulation of cardiac metabolism.</p></sec><sec id="s2-5"><title>SCoR2 regulates ketolytic energy availability through BDH1 stability</title><p>BDH1 catalyzes the first step of ketone body breakdown in the heart, the oxidation of β-hydroxybutyrate (BHB) to acetoacetate, allowing cardiac muscle cells to use ketone bodies as an alternative source of energy in the absence of glucose and/or fatty acids (<xref ref-type="bibr" rid="bib3">Aubert et al., 2016</xref>; <xref ref-type="bibr" rid="bib62">Nielsen et al., 2019</xref>). Cardiac-specific BDH1 overexpression is known to be protective in mice subjected to cardiac injury, attributed to increased cardiac ketone body oxidation and associated increase in antioxidant defenses (<xref ref-type="bibr" rid="bib88">Uchihashi et al., 2017</xref>).</p><p>S-Nitrosylation of BDH1 has been reported in proteomic screens (<xref ref-type="bibr" rid="bib53">Lau et al., 2021</xref>) but remains entirely uncharacterized. In the post-I/R heart, we confirmed that SNO-BDH1 was increased in SCoR2<sup>-/-</sup> mice relative to SCoR2<sup>+/+</sup> (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, quantified from Western blots in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). Notably, total BDH1 protein expression was also increased in SCoR2<sup>-/-</sup> mice 4 hr after injury (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, quantified from Western blots in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>), suggesting that SCoR2-controlled <italic>S</italic>-nitrosylation may regulate BDH1 stability. Indeed, the ratio of SNO-BDH1 to total BDH1 was not different in SCoR2<sup>-/-</sup> heart relative to SCoR2<sup>+/+</sup> (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). Such regulation of SNO-BDH1 by SCoR2 appears specific to the heart, as levels of SNO-BDH1 and BDH1 were unchanged in post-I/R SCoR2<sup>+/+</sup> versus SCoR2<sup>-/-</sup> liver (<xref ref-type="fig" rid="fig4">Figure 4D–F</xref>, quantified from western blots in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>). To assess effects of <italic>S</italic>-nitrosylation on BDH1 stability, we first identified the predominant site of SNO modification as Cys<sup>115</sup> (out of seven total Cys residues), since in vitro SNO-CoA treatment failed to increase SNO-BDH1 in the Cys115Ser (C115S) mutant relative to WT BDH1 (<xref ref-type="fig" rid="fig4">Figure 4G</xref>). We next assessed BDH1 stability using a pulse-chase assay with the translation inhibitor cycloheximide (CHX chase) to measure the rate of BDH1 protein degradation in HEK293 cells. WT BDH1 protein expression decreased steadily over 12–24 hr (<xref ref-type="fig" rid="fig4">Figure 4H</xref>; black bars), while addition of a cell permeant NO donor (ethyl ester CysNO, ECNO) markedly increased BDH1 stability (pink bars). This stabilizing effect of NO was lost upon mutation of Cys<sup>115</sup> in BDH1 (<xref ref-type="fig" rid="fig4">Figure 4H</xref>; blue and purple bars, quantified as area under the curve in <xref ref-type="fig" rid="fig4">Figure 4I</xref>, with a representative western blot in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>), validating SNO-mediated stabilization of BDH1 and localizing the primary effect of NO to this single Cys residue.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>SCoR2 regulates <italic>S</italic>-nitrosylation of BDH1 at Cys<sup>115</sup>, impacting ketolytic energy availability.</title><p>Quantification of SNO-BDH1 (<bold>A</bold>) and total BDH1 (<bold>B</bold>), relative to p97 ATPase loading control and to each other (<bold>C</bold>), in mouse heart (4 hr reperfusion); <italic>N</italic> = 8 SCoR2<sup>+/+</sup> (+/+), <italic>N</italic> = 6 SCoR2<sup>-/-</sup> (-/-). Representative western blots shown in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>. Quantification of SNO-BDH1 (<bold>D</bold>) and total BDH1 (<bold>E</bold>), relative to p97 ATPase loading control and to each other (<bold>F</bold>), in mouse liver (1 hr reperfusion); <italic>N</italic> = 4 each. (<bold>G</bold>) HEK293 cells transfected with empty vector (EV), WT, or C115S BDH1 were treated with 250 μM SNO-CoA or vehicle for 10 min, followed by SNORAC and blotted for SNO-BDH1 and BDH1, together with loading controls SNO-p97 ATPase and input p97 ATPase. Representative of four independent experiments. (<bold>H, I</bold>) CHX pulse-chase assay, in which HEK293 cells transfected with V5-tagged BDH1 were treated with 100 μM ECNO or vehicle, in addition to 100 μg/ml CHX for 6–24 hr. BDH1 protein expression was quantified relative to t=0 (pre-CHX) in (<bold>H</bold>), and area under the curve (AUC) quantified in (<bold>I</bold>); <italic>N</italic> = 3 samples/group. (<bold>J–M</bold>) Metabolites corresponding to ketolytic energy availability in mouse heart and plasma subjected to sham or I/R injury (1 or 4 hr reperfusion), quantified as ion abundance by LC/MS-based untargeted metabolite profiling: (<bold>J</bold>) plasma acetoacetic acid, (<bold>K</bold>) heart acetoacetic acid, (<bold>L</bold>) heart acetyl-CoA, (<bold>M</bold>) heart phosphocreatine. <italic>N</italic> = 5 mice per condition per genotype. (<bold>N</bold>) Model depicting effect of SCoR2 deletion on cardiac ketone body metabolism in SCoR2<sup>-/-</sup> mice. (<bold>O–R</bold>) Human heart samples (IRB# Pro00005621, <italic>N</italic> = 13 with diagnosis of non-ischemic cardiomyopathy (NICM) and <italic>N</italic> = 13 without known cardiac pathophysiology (healthy)) subjected to SNORAC measuring SNO-BDH1 expression relative to loading control (SNO-p97 ATPase), representative SNORAC shown in (<bold>O</bold>), quantification in (<bold>P</bold>). (<bold>Q, R</bold>) SCoR2 protein expression in human heart samples (<italic>N</italic> = 7 healthy, <italic>N</italic> = 10 NICM from same cohort), as determined by western blot relative to p97 ATPase (representative image in (<bold>Q</bold>), quantified in (<bold>R</bold>)). (<bold>S–U</bold>) Human heart samples (IRB# Pro00005621, <italic>N</italic> = 8–9 with diagnosis of ischemic cardiomyopathy (ICM; pink) and <italic>N</italic> = 10 without known cardiac pathophysiology (healthy; black)) subjected to SNORAC measuring SNO-BDH1 (<bold>S</bold>) or western blot measuring SCoR2 relative to loading control (SNO-p97 ATPase or p97, respectively). Representative SNORAC/western blot gels shown in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1G, H</xref>. Correlation of SNO-BDH1 (normalized to SNO-p97) versus BDH1 (normalized to p97) expression in healthy (<italic>N</italic> = 10) and ICM (<italic>N</italic> = 8) heart was assessed by simple linear regression in (<bold>U</bold>). Statistical significance in (<bold>A–C</bold>) determined by two-tailed Student’s <italic>t</italic>-test; (<bold>D–F</bold>) determined by two-tailed Mann–Whitney test; (<bold>H</bold>) determined by two-way ANOVA with Tukey’s multiple comparisons test; (<bold>I</bold>) determined by one-way ANOVA with Tukey’s multiple comparisons test; (<bold>J–L</bold>) determined by multiple independent Student’s <italic>t</italic>-tests performed between genotypes in each condition; (<bold>M, P</bold>) determined by two-tailed Mann–Whitney test; (<bold>R–T</bold>) determined by Student’s <italic>t</italic>-test; (<bold>U</bold>) determined by simple linear regression performed to identify SNO-BDH1 versus BDH1 relationship. <italic>R</italic><sup>2</sup> and p-value show the goodness of fit of the regression model and significance of slope difference from zero, respectively. *p ≤ 0.05, **p ≤ 0.01, ns = not significant.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig4">Figure 4G</xref>, indicating the relevant bands.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106601-fig4-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig4">Figure 4G</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106601-fig4-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata3"><label>Figure 4—source data 3.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig4">Figure 4O</xref>, indicating the relevant bands.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106601-fig4-data3-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata4"><label>Figure 4—source data 4.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig4">Figure 4O</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106601-fig4-data4-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata5"><label>Figure 4—source data 5.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig4">Figure 4Q</xref>, indicating the relevant bands.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106601-fig4-data5-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata6"><label>Figure 4—source data 6.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig4">Figure 4Q</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106601-fig4-data6-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106601-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Characterization of BDH1 <italic>S</italic>-nitrosylation at conserved SNO site Cys<sup>115</sup>.</title><p>(<bold>A</bold>) Representative gel from SNORAC measuring SNO-BDH1 and western blot measuring total BDH1, relative to p97 ATPase loading control, in mouse heart (4 hr reperfusion), quantified in <xref ref-type="fig" rid="fig4">Figure 4A–C</xref>. (<bold>B</bold>) SNO-BDH1 assessed by SNORAC in SCoR2<sup>+/+</sup> (+/+) and SCoR2<sup>-/-</sup> (-/-) liver tissue (<italic>N</italic> = 4 each) from mice (1 hr reperfusion), quantified in <xref ref-type="fig" rid="fig4">Figure 4D–F</xref>. (<bold>C</bold>) Representative Western blot, quantified in <xref ref-type="fig" rid="fig4">Figure 4H, I</xref>, denoting a CHX pulse-chase assay, in which HEK293 cells transfected with V5-tagged BDH1 were treated with 100 μg/ml CHX to block new protein synthesis, together with 100 μM ECNO or vehicle, with samples collected at 6–24 hr. Duplicates are shown by treatment condition. (<bold>D, E</bold>) Beta-hydroxybutyrate (β-HB) quantified as ion abundance in +/+ and -/- mouse heart and plasma by LC/MS-based untargeted metabolite profiling, <italic>N</italic> = 5 mice per condition per genotype. (<bold>F</bold>) Sequences of BDH1, or protein product of closest homology, from selected species aligned with constraint-based multiple alignment tool (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/tools/cobalt/cobalt.cgi">COBALT</ext-link>); red color shows differences from the <italic>H. sapiens</italic> BDH1 sequence. Cys<sup>115</sup> is indicated by a black arrow. <italic>T. nigroviridis</italic> protein product ID is CAG04267. Representative gel from SNORAC assessing SNO-BDH1 and SNO-PKM2 expression relative to SNO-p97 ATPase loading control (<bold>G</bold>) and from Western blot assessing BDH1, PKM2, and SCoR2 expression relative to p97 ATPase loading control (<bold>H</bold>) in human hearts without (<italic>N</italic> = 10) and with (<italic>N</italic> = 8–9) diagnosis of ischemic cardiomyopathy (ICM) (IRB # Pro00005621). Statistical significance in (<bold>D, E</bold>) determined by independent Student’s <italic>t</italic>-tests performed between genotypes at each time point.</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref> (panel A), indicating the relevant bands.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106601-fig4-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s1sdata2"><label>Figure 4—figure supplement 1—source data 2.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref> (panel A).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106601-fig4-figsupp1-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s1sdata3"><label>Figure 4—figure supplement 1—source data 3.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref> (panel B), indicating the relevant bands.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106601-fig4-figsupp1-data3-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s1sdata4"><label>Figure 4—figure supplement 1—source data 4.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref> (panel B).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106601-fig4-figsupp1-data4-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s1sdata5"><label>Figure 4—figure supplement 1—source data 5.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref> (panel C), indicating the relevant bands.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106601-fig4-figsupp1-data5-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s1sdata6"><label>Figure 4—figure supplement 1—source data 6.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref> (panel C).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106601-fig4-figsupp1-data6-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s1sdata7"><label>Figure 4—figure supplement 1—source data 7.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref> (panel G), indicating the relevant bands.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106601-fig4-figsupp1-data7-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s1sdata8"><label>Figure 4—figure supplement 1—source data 8.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref> (panel G).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106601-fig4-figsupp1-data8-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s1sdata9"><label>Figure 4—figure supplement 1—source data 9.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref> (panel H), indicating the relevant bands.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106601-fig4-figsupp1-data9-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s1sdata10"><label>Figure 4—figure supplement 1—source data 10.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref> (panel H).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106601-fig4-figsupp1-data10-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106601-fig4-figsupp1-v1.tif"/></fig></fig-group><p>We next sought the effects of SNO-BDH1 that might contribute to cardioprotection. We observed that acetoacetic acid, the ketone body produced by BDH1 in the heart, remained elevated in the plasma of SCoR2<sup>-/-</sup> mice after injury (<xref ref-type="fig" rid="fig4">Figure 4J</xref>), while acetoacetate level in the heart and BHB level in heart and plasma remained relatively unchanged between SCoR2<sup>+/+</sup> and SCoR2<sup>-/-</sup> (<xref ref-type="fig" rid="fig4">Figure 4K</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1D, E</xref>). Metabolism of ketone bodies produces acetyl-CoA as an energetic intermediate, and we observed an increase in acetyl-CoA in hearts from SCoR2<sup>-/-</sup> mice (<xref ref-type="fig" rid="fig4">Figure 4L</xref>). Energy in the form of acetyl-CoA is used for ATP production, and excess ATP energy can be stored in muscle tissue as phosphocreatine (p-Cr). At the sarcoplasmic reticulum, p-Cr can be used rapidly to synthesize ATP in energy-starved states such as ischemia, supplying ATP for continued myocardial contraction, which is cardioprotective (<xref ref-type="bibr" rid="bib52">Landoni et al., 2016</xref>). In the injured SCoR2<sup>-/-</sup> heart, we observed dramatically increased stored energy availability in the form of p-Cr, relative to SCoR2<sup>+/+</sup> at 4 hr post-I/R (<xref ref-type="fig" rid="fig4">Figure 4M</xref>). Together, these data support a role for increased energy availability in cardioprotection of SCoR2<sup>-/-</sup> mice after I/R injury (summarized in the model shown in <xref ref-type="fig" rid="fig4">Figure 4N</xref>).</p></sec><sec id="s2-6"><title>Regulated <italic>S</italic>-nitrosylation by SCoR2 in human hearts</title><p>BDH1 Cys<sup>115</sup> is conserved in mammals (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1F</xref>), suggesting critical function. We therefore sought confirmation of a role for SNO-BDH1 in humans. <italic>S</italic>-nitrosylation of BDH1 was detected in human heart tissue, and SNO-BDH1 was elevated in hearts from patients with non-ischemic cardiomyopathy (NICM) (<xref ref-type="fig" rid="fig4">Figure 4O</xref>, representative image; quantified in <xref ref-type="fig" rid="fig4">Figure 4P</xref>). We reasoned that <italic>S</italic>-nitrosylation of BDH1 may be regulated by SCoR2 in humans. Expression of SCoR2 was, in fact, decreased in heart tissue from patients with NICM relative to healthy human heart tissue (<xref ref-type="fig" rid="fig4">Figure 4Q, R</xref>), suggesting an inverse relationship between SCoR2 activity and SNO-BDH1 levels, as seen in mice.</p><p>Interestingly, in patients with ischemic cardiomyopathy (ICM), SNO-BDH1 was decreased and SCoR2 levels were preserved, indicating context-specific regulation (and possibly maladaptive change; <xref ref-type="fig" rid="fig4">Figure 4S, T</xref>, representative SNORAC/western blot in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). Most importantly, we observed a significant correlation between SNO-BDH1 and total BDH1 (<xref ref-type="fig" rid="fig4">Figure 4U</xref>), suggesting <italic>S</italic>-nitrosylation may enhance BDH1 stability in human heart tissue, supporting our findings in cell culture (<xref ref-type="fig" rid="fig4">Figure 4H, I</xref>). Altogether, our data demonstrate that <italic>S</italic>-nitrosylation of metabolic proteins may correlate with human disease, suggests that SNO-BDH1 may be a protective locus that is regulated by SCoR2, and identifies a possible signature of SCoR2 deficiency in human NICM.</p></sec><sec id="s2-7"><title>SCoR2 regulates glycolytic and PPP intermediates through <italic>S</italic>-nitrosylation of PKM2</title><p>PKM2 is the injury-upregulated splice variant of muscle-type pyruvate kinase, which includes a regulatory SNO-site controlling PKM2 conversion of phosphoenolpyruvate to pyruvate in glycolysis. <italic>S</italic>-nitrosylation of PKM2 at Cys<sup>423/424</sup> inhibits glycolytic flux, thereby shunting glycolytic intermediates into the PPP (<xref ref-type="bibr" rid="bib102">Zhou et al., 2019</xref>; <xref ref-type="bibr" rid="bib77">Siragusa et al., 2019</xref>) to produce antioxidant NADPH along with nucleotide precursors. The PPP can also generate newly identified polyol precursors subject to additional SCoR2 regulation, as detailed below. PKM2 is upregulated by ischemic injury, and SNO-PKM2 is known to be protective in the context of ischemia in the kidney (<xref ref-type="bibr" rid="bib102">Zhou et al., 2019</xref>) and of oxidative stress in the endothelium (<xref ref-type="bibr" rid="bib77">Siragusa et al., 2019</xref>). Notably, hearts of patients with ICM showed a significant increase in SNO-PKM2 (<xref ref-type="fig" rid="fig5">Figure 5A</xref>; representative SNORAC and western blot in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1G, H</xref>), consistent with a cardioprotective effect.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>SCoR2 regulates carbohydrate metabolism, including polyols, to provide antioxidative protection from injury via the pentose phosphate shunt pathway (PPP).</title><p>(<bold>A</bold>) Human heart samples (IRB# Pro00005621, <italic>N</italic> = 9 with diagnosis of ischemic cardiomyopathy (ICM) and <italic>N</italic> = 10 without known cardiac pathophysiology (healthy)) subjected to SNORAC measuring SNO-PKM2 relative to loading control (SNO-p97 ATPase). Representative SNORAC/Western blot gels shown in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1G, H</xref>. (<bold>B–J</bold>) Metabolites quantified by ion abundance in SCoR2<sup>+/+</sup> (+/+) and SCoR2<sup>-/-</sup> (-/-) mouse heart and plasma by LC/MS-based untargeted metabolite profiling; <italic>N</italic> = 5 each condition. (<bold>B</bold>) Heart lactate. (<bold>C–K</bold>) Metabolites organized by relationship to the PPP, as inputs (<bold>C, D</bold>), products (<bold>E–H</bold>), or polyol compounds that are categorized as downstream end products of the PPP (<bold>I, J</bold>). NADPH measured in heart lysate after 2 hr reperfusion, erythrose 4-phosphate measured after 4 hr reperfusion. (<bold>K</bold>) Recombinant SCoR2 activity quantified via NADPH consumption by spectrophotometer in the presence of canonical substrate (100 μM SNO-CoA) or carbohydrates (1 mM); [SCoR2]=186 nM, [NADPH]=100 μM. Results presented as specific activity of SCoR2 (μM substrate consumed/min/mg protein). Assay performed in triplicate. (<bold>L</bold>) Summary model showing SCoR2-mediated regulation of carbohydrate metabolism, including PPP and polyol compounds, to generate NADPH and phosphocreatine in the mouse heart. Green arrows indicate pathway upregulation in the absence of SCoR2, and red arrows indicate downregulation. Blue boxes indicate metabolic pathways, tan boxes indicate metabolites, and pink boxes indicate metabolites of particular significance. Thick black arrows indicate directions of SCoR2-regulated metabolic changes. This panel was created using <ext-link ext-link-type="uri" xlink:href="https://biorender.com/mb3bycd">Biorender.com</ext-link>. Statistical significance in (<bold>A</bold>) determined by Student’s <italic>t</italic>-test; (<bold>B–H, J</bold>) determined by multiple independent Student’s <italic>t</italic>-tests performed between genotypes in each condition; (<bold>I</bold>) determined by two-tailed Mann–Whitney test; (<bold>K</bold>) determined by two-tailed Mann–Whitney test between SNO-CoA condition and each carbohydrate condition (<italic>N</italic> = 3–8 independent replicates per condition). *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106601-fig5-v1.tif"/></fig><p>In 4 hr post-I/R heart, the level of lactate, a product of inefficient glycolysis during ischemia that is associated with worse clinical outcomes in patients with MI (<xref ref-type="bibr" rid="bib54">Lazzeri et al., 2015</xref>), was markedly reduced (<xref ref-type="fig" rid="fig5">Figure 5B</xref>), suggesting reduced activity of the glycolysis pathway. More directly, we observed increased glycolytic and non-glycolytic input into the PPP in SCoR2<sup>-/-</sup> heart (<xref ref-type="table" rid="table1">Table 1</xref>), including plasma pyruvate (<xref ref-type="fig" rid="fig5">Figure 5C</xref>) and arabinose (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). Pyruvate is produced through multiple metabolic pathways, including non-glycolytic pathways, and can enter the PPP through conversion to xylose. Together, these findings indicate that metabolites available to the PPP are increased in the absence of SCoR2, consistent with inhibition of PKM2 by <italic>S</italic>-nitrosylation (<xref ref-type="fig" rid="fig3">Figure 3B</xref>) (as observed in multiple tissues [<xref ref-type="bibr" rid="bib102">Zhou et al., 2019</xref>; <xref ref-type="bibr" rid="bib77">Siragusa et al., 2019</xref>] and known to be protective in the setting of ischemia [<xref ref-type="bibr" rid="bib102">Zhou et al., 2019</xref>]). We also observed that products of the PPP were increased in SCoR2<sup>-/-</sup> heart, including NADPH (<xref ref-type="fig" rid="fig5">Figure 5E</xref>) and erythrose 4-phosphate (<xref ref-type="fig" rid="fig5">Figure 5F</xref>), as well as increased ribose (<xref ref-type="fig" rid="fig5">Figure 5G</xref>) and deoxyribose (<xref ref-type="fig" rid="fig5">Figure 5H</xref>) in SCoR2<sup>-/-</sup> plasma. Altogether, this metabolic signature is consistent with the previously described inhibition of PKM2 by <italic>S</italic>-nitrosylation in the absence of SCoR2 (<xref ref-type="bibr" rid="bib102">Zhou et al., 2019</xref>).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Input metabolites to the pentose phosphate pathway (PPP) via xylulose.</title><p>Relative quantity, quantified in mean ion abundance ± standard deviation by LC/MS-based untargeted metabolomic platform, as described in the Methods.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Metabolite</th><th align="left" valign="bottom">Organ</th><th align="left" valign="bottom" colspan="3">SCoR2<sup>+/+</sup></th><th align="left" valign="bottom" colspan="3">SCoR2<sup>-/-</sup></th></tr></thead><tbody><tr><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"><bold>sham</bold></td><td align="left" valign="top"><bold>MI (1 hr</bold>)</td><td align="left" valign="top"><bold>MI (4 hr</bold>)</td><td align="left" valign="top"><bold>sham</bold></td><td align="left" valign="top"><bold>MI (1 hr</bold>)</td><td align="left" valign="top"><bold>MI (4 hr</bold>)</td></tr><tr><td align="left" valign="top">Galactaric acid</td><td align="left" valign="top">Heart</td><td align="left" valign="top">4.88E+04 +/- 2.14E+04</td><td align="left" valign="top">7.08E+04 +/- 3.62E+04</td><td align="left" valign="top">2.16E+04 +/- 1.64E+04</td><td align="left" valign="top">1.09E+05 +/- 2.37E+04</td><td align="left" valign="top">1.17E+05 +/- 2.44E+04</td><td align="left" valign="top">2.84E+05 +/- 2.13E+05</td></tr><tr><td align="left" valign="top">Galactaric acid</td><td align="left" valign="top">Plasma</td><td align="left" valign="top">4.90E+05 +/- 1.83E+05</td><td align="left" valign="top">3.83E+05 +/- 8.86E+04</td><td align="left" valign="top">8.05E+05 +/- 2.16E+05</td><td align="left" valign="top">6.14E+06 +/- 1.84E+06</td><td align="left" valign="top">5.82E+06 +/- 2.11E+06</td><td align="left" valign="top">1.42E+07 +/- 6.43E+06</td></tr><tr><td align="left" valign="top">Galacturonic acid</td><td align="left" valign="top">Heart</td><td align="left" valign="top">4.70E+04 +/- 4.03E+04</td><td align="left" valign="top">5.53E+04 +/- 2.38E+04</td><td align="left" valign="top">1.24E+05 +/- 2.36E+04</td><td align="left" valign="top">3.71E+05 +/- 1.63E+05</td><td align="left" valign="top">3.47E+05 +/- 8.03E+04</td><td align="left" valign="top">9.85E+05 +/- 5.72E+05</td></tr><tr><td align="left" valign="top">Galacturonic acid</td><td align="left" valign="top">Plasma</td><td align="left" valign="top">6.06E+07 +/- 2.18E+07</td><td align="left" valign="top">5.32E+07 +/- 8.19E+06</td><td align="left" valign="top">1.54E+08 +/- 3.76E+07</td><td align="left" valign="top">5.05E+08 +/- 9.52E+07</td><td align="left" valign="top">4.42E+08 +/- 7.53E+07</td><td align="left" valign="top">8.55E+08 +/- 2.53E+08</td></tr><tr><td align="left" valign="top">Glucaric acid</td><td align="left" valign="top">Heart</td><td align="left" valign="top">3.08E+05 +/- 1.36E+05</td><td align="left" valign="top">3.31E+05 +/- 9.75E+04</td><td align="left" valign="top">4.46E+05 +/- 1.74E+05</td><td align="left" valign="top">9.58E+06 +/- 4.84E+06</td><td align="left" valign="top">9.93E+06 +/- 2.53E+06</td><td align="left" valign="top">3.35E+07 +/- 2.68E+07</td></tr><tr><td align="left" valign="top">Glucaric acid</td><td align="left" valign="top">Plasma</td><td align="left" valign="top">2.13E+06 +/- 6.93E+05</td><td align="left" valign="top">2.26E+06 +/- 7.27E+05</td><td align="left" valign="top">5.92E+06 +/- 1.28E+06</td><td align="left" valign="top">1.81E+08 +/- 3.10E+07</td><td align="left" valign="top">1.66E+08 +/- 4.77E+07</td><td align="left" valign="top">2.68E+08 +/- 9.96E+07</td></tr><tr><td align="left" valign="top">Xylose</td><td align="left" valign="top">Plasma</td><td align="left" valign="top">1.36E+06 +/- 1.95E+05</td><td align="left" valign="top">1.35E+06 +/- 2.51E+05</td><td align="left" valign="top">1.68E+06 +/- 1.61E+05</td><td align="left" valign="top">3.37E+06 +/- 7.05E+05</td><td align="left" valign="top">2.91E+06 +/- 5.66E+05</td><td align="left" valign="top">4.70E+06 +/- 1.35E+06</td></tr><tr><td align="left" valign="top">Lyxose</td><td align="left" valign="top">Plasma</td><td align="left" valign="top">1.08E+06 +/- 1.69E+05</td><td align="left" valign="top">1.10E+06 +/- 1.88E+05</td><td align="left" valign="top">1.39E+06 +/- 1.71E+05</td><td align="left" valign="top">2.84E+06 +/- 6.11E+05</td><td align="left" valign="top">2.41E+06 +/- 4.26E+05</td><td align="left" valign="top">4.02E+06 +/- 1.20E+06</td></tr></tbody></table></table-wrap></sec><sec id="s2-8"><title>SCoR2 regulates endogenous production of harmful polyol compounds</title><p>Regulation of polyol metabolism by SCoR2 may contribute to protection from myocardial ischemia. Elevated levels of polyols, organic metabolites with &gt;1 hydroxyl group, have recently been associated with short-term (&lt;3 year) risk for major adverse cardiovascular events (<xref ref-type="bibr" rid="bib97">Witkowski et al., 2023</xref>; <xref ref-type="bibr" rid="bib98">Witkowski et al., 2024</xref>). We observed that two polyols, arabitol/ribitol and sorbitol, were markedly decreased in plasma from SCoR2<sup>-/-</sup> mice relative to SCoR2<sup>+/+</sup> (<xref ref-type="fig" rid="fig5">Figure 5I, J</xref>). Additionally, plasma levels of each polyol rose at 4 hr post-I/R relative to sham or 1 hr post-I/R in SCoR2<sup>+/+</sup> mice, but not in SCoR2<sup>-/-</sup> mice.</p><p>Endogenous polyol production remains relatively uncharacterized in humans. Some polyols may derive from PPP metabolites (xylulose, ribulose, ribose, erythrose, etc.) (<xref ref-type="bibr" rid="bib90">Wamelink and Williams, 2022</xref>; <xref ref-type="bibr" rid="bib42">Huck et al., 2004</xref>) via actions of reductase enzymes (<xref ref-type="bibr" rid="bib27">Hamada et al., 1991</xref>), but rigorous evidence is lacking. To test whether SCoR2 might directly generate polyols that we find to be elevated in the absence of SCoR2 (arabitol/ribitol, sorbitol; <xref ref-type="fig" rid="fig5">Figure 5I, J</xref>), we measured reduction of the corresponding carbohydrates (i.e., arabinose, ribose, glucose, and fructose) in the presence of recombinant SCoR2 (vs. the canonical SCoR2 substrate SNO-CoA as positive control). Using multiple carbohydrates known or predicted to form polyols upon reduction as potential substrates, SCoR2 demonstrated no direct reductase activity as measured by NADPH consumption (<xref ref-type="fig" rid="fig5">Figure 5K</xref>). The related enzyme AKR1B1 can reduce glucose to the polyol sorbitol, but glucose is not a good substrate for AKR1A1/SCoR2 <xref ref-type="bibr" rid="bib22">Fujii et al., 2021</xref>; <xref ref-type="bibr" rid="bib16">Danesh et al., 2003</xref> and was not reduced in our assay (<xref ref-type="fig" rid="fig5">Figure 5K</xref>).</p></sec><sec id="s2-9"><title>Alternative substrates of SCoR2 in polyol metabolism</title><p>SCoR2 has been formally classified as an aldoketoreductase. However, putative carbonyl substrates of SCoR2/AKR1A1 have not been validated in situ and were not detectable in SCoR2<sup>-/-</sup> heart or plasma (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). These data are consistent with SCoR2 functioning primarily as a denitrosylase to regulate polyol metabolism via multiple substrate enzymes, rather than as a direct carbohydrate reductase. Taken together, our findings lead to an overall model (<xref ref-type="fig" rid="fig5">Figure 5L</xref>) in which SCoR2 reprograms cardiac metabolism through multiple metabolic pathways including cardiac ketolysis, glycolysis, PPP, and polyol metabolism, to increase protective NADPH and phosphocreatine in the mouse heart, while decreasing lactate and multiple polyols that are associated with poor cardiovascular outcomes.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>The cardioprotective role of NO in pre-clinical models of acute MI is well established (<xref ref-type="bibr" rid="bib24">Gonzalez et al., 2008</xref>; <xref ref-type="bibr" rid="bib17">Dezfulian et al., 2009</xref>; <xref ref-type="bibr" rid="bib18">Duranski et al., 2005</xref>; <xref ref-type="bibr" rid="bib32">Hendgen-Cotta et al., 2008</xref>). However, the ability of NO donors to reduce I/R damage has been disappointing in the clinical setting (<xref ref-type="bibr" rid="bib76">Siddiqi et al., 2014</xref>; <xref ref-type="bibr" rid="bib47">Jones et al., 2015</xref>). One explanation for these failures is the absence of drug targets or cardioprotective mechanisms by which to assess efficacy of NO donors. This challenge is circumvented through enzymatically regulated <italic>S</italic>-nitrosylation, where the target enzyme has been genetically validated. In particular, the denitrosylase SCoR2 (<xref ref-type="bibr" rid="bib1">Anand et al., 2014</xref>) regulates multiple metabolic pathways, including ketolysis, glycolysis, PPP, and polyol metabolism, that have established roles in cardioprotection, but were not previously known to be coordinately regulated. Our studies thus identify a comprehensive role for SCoR2 in regulating cardiac metabolism and suggest a new approach to cardioprotection through global metabolic reprogramming.</p><p>A large body of evidence supports the benefits of ketones in acute myocardial injury. BDH1 catalyzes the initial step in the breakdown of the ketone BHB in extrahepatic tissues, and cardiac-specific knockout of BDH1 in mice leads to more severe ventricular dysfunction following ischemia (<xref ref-type="bibr" rid="bib38">Horton et al., 2019</xref>). Conversely, cardiac-specific BDH1 overexpression improves contractile function in response to injury (<xref ref-type="bibr" rid="bib88">Uchihashi et al., 2017</xref>). Ketone bodies secreted from the liver are a critical source of myocardial energy during fasting (<xref ref-type="bibr" rid="bib59">Mitchell et al., 1995</xref>; <xref ref-type="bibr" rid="bib36">Homilius et al., 2023</xref>; <xref ref-type="bibr" rid="bib15">Cotter et al., 2013</xref>) and also in the failing (<xref ref-type="bibr" rid="bib3">Aubert et al., 2016</xref>; <xref ref-type="bibr" rid="bib62">Nielsen et al., 2019</xref>) and ischemic heart (<xref ref-type="bibr" rid="bib107">Zuurbier et al., 2020</xref>), where they reduce infarct size and improve post-I/R contractile function (<xref ref-type="bibr" rid="bib58">Marina Prendes et al., 2005</xref>; <xref ref-type="bibr" rid="bib78">Snorek et al., 2012</xref>; <xref ref-type="bibr" rid="bib40">Hron et al., 1978</xref>). Exogenous BHB reduces infarct size in rats (<xref ref-type="bibr" rid="bib106">Zou et al., 2002</xref>) and mice (<xref ref-type="bibr" rid="bib99">Yu et al., 2018</xref>) subjected to I/R injury by increasing ATP production and is beneficial in patients with cardiogenic shock (<xref ref-type="bibr" rid="bib4">Berg-Hansen et al., 2023</xref>), providing evidence that ketolysis contributes to superior metabolism in the setting of acute I/R injury. Circulating ketone bodies are elevated in humans with congestive heart failure (<xref ref-type="bibr" rid="bib57">Lommi et al., 1996</xref>) and are associated with improved cardiac function (<xref ref-type="bibr" rid="bib71">Selvaraj et al., 2020</xref>) and a lower risk of adverse events in acute MI (<xref ref-type="bibr" rid="bib68">Sato et al., 2023</xref>). Cardiac ketone body metabolism, beginning with BDH1-mediated breakdown of BHB, is thus a validated protective pathway in acute I/R injury and is beneficial in the context of human cardiovascular disease.</p><p>In this context, we have discovered that SCoR2 regulates <italic>S</italic>-nitrosylation of cardiac BDH1 at Cys<sup>115</sup>, thereby governing its stability. BDH1 expression is thus increased in SCoR2<sup>-/-</sup> hearts, in accord with its increased <italic>S</italic>-nitrosylation. Increased expression of BDH1 increases capacity for ketolysis, improving energy reserves (i.e., p-Cr) during ischemia (<xref ref-type="bibr" rid="bib36">Homilius et al., 2023</xref>), as we confirm here. Many studies, including over 40 controlled trials in patients with CAD, HF, or cardiac surgery (<xref ref-type="bibr" rid="bib52">Landoni et al., 2016</xref>), have demonstrated that p-Cr is cardioprotective (<xref ref-type="bibr" rid="bib52">Landoni et al., 2016</xref>; <xref ref-type="bibr" rid="bib74">Sharov et al., 1986</xref>; <xref ref-type="bibr" rid="bib64">Prabhakar et al., 2003</xref>; <xref ref-type="bibr" rid="bib100">Zhang et al., 2015</xref>; <xref ref-type="bibr" rid="bib66">Qaed et al., 2019</xref>; <xref ref-type="bibr" rid="bib92">Wang et al., 2021</xref>), an effect attributed to increased energy availability. Strategies to increase p-Cr in the post-ischemic myocardium are thus a promising avenue to reduce post-MI tissue damage. In this light, we show that inhibition of SCoR2 results in increased p-Cr.</p><p>PKM2 is a pyruvate kinase splice variant expressed in development, injury, and cancer (<xref ref-type="bibr" rid="bib13">Cheon et al., 2016</xref>; <xref ref-type="bibr" rid="bib91">Wang et al., 2012</xref>). PKM2 inhibition is strongly linked to tissue protection, regeneration, and repair (<xref ref-type="bibr" rid="bib102">Zhou et al., 2019</xref>; <xref ref-type="bibr" rid="bib77">Siragusa et al., 2019</xref>; <xref ref-type="bibr" rid="bib29">Hauck et al., 2021</xref>; <xref ref-type="bibr" rid="bib12">Cheng et al., 2017</xref>), including in the heart where inhibition (<xref ref-type="bibr" rid="bib12">Cheng et al., 2017</xref>) or genetic deletion (<xref ref-type="bibr" rid="bib29">Hauck et al., 2021</xref>) leads to reduced infarct size. <italic>S</italic>-nitrosylation of PKM2 inhibits activity and thus progression of intermediates through glycolysis (<xref ref-type="bibr" rid="bib102">Zhou et al., 2019</xref>); instead, glucose 6-phosphate is shunted into the PPP, where it is used to synthesize the antioxidant NADPH and 5-carbon sugars for biosynthesis (<xref ref-type="bibr" rid="bib85">TeSlaa et al., 2023</xref>). This is protective in the setting of MI (<xref ref-type="bibr" rid="bib29">Hauck et al., 2021</xref>; <xref ref-type="bibr" rid="bib12">Cheng et al., 2017</xref>). The PPP is responsible for producing a portion of the cardiac NADPH pool, and this pathway is upregulated in stressed or injured cardiac tissue (<xref ref-type="bibr" rid="bib26">Gupte et al., 2006</xref>; <xref ref-type="bibr" rid="bib93">Wang et al., 2022</xref>; <xref ref-type="bibr" rid="bib105">Zoccarato et al., 2023</xref>). SNO-PKM2, a validated SCoR2 substrate, protects against ischemic kidney injury and endothelial damage (<xref ref-type="bibr" rid="bib77">Siragusa et al., 2019</xref>) via increased flux through the PPP shunt (<xref ref-type="bibr" rid="bib102">Zhou et al., 2019</xref>; <xref ref-type="bibr" rid="bib104">Zhou et al., 2023b</xref>). We demonstrate that deletion of SCoR2 leads to an increase in SNO-PKM2 in the heart, accompanied by inhibition of glycolysis (decreased lactate) and stimulation of the PPP (increased NADPH, erythrose 4-phosphate, and ribose). We also observe an increase in other inputs into the PPP (primarily those converging on xylulose, such as galactaric acid, xylose, and lyxose, among others), supporting a comprehensive role for SCoR2 in regulation of the protective PPP shunt in the context of acute ischemic injury.</p><p>Polyols are relatively understudied organic metabolites containing more than 1 hydroxyl group. The ‘polyol pathway’ historically refers specifically to sorbitol <xref ref-type="bibr" rid="bib23">Garg and Gupta, 2022</xref>; however, there are many other polyols that are metabolically relevant in mammals, as first described in the mid-20th century (<xref ref-type="bibr" rid="bib43">Hutcheson et al., 1956</xref>; <xref ref-type="bibr" rid="bib86">Touster and Harwell, 1958</xref>). Endogenous production of polyols, well characterized in microorganisms (<italic>Lactobacillus</italic>, <italic>E. avium</italic>, <italic>L. casei</italic>, and others) (<xref ref-type="bibr" rid="bib67">Rice et al., 2020</xref>; <xref ref-type="bibr" rid="bib61">Monedero et al., 2010</xref>), has remained underappreciated and relatively uncharacterized in humans. Recent evidence of endogenous erythritol synthesis in human blood (<xref ref-type="bibr" rid="bib37">Hootman et al., 2017</xref>), and in A549 lung cancer cells by the reductases ADH and SORD (<xref ref-type="bibr" rid="bib69">Schlicker et al., 2019</xref>), casts doubt on the view that polyols are not endogenously produced in humans (<xref ref-type="bibr" rid="bib35">Hiele et al., 1993</xref>). Additionally, heritable genetic mutations (i.e., in transketolase <xref ref-type="bibr" rid="bib6">Boyle et al., 2016</xref>, transaldolase <xref ref-type="bibr" rid="bib89">Verhoeven et al., 2001</xref>, and ribose-5-phosphate isomerase <xref ref-type="bibr" rid="bib42">Huck et al., 2004</xref>) may lead to aberrant accumulation of certain polyols (ribitol, arabitol, and erythritol), suggesting close connections to the PPP. Many polyols are structurally related to PPP intermediates, such as arabitol, xylitol, and ribitol, and are likely derived at least in part from these compounds (<xref ref-type="bibr" rid="bib90">Wamelink and Williams, 2022</xref>; <xref ref-type="bibr" rid="bib42">Huck et al., 2004</xref>). Most studies appear to presume that any polyols produced are simply excreted from the body (<xref ref-type="bibr" rid="bib6">Boyle et al., 2016</xref>).</p><p>However, there is tantalizing new evidence that polyols impact cardiovascular health (<xref ref-type="bibr" rid="bib97">Witkowski et al., 2023</xref>; <xref ref-type="bibr" rid="bib98">Witkowski et al., 2024</xref>). Erythritol, xylitol, threitol, arabitol, and myo-inositol are highly associated with incident risk for major adverse cardiovascular events, and erythritol, in particular, is reported to enhance in vitro platelet reactivity and in vivo thrombosis rate (<xref ref-type="bibr" rid="bib97">Witkowski et al., 2023</xref>). Our untargeted metabolomic analysis revealed that SCoR2 deletion causes a marked reduction in these polyol ‘off-shoots’ from the PPP, particularly arabitol/ribitol (indistinguishable in our analysis) and sorbitol, a difference that widens after 4 hr of reperfusion relative to sham injury. We present strong evidence that this effect is not mediated through direct reduction of carbohydrates by SCoR2, in contrast with a recent report (<xref ref-type="bibr" rid="bib39">Hoshino et al., 2024</xref>) (where the actual data are negative, supporting our findings) and literature viewpoint. Rather, the many observed changes in carbohydrates and corresponding polyols are seemingly well rationalized by the widespread alterations in <italic>S</italic>-nitrosylation of metabolic enzymes (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>) accompanying SCoR2 deletion. Indeed, multiple reductase enzymes were identified in the SCoR2-dependent nitrosoproteome (e.g., ALDH1B1 and DHRS7B, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>), some of which may catalyze direct reduction of carbohydrates to polyols in an <italic>S</italic>-nitrosylation- and SCoR2-dependent manner. Multiple reductase and aldolase enzymes were recently identified as interacting partners with polyols (such as arabitol) and related carbohydrates (such as arabinose, ribulose, xylose, ribose, and xylulose) (<xref ref-type="bibr" rid="bib34">Hicks et al., 2023</xref>), including aldolase B, MDH2, PDH, and IDH3 that all have been identified in SNO-proteomic screens (<xref ref-type="bibr" rid="bib60">Mnatsakanyan et al., 2019</xref>) and may be SCoR2-regulated. Reduction in polyol levels thus represents a fourth SCoR2-regulated metabolic pathway contributing to comprehensive metabolic reprogramming during I/R injury.</p><p>The emerging concept that protein <italic>S</italic>-nitrosylation can be regulated independently of NO synthesis (i.e., by SNO metabolism) changes the therapeutic paradigm in myocardial ischemia. Protein denitrosylases, including both GSNOR (<xref ref-type="bibr" rid="bib56">Lima et al., 2009</xref>; <xref ref-type="bibr" rid="bib83">Tang et al., 2023</xref>; <xref ref-type="bibr" rid="bib10">Castillo et al., 2021</xref>; <xref ref-type="bibr" rid="bib25">Grimmett et al., 2021</xref>; <xref ref-type="bibr" rid="bib28">Hatzistergos et al., 2015</xref>) and thioredoxin (<xref ref-type="bibr" rid="bib63">Perone and Lembo, 2020</xref>; <xref ref-type="bibr" rid="bib84">Tao et al., 2004</xref>), have been shown to play important roles in cardiac injury and repair. However, a general schema for how these enzymes confer protection has been missing. Here we establish a cardioprotective framework for SCoR2 through metabolic regulation, whereby SCoR2 inhibition coordinately orchestrates multiple metabolic pathways for therapeutic gain: stimulation of ketolysis, inhibition of glycolysis, increased PPP shunting, and reduction in polyol compounds converge to protect the heart (<xref ref-type="fig" rid="fig5">Figure 5L</xref>). These findings help to cement SCoR2 as a major regulator of metabolism in the injured myocardium and new class of pharmaceutical target.</p><sec id="s3-1"><title>Limitations</title><p>The results presented here are purposefully limited to the acute response to cardiac tissue injury and do not explore whether deletion or inhibition of SCoR2 may be beneficial in long-term recovery from MI. Metabolic regulation in chronic injury may involve alternative pathways. The protection offered by SCoR2-mediated metabolic reprogramming is also specific to MI injury, although suggestive findings are shown in human cardiomyopathy. We identified the critical enzymes PKM2 and BDH1 via unbiased multi-omic screens, and we surmise they coordinately regulate increased flux through the PPP and ketolysis pathways upon function-regulating <italic>S</italic>-nitrosylation, thereby explaining improved energy balance, but isotope tracing experiments would be necessary to confirm this.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Cell lines</title><p>HEK293 cells (ATCC CRL-1573) were obtained from ATCC and cultured in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum and antibiotic/antimycotic solution (Gibco 15240096) (complete DMEM). All cells were grown at 37°C under 5% CO<sub>2</sub>.</p></sec><sec id="s4-2"><title>Plasmid construction and mutagenesis</title><p>The BDH1 (human) cDNA in pDONR223 entry vector was obtained from DNAsu (clone:HsCD00352477). This entry vector was cloned into Gateway pcDNA-DEST40 (mammalian expression, under CMV promoter; cat#43-0101; Invitrogen) with V5 epitope tag, using Gateway LR Clonase II (cat#11791-020; Invitrogen) enzyme reaction, and the LR reaction was transformed into One Shot Omnima cells (cat# C8540-03; Invitrogen) and streaked onto selective Amp+ plates. A single colony was isolated, expanded in LB + Amp media, and plasmid purified by QIAGEN Plasmid Maxi Kit (cat#12362; QIAGEN). The resulting plasmid was sequenced to confirm correct gene and vector sequence. C115S-BDH1 mutant was generated using QuikChange II Site-Directed Mutagenesis Kit (cat# 200523; Agilent) using mutagenesis primers (forward: 5′-<named-content content-type="sequence">CGTCCAGCTCAATGTCTCCAGCAGCGAAGAGG</named-content>; reverse: 5′-<named-content content-type="sequence">CCTCTTCGCTGCTGGAGACATTGAGCTGGACG</named-content>) from Invitrogen. Empty vector (pcDNA3.1(+); Invitrogen) was expanded and sequenced as described above.</p></sec><sec id="s4-3"><title>Transfection</title><p>For BDH1 transfections, HEK293 cells were plated onto dishes coated with 5 mg/cm<sup>2</sup> poly-<sc>d</sc>-lysine (Corning) and cultured for 24 hr in growth media. Cells were transfected with indicated empty vector, WT, or C115S BDH1 plasmids using PolyJet transfection reagent (Signagen) per manufacturer’s instructions. After 24 hr, cells were treated with vehicle or 100 μM Ethyl ester SNO-cysteine (ECNO), which was freshly prepared by mixing equal volumes of 2 M sodium nitrite with 2 M acidified ethyl ester cysteine (0.5 M HCl) (Millipore-Sigma) to generate 1 M ECNO, which was immediately added to designated cells at a final concentration of 100 μM. The vehicle was prepared in the same manner, with omission of ethyl ester cysteine from 0.5 M HCl. At the completion of the experiment, cells were harvested, pelleted, washed 1x with cold PBS, and subsequently resuspended in NP40 lysis buffer for biochemical analysis.</p></sec><sec id="s4-4"><title>Cycloheximide pulse-chase assay</title><p>Cycloheximide pulse-chase assay (CHX chase) was performed using CHX (stock concentration: 10 mg/ml in ddH<sub>2</sub>O; Sigma-Aldrich, cat#01810) added directly to cell culture media (at the time of ECNO/vehicle addition) to a final concentration of 100 μg/ml for the indicated time period. At the end of the indicated time period, cells were harvested, washed 1x with cold PBS, and immediately frozen at –80°C. Once all time points were collected, all samples were thawed and immediately lysed in NP40 lysis buffer for biochemical analysis.</p></sec><sec id="s4-5"><title>Cloning, expression, and purification of recombinant SCoR2</title><p>The human <italic>SCoR2</italic>/<italic>AKR1A1</italic> coding sequence was previously cloned into the pET21b vector (<xref ref-type="bibr" rid="bib1">Anand et al., 2014</xref>) to introduce a C-terminal 6xHis tag on the expressed protein. The recombinant SCoR2 protein was purified from BL21-CodonPlus Competent <italic>E. coli</italic> cells (Agilent). Overnight <italic>E. coli</italic> cultures were sub-cultured into 1 l of LB medium at 5%. At OD600 of 0.5, cultures were induced with 1 mM IPTG (Invitrogen) and grown for a further 4 hr at 28°C. Cultures were centrifuged at 4000 × <italic>g</italic> for 10 min to harvest the cells. Cell pellets from 1 l cultures were lysed in 10 ml of 1x PBS buffer containing 1 mM PMSF (cat# P7626; Sigma), protease-inhibitor cocktail (Roche), DNAse 1 (cat# 260913; Sigma-Aldrich; final: 5 μg/ml) and lysozyme (Sigma, cat#L6876; final: 1 mg/ml) by sonication. Supernatant was clarified and SCoR2-His purified via HisTrap column (Cytiva; cat#17524801); binding with 20 mM imidazole and elution with 500 mM imidazole using Cytiva AKTA Pure chromatography system, followed by buffer exchange to assay buffer (50 mM borate, 0.1 mM EDTA, pH 9.0). Protein was concentrated using Ultra-15 centrifugal filters (Amicon), and concentration was determined by Bicinchoninic Acid (BCA) assay (Thermo Scientific; cat#23223/4). Purification was assessed by SDS-PAGE followed by Imperial Protein Stain (Thermo Fisher).</p></sec><sec id="s4-6"><title>Mice</title><p>Mouse studies were approved by the Case Western Reserve University Institutional Animal Care and Use Committee (IACUC). Housing and procedures complied with the Guide for the Care and Use of Laboratory Animals and the American Veterinary Medical Association guidelines on euthanasia. <italic>SCoR2/Akr1a1</italic> refers to the same gene and protein (<xref ref-type="bibr" rid="bib102">Zhou et al., 2019</xref>), so ‘<italic>Akr1a1</italic><sup>-/-</sup>’ and ‘<italic>SCoR2</italic><sup>-/-</sup>’ in this versus other publications refer to an identical mouse line. <italic>SCoR2<sup>+/−</sup></italic> (<italic>Akr1a1</italic><sup>+/-</sup>) mice were made by Deltagen, Inc as described previously (<xref ref-type="bibr" rid="bib102">Zhou et al., 2019</xref>). Briefly, exon 2 was replaced with a LacZ/NEO cassette to disrupt in-frame translation, and mice were genotyped by PCR using primers forward: 5′-<named-content content-type="sequence">GCAGAGATTCAACAAGTCTCCCCTC</named-content>-3′; mutant reverse: 5′-<named-content content-type="sequence">GGGCCAGCTCATTCCTCCCACTCAT</named-content>-3′; and wild-type reverse: 5′-<named-content content-type="sequence">AGCTAAGGCTCCGAGCAGTGCTAAC</named-content>-3′. The mice used in these studies were bred using <italic>SCoR2</italic><sup>-/-</sup> male mice mated with <italic>SCoR2</italic><sup>+/-</sup> female mice (since <italic>SCoR2</italic><sup>-/-</sup> female mice do not breed efficiently) to generate <italic>SCoR2</italic><sup>-/-</sup> offspring used for the experiments described here. <italic>SCoR2</italic><sup>+/+</sup> mice were the offspring of <italic>SCoR2</italic><sup>+/-</sup> male and female mice and were occasionally backcrossed during the generation of the data in this manuscript. <italic>SCoR2</italic><sup>-/-</sup> mice were fed with AIN-93M diet supplemented with 1% L-ascorbic acid (vitamin C) (Research Diets, Cat# D16021012, custom diet) to correct for the inability of <italic>Akr1a1</italic>/<italic>SCoR2</italic><sup>-/-</sup> mice to synthesize L-ascorbic acid, as described previously (<xref ref-type="bibr" rid="bib51">Lai et al., 2017</xref>). <italic>SCoR2</italic><sup>+/+</sup> mice were fed with a control AIN-93M diet (Research Diets, Cat# D10012M).</p></sec><sec id="s4-7"><title>Myocardial I/R injury</title><p>Healthy male SCoR2<sup>+/+</sup> and SCoR2<sup>-/-</sup> mice (C57BL/6J background) aged 9–16 weeks were used for surgery. The female heart differs from the male heart in post-MI survival and cardiac function (<xref ref-type="bibr" rid="bib75">Shioura et al., 2008</xref>; <xref ref-type="bibr" rid="bib48">Kam et al., 2004</xref>; <xref ref-type="bibr" rid="bib7">Bridgman et al., 2005</xref>; <xref ref-type="bibr" rid="bib8">Brower et al., 2003</xref>; <xref ref-type="bibr" rid="bib49">Korte et al., 2005</xref>) and is more resilient following injury (<xref ref-type="bibr" rid="bib65">Pullen et al., 2020</xref>), making protection from tissue injury in female SCoR2<sup>-/-</sup> mice difficult to discern. Thus, distinct biology underlies the cardiac response to injury in female mice, and SCoR2<sup>-/-</sup>-mediated cardioprotection in female mice is deserving of a separate study. Myocardial I/R injury was carried out as described previously (<xref ref-type="bibr" rid="bib101">Zhang et al., 2016</xref>). Briefly, mice were anesthetized, intubated, and actively ventilated (respiration rate = ~133 /min and tidal volume = ~200 μl). The thoracic cavity was accessed through the left, third intercostal space, and the pericardium was resected to visualize the LAD artery. A ligature of 7-0 silk suture was placed around the LAD and tightened to fully occlude arterial flow as verified by ischemic change in coloration of the anterior wall and by EKG tracings (ST-segment elevation). Following 30 min of ischemia, reperfusion was initiated by untying the suture. Following the closure of the chest, pneumothorax was resolved by blunt needle aspiration. Mice were given 0.9% saline i.p. (0.5 ml/25 g body weight) and were recovered under temperature support. Following 1–4 hr reperfusion, mice for organ harvesting were anesthetized, whole blood harvested from IVC, spun and plasma collected, and LV, RV, and lung tissue harvested and snap-frozen in liquid nitrogen for biochemical analysis. Mice harvested for tissue following 1 hr reperfusion were excluded from survival analysis (<xref ref-type="fig" rid="fig1">Figure 1G</xref>). Mice destined for infarct size evaluation following 24 hr reperfusion were anesthetized, the chest was opened, and a catheter was inserted into the transverse aorta. The right atrium was opened and 0.5 ml of 0.9% saline was administered through the aortic cannula to exsanguinate the heart. The LAD was then occluded with the in-dwelling suture, and 0.2 ml of Evans blue (2% wt/vol) was injected into the LAD via the ascending aorta before the heart was extracted. The isolated heart was then frozen and sliced into segments 1 mm thick, and slices were placed in 1% TTC (2,3,5-triphenyltetrazolium chloride) in saline at 37°C for 20 min. TTC-stained slices were fixed in 10% formalin for 20 min before photographic documentation. Images were analyzed as described previously (<xref ref-type="bibr" rid="bib101">Zhang et al., 2016</xref>), with Image Pro Plus to evaluate area-at-risk (red), area of necrosis (white), and total LV area.</p></sec><sec id="s4-8"><title>Echocardiography</title><p>Following 24 hr reperfusion, mice were anesthetized with 2,2,2-tribromoethanol (0.25 mg/g body weight, IP), and transthoracic echocardiography was performed using a Vevo 770 High-Resolution Imaging System equipped with an RMV-707B 30-MHz probe (VisualSonics). Standard M-mode sampling was used through the left ventricular short axis at the midpapillary level. Ejection fraction, fractional shortening, LVID-s, and other parameters were determined using the system’s software.</p></sec><sec id="s4-9"><title>Troponin-1 and LDH measurement</title><p>Mouse cardiac troponin-1 and LDH were measured using troponin-1 ELISA (cat#: KT-470; Kamiya) and LDH activity assay (cat#: MAK066-1KT; Sigma) kits, respectively, according to the manufacturer’s instructions.</p></sec><sec id="s4-10"><title>Terminal uridine deoxynucleotidyl transferase dUTP nick end labeling (TUNEL assay)</title><p>Heart tissue from SCoR2+/+and SCoR2-/- mice post-MI was harvested, fixed in 4% paraformaldehyde overnight, switched to PBS, and sectioned with 10 μm thickness onto microscope slides in preparation for TUNEL assay. Slides were baked at 60°C for 75 min, deparaffinized in two changes of xylene, rehydrated in graded ethanols (100%, 95%, 70%), and washed in PBS. Slides were pretreated with IHC Select Proteinase K (Chemicon International; cat# 21627) at final concentration of 20 μg/ml for 10 min at 25°C, then washed twice in dH<sub>2</sub>O. Endogenous peroxidase activity was quenched with Peroxidazed 1 (BioCare Medical; cat# PX968G) for 8 min at 25°C, followed by 2x washes in dH<sub>2</sub>O. Excess liquid was removed and 900 μl equilibration buffer (Chemicon Intl ApopTag Peroxidase In Situ Apoptosis Detection Kit; cat# S7100) applied for 10 s at 25°C. Excess liquid tapped off, and TdT enzyme applied (ApopTag kit, 80% reaction buffer + 20% TdT enzyme) for 1 hr incubation at 37°C in a humidified chamber. TdT enzyme activity stopped with stop/wash buffer, agitated for 15 s, incubated for 10 min at 25°C, and washed 3x in PBS. Anti-digoxigenin peroxidase conjugate (ApopTag kit) was applied and incubated for 30 min at 25°C in a humidified chamber, followed by four washes in PBS. Two drops DAB chromogen added to 2.0 ml DAB substrate to form Betazoid DAB (BioCare; cat# BDB2004L), and slides incubated in Betazoid DAB for 5 min in the dark at 25°C, followed by 3 washes in dH<sub>2</sub>O and 5 min incubation in dH<sub>2</sub>O. Slides were then counterstained with CAT Hematoxylin (BioCare; cat# CATHE-M) for 30 s, rinsed in dH<sub>2</sub>O, dipped 10 x in PBS, rinsed in tap water, air dried overnight, dipped in xylene for 10 s, and coverslip applied with a resinous medium. Slides were imaged using brightfield 10x on a confocal microscope, TUNEL<sup>+</sup> nuclei quantified and analyzed by GraphPad Prism.</p></sec><sec id="s4-11"><title><italic>S</italic>-Nitrosothiol resin assisted capture</title><p>SNORAC (<xref ref-type="bibr" rid="bib21">Forrester et al., 2009</xref>) was carried out as described previously (<xref ref-type="bibr" rid="bib102">Zhou et al., 2019</xref>). Mouse heart samples were mechanically homogenized in lysis buffer containing 100 mM HEPES/1 mM EDTA/100 μM neocuproine (HEN), 50 mM NaCl, 0.1% (vol/vol) Nonidet P-40, the thiol-blocking agent 0.2% <italic>S</italic>-methylmethanethiosulfonate (MMTS), 1 mM PMSF and protease inhibitor (Roche). After centrifugation (10,000 × <italic>g</italic>, 4°C, 20 min, x2), SDS and MMTS were added to the supernatant to 2.5% and 0.2%, respectively, and incubated at 50° C for 20 min. Proteins were precipitated with –20°C acetone, and redissolved in 1 ml of HEN/1% SDS, repeated, and the final pellets were resuspended in HEN/1% SDS and protein concentrations determined using the BCA method. Total lysates (typically 1–2  mg) were incubated with freshly prepared 50 mM ascorbate and 100 μl thiopropyl-Sepharose (50% slurry; made in-house as described previously; <xref ref-type="bibr" rid="bib73">Seth et al., 2023</xref>) and rotated end-over-end in the dark for 3 hr. The bound SNO-proteins were sequentially washed with HEN/1% SDS and 10% HEN/0.1% SDS; SNO-proteins were then eluted with 10% HEN/1% SDS/10% β-mercaptoethanol and analyzed by SDS/PAGE and immunoblotting with antibodies targeting proteins of interest.</p></sec><sec id="s4-12"><title>Protein extraction and digestion (SCoR2 nitrosoproteome analysis)</title><p>For the SCoR2 nitrosoproteome analysis (SNORAC coupled to LC–MS/MS), SNO-proteins from heart lysates from <italic>N</italic> = 4 mice for each condition were bound to thiopropyl-Sepharose beads, eluted using 2X Laemmli buffer with 10% β-mercaptoethanol, and provided to IQ Proteomics (Framingham, MA). Proteins were extracted by methanol–chloroform precipitation and digested with 0.5 μg of LysC for 12 hr at room temperature followed by 1 μg of trypsin (Promega) in 100 mM EPPS buffer (pH 8.0) for 4 hr at 37°C. A miscleavage rate check was performed on two random samples to ensure efficient digestion of proteins. Each of the eight tryptic peptide samples was labeled with 120 μg of Tandem Mass Tag (TMT10; Pierce) isobaric reagents for 2 hr at room temperature. A label efficiency check was performed by pooling 1 μl from each sample within a single plex to ensure at least 98% labeling of all N-termini and lysine residues. All samples were quenched with hydroxylamine (0.5%), acidified with trifluoroacetic acid (2%), pooled, and dried by vacuum centrifugation. Pooled TMT10 labeled peptides were reconstituted in 0.1% TFA and subjected to orthogonal basic-pH reverse phase fractionation on a 2.1 × 50 mm column packed with 1.8 μm ZORBAX Extend-C18 material (Agilent) and equilibrated with buffer A (5% acetonitrile in 10 mM ammonium bicarbonate, pH 8). Peptides were fractionated utilizing a 7-min linear gradient from 5% to 50% buffer B (90% acetonitrile in 10 mM ammonium bicarbonate, pH 8) at a flow rate of 0.3 ml/min. A total of six fractions were collected and consolidated into three fractions and vacuum dried. The peptides were reconstituted in 0.2% FA and desalted with Empore-C18 (3 M) in-house packed StageTips prior to analysis by mass spectrometry (MS).</p></sec><sec id="s4-13"><title>MS analysis and data search (SCoR2 nitrosoproteome analysis)</title><p>All mass spectra were acquired on an Orbitrap Fusion Lumos coupled to an EASY nanoLC-1200 (Thermo Fisher) liquid chromatography system by IQ Proteomics (Framingham, MA). Approximately 2 μg of peptides were loaded on a 75-μm capillary column packed in-house with Sepax GP-C18 resin (1.8 μm, 150 Å, Sepax) to a final length of 35 cm. Peptides were separated using a 120-min linear gradient from 10% to 40% acetonitrile in 0.1% formic acid. The mass spectrometer was operated in a data-dependent mode. The scan sequence began with FTMS1 spectra (resolution = 120,000; mass range of 350–1400 <italic>m</italic>/<italic>z</italic>; max injection time of 50 ms; AGC target of 1e6; dynamic exclusion for 60 s with a ±10 ppm window). The 10 most intense precursors were selected within a 2-s cycle and fragmented via collisional-induced dissociation in the ion trap (normalized collision energy (NCE) = 35; max injection time = 35 ms; isolation window of 0.7 Da; AGC target of 1e4). Following the ITMS2 acquisition, a real-time search algorithm was employed to score each peptide and only trigger synchronous-precursor-selection (SPS) MS3 quantitative spectra for high confidence scoring peptides as determined by a linear discriminant approach. Following MS2 acquisition, an SPS MS3 method was enabled to select eight MS2 product ions for high energy collisional-induced dissociation with analysis in the Orbitrap (NCE = 55 for TMT10; resolution = 50,000; max injection time = 86 ms; AGC target of 1.4e5; isolation window at 1.2 Da for +2 <italic>m</italic>/<italic>z</italic>, 1.0 Da for +3 <italic>m</italic>/<italic>z</italic>, or 0.8 Da for +4 to +6 <italic>m</italic>/<italic>z</italic>). All mass spectra were converted to mzXML using a modified version of ReAdW.exe. MS/MS spectra were searched against a concatenated 2018 mouse Uniprot protein database containing common contaminants (forward + reverse sequences) using the SEQUEST algorithm (<xref ref-type="bibr" rid="bib20">Eng et al., 1994</xref>). Database search criteria are as follows: fully tryptic with two missed cleavages; a precursor mass tolerance of 50 ppm and a fragment ion tolerance of 1 Da; oxidation of methionine (+15.9949 Da) was set as differential modifications. Static modifications were carboxyamidomethylation of cysteines (+57.0215 Da) and TMT on lysines and N-termini of peptides (modification mass for TMT10 is +229.1629 Da). Peptide-spectrum matches were filtered using linear discriminant analysis (<xref ref-type="bibr" rid="bib44">Huttlin et al., 2010</xref>) and adjusted to a 1% peptide false discovery rate (FDR) (<xref ref-type="bibr" rid="bib19">Elias and Gygi, 2007</xref>) and collapsed further to a final 1.0% protein-level FDR. Proteins were quantified by summing the total reporter intensities across all matching PSMs.</p></sec><sec id="s4-14"><title>LC–MS/MS analysis and data search (SCoR2 interactome)</title><p>For the SCoR2 interactome analysis, hearts isolated from <italic>N</italic> = 4 wild-type mice were mechanically homogenized in non-denaturing lysis buffer (20 mM Tris-HCl (pH 8.0), 137 mM NaCl, 1% NP-40, 2 mM EDTA), clarified, and incubated with 10 µg of anti-SCoR2/AKR1A1 antibody (15054–1-AP, Proteintech) for 2 hr at room temperature. The sample was then incubated with 0.25 mg pre-washed protein A/G magnetic beads (cat# 88802; Thermo Scientific) for 1 hr at room temperature while mixing and placed into a magnet for washing steps. Proteins were eluted from beads with 0.1 M glycine (pH 2.0) for 10 min at room temperature with agitation, magnetically separated, sample collected, neutralized with 15 µl alkaline buffer (Tris, pH 8.0), and sent to the CWRU Proteomics and Small Molecule MS Core facility. Proteins were reduced with 10 mM dithiothreitol for 1 hr at 37°C, followed by alkylation with 25 mM iodoacetamide for 30 min in the dark. After reduction/alkylation of proteins, dual digestion was performed with 0.3 μg of lysyl endopeptidase on a dry bath shaker for 1 hr at 37°C followed by the addition of 0.3 μg of trypsin with incubation overnight at 37°C. After digestion, samples were filtered with 0.22  μM spin filters to remove any particulates before MS analysis (Costar Spin-X; Sigma-Aldrich). Peptides were identified using data-dependent MS acquisition.</p><p>Samples were analyzed on an Orbitrap Eclipse mass spectrometer (Thermo Electron, San Jose, CA) equipped with a Waters nanoACQUITY LC system (Waters, Taunton, MA). Peptides were desalted in a trap column (180  μm × 20  mm, packed with C18 Symmetry, 5  μm, 100 Å; Waters) and subsequently resolved on a reversed-phase column 75  μm × 250  mm nanocolumn, packed with C18 BEH130, 1.7  μm, 130 Å (Waters). Liquid chromatography was carried out at ambient temperature at a flow rate of 300 nl/min using a gradient mixture of 0.1% formic acid in water (solvent A) and 0.1% formic acid in acetonitrile (solvent B). The gradient used ranged from 1% to 60% solvent B over 90  min. Nanospray was conducted in a positive ion mode with a voltage of 2.4 kV. A full scan was obtained for eluted peptides in the range of 375–1500 atomic mass units followed by 25 data-dependent MS/MS scans.</p><p>MS/MS spectra were generated by collision-induced dissociation of the peptide ions at NCE of 35% to generate a series of b- and y-ions as major fragments. A 1-hr wash step was performed between each sample.</p><p>LC-MS/MS results were analyzed in Mascot (version 2.7.0) (Matrix Science, London, United Kingdom). The database used was <italic>Mus musculus</italic> UniProt (17,089 proteins). Search settings were as follows: trypsin enzyme specificity; mass accuracy window for precursor ion, 10.0 ppm; mass accuracy window for fragment ions, 0.60 Da, and 1 missed cleavage. For the interactome experiment, carbamidomethyl of cysteine was specified in Mascot as a fixed modification and oxidation of methionine was specified in Mascot as a variable modification.</p></sec><sec id="s4-15"><title>LC/MS-based untargeted metabolite profiling (metabolomic analysis)</title><p>Metabolite extraction and ratiometric profiling utilized acetonitrile (ACN), isopropanol (IPA), and methanol (MeOH) that were purchased from Fisher Scientific. High-purity Millipore filtered and deionized water (ddH<sub>2</sub>O; &gt;18 MOhm) was used in extraction media and chromatography mobile phases. OmniTrace glacial acetic acid and ammonium hydroxide were obtained from EMD Chemicals. Ammonium acetate, ammonium formate, and all other chemicals and standards were obtained from Sigma-Aldrich in the best available grade.</p><p>The left ventricle was isolated from mice post-sham, 1 hr I/R, or 4 hr I/R, <italic>N</italic> = 5 each condition and snap frozen in liquid nitrogen. Once received, tissue samples were washed with ice-cold PBS, followed by metabolite extraction using −70°C 80:20 methanol:water (LC/MS grade methanol, Fisher Scientific). The tissue–methanol mixture was subjected to bead-beating for 45  s using a Tissuelyser cell disrupter (QIAGEN). Extracts were centrifuged for 5  min at 18,500 × <italic>g</italic> to pellet insoluble protein, and supernatants were transferred to clean tubes. The extraction procedure was repeated two additional times, and all three supernatants were pooled, dried in a Vacufuge (Eppendorf), and stored at −80°C until analysis. The methanol-insoluble protein pellet was solubilized in 0.2  M NaOH at 95°C for 20  min and protein was quantified using a Bio-Rad DC assay. On the day of metabolite analysis, dried cell extracts were reconstituted in 70% acetonitrile at a relative protein concentration of 4  μg/ml, and 4  μl of this reconstituted extract was injected for LC/MS-based targeted and untargeted metabolite profiling.</p><p>Tissue extracts were analyzed by LC/MS as described previously (<xref ref-type="bibr" rid="bib11">Chen et al., 2018</xref>), using a platform comprised of an Agilent Model 1290 Infinity II liquid chromatography system coupled to an Agilent 6550 iFunnel time-of-flight MS analyzer. Chromatography of metabolites utilized aqueous normal phase chromatography on a Diamond Hydride column (Microsolv, cat# 70000-15D-2, 4 μm, 2.1 mm ID × 150 mm length, 100 A). Mobile phases consisted of (A) 50% isopropanol, containing 0.025% acetic acid, and (B) 90% acetonitrile containing 5  mM ammonium acetate. To eliminate the interference by metal ions on chromatographic peak integrity and electrospray ionization, EDTA was added to the mobile phase at a final concentration of 5  μM. The following gradient was applied: 0–1.0  min, 99% B; 1.0–15.0  min, to 20% B; 15.0–29.0, 0% B; 29.1–37  min, 99% B. Raw data were analyzed using MassHunter Profinder 8.0 and MassProfiler Professional (MPP) 15.1 software (Agilent). Student’s <italic>t</italic>-tests (p &lt; 0.05) were performed to identify significant differences between groups.</p><p>Peripheral blood was isolated fresh from murine IV post-sham, 1 hr I/R, or 4 hr I/R, <italic>N</italic> = 5 each condition, into BD microtainer (cat#365967; BD) tubes for blood separation after 30 min room-temperature incubation followed by centrifugation at 1500 × <italic>g</italic> for 5 min. Plasma was then snap-frozen and sent for LC/MS analysis. Plasma metabolites were extracted by the addition of 1 part plasma to 20 parts 70% acetonitrile in ddH<sub>2</sub>O (vol:vol). The mixture was briefly vortexed and then centrifuged for 5  min at 16,000 ×<italic> g</italic> to pellet precipitated proteins. An aliquot of the resulting extract (3  μl) was subjected to LC/MS-based untargeted metabolite profiling in both positive and negative ion modes.</p></sec><sec id="s4-16"><title>Metabolite structure specification</title><p>To ascertain the identities of differentially expressed metabolites (p &lt; 0.05), LC/MS data were searched against an in-house annotated personal metabolite database created using MassHunter PCDL manager 8.0 (Agilent), based on monoisotopic neutral masses (&lt;5  ppm mass accuracy) and chromatographic retention times. A molecular formula generator (MFG) algorithm in MPP was used to generate and score empirical molecular formulae, based on a weighted consideration of monoisotopic mass accuracy, isotope abundance ratios, and spacing between isotope peaks. A tentative compound ID was assigned when the PCDL database and MFG scores concurred for a given candidate molecule. Tentatively assigned molecules were verified based on a match of LC retention times and/or MS/MS fragmentation spectra for pure molecule standards contained in a growing in-house metabolite database.</p></sec><sec id="s4-17"><title>Bioinformatics</title><p>All studies were done in at least triplicate, unless otherwise noted. Studies using mice utilized at least 3 mice per condition/treatment. All metabolomic studies used 5 mice per group. Co-IP mass spectrometry data (CWRU) were obtained as unique spectrum count, and SNORAC mass spectrometry data (IQ Proteomics) were obtained as normalized summed signal/noise values for each identified protein. In the interactome study, proteins with an average of ≥1 unique spectrum count across three mouse heart samples were identified as interacting proteins and included in the ‘interactome’ list. In the SNORAC/MS nitrosoproteome study, all SNO-proteins identified in SCoR2<sup>-/-</sup> mouse heart with values ≥1.2-fold change relative to those identified in SCoR2<sup>+/+</sup> mouse heart, in at least two out of four experimental sets, were included in the final ‘SNO-ome’ list.</p></sec><sec id="s4-18"><title>Western blot analysis</title><p>Proteins were extracted from cells or tissues and subjected to 4–20% Criterion Precast Midi Protein Gel electrophoresis. Blotted membranes were incubated overnight at 4°C with primary antibodies, washed with PBS +0.1% Tween-20, then incubated with HRP-conjugated secondary antibody (anti-mouse or anti-rabbit IgG (Promega)) for 1 hr followed by chemiluminescent detection (ECL (GE Healthcare)). Antibodies employed in Western blotting included: rabbit polyclonal anti-AKR1A1/SCoR2 (15054-1-AP, Proteintech Group), rabbit monoclonal anti-PKM2 (D78A4, Cell Signaling), mouse monoclonal anti-p97 (10R-P104A, Fitzgerald), rabbit polyclonal anti-BDH1 (15417-1-AP, Proteintech Group). Coomassie blots used Imperial Protein Stain (cat#24615; Thermo Scientific) with 1 hr staining followed by 3 hr washing. Quantification of Western blots was carried out with ImageJ (NIH).</p></sec><sec id="s4-19"><title>Assay of NADPH-dependent SCoR2 activity with SNO-CoA or carbohydrates as substrate</title><p>The NADPH-dependent SNO-CoA reductase activity of recombinant SCoR2 was determined spectrophotometrically as described previously. Briefly, the assays were performed in 50 mM phosphate buffer (pH 7.0; containing 0.1 mM EDTA and DTPA) with 186 nM SCoR2, 100 μM NADPH and substrate: 100 μM SNO-CoA as positive control or 1 mM of specific test carbohydrates (L-(+)-arabinose, D-(-)-ribose, D-(-)-erythrose, D-(+)-glucose, D-(-)-fructose, D-(+)-galactose, sucrose, D-ribulose, and D-xylulose). Reactions were initiated by the addition of recombinant SCoR2 and allowed to proceed for 1 min while NADPH consumption was measured by spectrophotometer.</p></sec><sec id="s4-20"><title>NADPH-Glo assay</title><p>NADPH/NADP<sup>+</sup> assay was performed with NADP/NADPH-Glo Assay kit (Promega), as per the manufacturer’s instructions. Mouse heart samples (2 μg/ml) were mechanically homogenized in EBC lysis buffer containing protease inhibitor cocktail (Roche), clarified, plated in triplicate, and manufacturer’s protocol followed. Luminescence was recorded using Promega GloMax Discover instrument.</p></sec><sec id="s4-21"><title>cGMP measurement</title><p>GMP ELISA was performed using Cyclic GMP Complete kit (Enzo; cat#ADI-900-164) as per the manufacturer’s instructions. Mouse heart samples (post-I/R with 1 hr reperfusion) were homogenized in 10 volumes of 0.1 M HCl, centrifuged at 600 × <italic>g</italic> for 10 min, and supernatant diluted 1:20 and run directly in the assay. Assay results in pmol cGMP/ml were normalized between samples by dividing by protein concentration as determined by BCA assay, and results displayed as pmol cGMP/mg total protein.</p></sec><sec id="s4-22"><title>Human subjects</title><p>De-identified human post-mortem myocardial specimens with basic clinical data (sample type, sex, age, and race) were collected by the Duke Human Heart Repository under a non-human subjects research exemption granted by the Duke University Medical Center Institutional Review Board (# Pro00005621). A similar exemption was granted by the Case Western Reserve University IRB (study#: STUDY20230090) for experiments conducted at CWRU with this human tissue. Patient population characteristics are presented in <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>.</p></sec><sec id="s4-23"><title>Mouse subjects</title><p>All experimental procedures were approved by the Institutional Animal Care and Use Committee of Case Western Reserve University School of Medicine (protocol 2013-0091) and were conducted in accordance with the NIH <italic>Guide for the Care and Use of Laboratory Animals</italic> (National Academies Press, 2011). All potentially painful procedures were conducted under a surgical plane of anesthesia (typically ketamine/xylazine 100/10 mg/kg), and mice were sacrificed by methods compliant with the American Veterinary Medical Association (AVMA) <italic>Guidelines for Euthanasia of Animals</italic> (2013 edition).</p></sec><sec id="s4-24"><title>Statistical analysis</title><p>Data are presented as mean ± SD except where noted, with median and range reported in supplementary materials (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>). Parametric and non-parametric tests of statistical significance, as appropriate and indicated within each figure legend, were used to test for strain and treatment effects. Parametric tests were used if normality was satisfied, and non-parametric tests were used if normality was not satisfied or could not be confirmed due to <italic>n</italic> &lt; 5 independent replicates. Analysis was performed using GraphPad Prism software (v9). Under all conditions, p-values &lt;0.05 were taken to indicate a statistically significant difference between groups.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>Reviewing editor, eLife</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con3"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con5"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con6"><p>Resources</p></fn><fn fn-type="con" id="con7"><p>Investigation</p></fn><fn fn-type="con" id="con8"><p>Investigation</p></fn><fn fn-type="con" id="con9"><p>Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con11"><p>Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con12"><p>Conceptualization, Supervision, Funding acquisition, Project administration</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>De-identified human post-mortem myocardial specimens with basic clinical data (sample type, sex, age, and race) were collected by the Duke Human Heart Repository (Duke University IRB# Pro00005621) and obtained in the de-identified state. Experiments at CWRU involving these samples (study#: STUDY20230090) were determined by the CWRU IRB to be categorized as research not involving human subjects and therefore not requiring separate CWRU IRB review and approval.</p></fn><fn fn-type="other"><p>All experimental procedures were approved by the Institutional Animal Care and Use Committee of Case Western Reserve University School of Medicine and were conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals (National Academies Press, 2011). All potentially painful procedures were conducted under a surgical plane of anesthesia (typically ketamine/xylazine 100/10 mg/kg), and mice were sacrificed by methods compliant with the American Veterinary Medical Association (AVMA) Guidelines for Euthanasia of Animals (2013 edition).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>SCoR2-dependent cardiac <italic>S</italic>-nitrosoproteome and SCoR2 interactome.</title></caption><media xlink:href="elife-106601-supp1-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>SCoR2-dependent cardiac and plasma metabolome.</title></caption><media xlink:href="elife-106601-supp2-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>Statistical values for all quantitative experimental results.</title></caption><media xlink:href="elife-106601-supp3-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>Population characteristics of patients from whom heart samples were assessed.</title></caption><media xlink:href="elife-106601-supp4-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-106601-mdarchecklist1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data are available in the main text or in the supplementary materials.</p></sec><ack id="ack"><title>Acknowledgements</title><p>The authors acknowledge the assistance of Kathleen Lundberg at the Proteomics and Small Molecule Mass Spectrometry Core and of Adam Kresak and Jennifer Mikulan at the Tissue Resource Core at Case Western Reserve University, Isobel Taylor for assisting with metabolomics data acquisition at Weill Cornell Graduate School of Medical Sciences, the staff at the Human Heart Repository at Duke University, and the IQ Proteomics team in Framingham, MA. This work was supported in part by: National Institutes of Health grant P01HL158507 (JSS). National Institutes of Health grant R01HL126900 (JSS). National Institutes of Health grant RO1DK119506 (JSS). National Institutes of Health grant RO1DK128347 (JSS). American Heart Association-Allen grant 19PABH134580006 (JSS). National Institutes of Health grant R01HL157151 (WJK and JSS) National Institutes of Health grant RO1AR076029 (QC). National Institutes of Health grant RO1NS131322 (SSG). National Institutes of Health MSTP grant 2T32GM007250-44 (ZWG).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anand</surname><given-names>P</given-names></name><name><surname>Hausladen</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>YJ</given-names></name><name><surname>Zhang</surname><given-names>GF</given-names></name><name><surname>Stomberski</surname><given-names>C</given-names></name><name><surname>Brunengraber</surname><given-names>H</given-names></name><name><surname>Hess</surname><given-names>DT</given-names></name><name><surname>Stamler</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Identification of S-nitroso-CoA reductases that regulate protein S-nitrosylation</article-title><source>PNAS</source><volume>111</volume><fpage>18572</fpage><lpage>18577</lpage><pub-id pub-id-type="doi">10.1073/pnas.1417816112</pub-id><pub-id pub-id-type="pmid">25512491</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aragam</surname><given-names>KG</given-names></name><name><surname>Chaffin</surname><given-names>M</given-names></name><name><surname>Levinson</surname><given-names>RT</given-names></name><name><surname>McDermott</surname><given-names>G</given-names></name><name><surname>Choi</surname><given-names>SH</given-names></name><name><surname>Shoemaker</surname><given-names>MB</given-names></name><name><surname>Haas</surname><given-names>ME</given-names></name><name><surname>Weng</surname><given-names>L-C</given-names></name><name><surname>Lindsay</surname><given-names>ME</given-names></name><name><surname>Smith</surname><given-names>JG</given-names></name><name><surname>Newton-Cheh</surname><given-names>C</given-names></name><name><surname>Roden</surname><given-names>DM</given-names></name><name><surname>London</surname><given-names>B</given-names></name><name><surname>Wells</surname><given-names>QS</given-names></name><name><surname>Ellinor</surname><given-names>PT</given-names></name><name><surname>Kathiresan</surname><given-names>S</given-names></name><name><surname>Lubitz</surname><given-names>SA</given-names></name><collab>GRADE Investigators</collab><collab>Genetic Risk Assessment of Defibrillator Events Investigators</collab></person-group><year iso-8601-date="2019">2019</year><article-title>Phenotypic refinement of heart failure in a national biobank facilitates genetic discovery</article-title><source>Circulation</source><volume>139</volume><fpage>489</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.118.035774</pub-id><pub-id pub-id-type="pmid">30586722</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aubert</surname><given-names>G</given-names></name><name><surname>Martin</surname><given-names>OJ</given-names></name><name><surname>Horton</surname><given-names>JL</given-names></name><name><surname>Lai</surname><given-names>L</given-names></name><name><surname>Vega</surname><given-names>RB</given-names></name><name><surname>Leone</surname><given-names>TC</given-names></name><name><surname>Koves</surname><given-names>T</given-names></name><name><surname>Gardell</surname><given-names>SJ</given-names></name><name><surname>Krüger</surname><given-names>M</given-names></name><name><surname>Hoppel</surname><given-names>CL</given-names></name><name><surname>Lewandowski</surname><given-names>ED</given-names></name><name><surname>Crawford</surname><given-names>PA</given-names></name><name><surname>Muoio</surname><given-names>DM</given-names></name><name><surname>Kelly</surname><given-names>DP</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The failing heart relies on ketone bodies as a fuel</article-title><source>Circulation</source><volume>133</volume><fpage>698</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.115.017355</pub-id><pub-id pub-id-type="pmid">26819376</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Berg-Hansen</surname><given-names>K</given-names></name><name><surname>Christensen</surname><given-names>KH</given-names></name><name><surname>Gopalasingam</surname><given-names>N</given-names></name><name><surname>Nielsen</surname><given-names>R</given-names></name><name><surname>Eiskjær</surname><given-names>H</given-names></name><name><surname>Møller</surname><given-names>N</given-names></name><name><surname>Birkelund</surname><given-names>T</given-names></name><name><surname>Christensen</surname><given-names>S</given-names></name><name><surname>Wiggers</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2023">2023</year><source>Beneficial Effects of Ketone Ester in Patients With Cardiogenic Shock</source><publisher-name>JACC Heart Fail</publisher-name><pub-id pub-id-type="doi">10.1016/j.jchf.2023.05.029</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolli</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research</article-title><source>Journal of Molecular and Cellular Cardiology</source><volume>33</volume><fpage>1897</fpage><lpage>1918</lpage><pub-id pub-id-type="doi">10.1006/jmcc.2001.1462</pub-id><pub-id pub-id-type="pmid">11708836</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyle</surname><given-names>L</given-names></name><name><surname>Wamelink</surname><given-names>MMC</given-names></name><name><surname>Salomons</surname><given-names>GS</given-names></name><name><surname>Roos</surname><given-names>B</given-names></name><name><surname>Pop</surname><given-names>A</given-names></name><name><surname>Dauber</surname><given-names>A</given-names></name><name><surname>Hwa</surname><given-names>V</given-names></name><name><surname>Andrew</surname><given-names>M</given-names></name><name><surname>Douglas</surname><given-names>J</given-names></name><name><surname>Feingold</surname><given-names>M</given-names></name><name><surname>Kramer</surname><given-names>N</given-names></name><name><surname>Saitta</surname><given-names>S</given-names></name><name><surname>Retterer</surname><given-names>K</given-names></name><name><surname>Cho</surname><given-names>MT</given-names></name><name><surname>Begtrup</surname><given-names>A</given-names></name><name><surname>Monaghan</surname><given-names>KG</given-names></name><name><surname>Wynn</surname><given-names>J</given-names></name><name><surname>Chung</surname><given-names>WK</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Mutations in TKT Are the cause of a syndrome including short stature, developmental delay, and congenital heart defects</article-title><source>The American Journal of Human Genetics</source><volume>98</volume><fpage>1235</fpage><lpage>1242</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2016.03.030</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bridgman</surname><given-names>P</given-names></name><name><surname>Aronovitz</surname><given-names>MA</given-names></name><name><surname>Kakkar</surname><given-names>R</given-names></name><name><surname>Oliverio</surname><given-names>MI</given-names></name><name><surname>Coffman</surname><given-names>TM</given-names></name><name><surname>Rand</surname><given-names>WM</given-names></name><name><surname>Konstam</surname><given-names>MA</given-names></name><name><surname>Mendelsohn</surname><given-names>ME</given-names></name><name><surname>Patten</surname><given-names>RD</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Gender-specific patterns of left ventricular and myocyte remodeling following myocardial infarction in mice deficient in the angiotensin II type 1a receptor</article-title><source>American Journal of Physiology. Heart and Circulatory Physiology</source><volume>289</volume><fpage>H586</fpage><lpage>H592</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00474.2004</pub-id><pub-id pub-id-type="pmid">15764682</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brower</surname><given-names>GL</given-names></name><name><surname>Gardner</surname><given-names>JD</given-names></name><name><surname>Janicki</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Gender mediated cardiac protection from adverse ventricular remodeling is abolished by ovariectomy</article-title><source>Molecular and Cellular Biochemistry</source><volume>251</volume><fpage>89</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">14575309</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="web"><person-group person-group-type="author"><collab>Cardiovascular Disease Knowledge Portal</collab></person-group><year iso-8601-date="2022">2022</year><article-title>Cardiovascular disease knowledge portal (broadcvdi.org)</article-title><ext-link ext-link-type="uri" xlink:href="https://cvd.hugeamp.org/gene.html?gene=AKR1A1">https://cvd.hugeamp.org/gene.html?gene=AKR1A1</ext-link><date-in-citation iso-8601-date="2024-11-20">November 20, 2024</date-in-citation></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castillo</surname><given-names>OA</given-names></name><name><surname>Herrera</surname><given-names>G</given-names></name><name><surname>Manriquez</surname><given-names>C</given-names></name><name><surname>Rojas</surname><given-names>AF</given-names></name><name><surname>González</surname><given-names>DR</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Pharmacological inhibition of S-Nitrosoglutathione reductase reduces cardiac damage induced by Ischemia-Reperfusion</article-title><source>Antioxidants</source><volume>10</volume><elocation-id>555</elocation-id><pub-id pub-id-type="doi">10.3390/antiox10040555</pub-id><pub-id pub-id-type="pmid">33918310</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Kirk</surname><given-names>K</given-names></name><name><surname>Shurubor</surname><given-names>YI</given-names></name><name><surname>Zhao</surname><given-names>D</given-names></name><name><surname>Arreguin</surname><given-names>AJ</given-names></name><name><surname>Shahi</surname><given-names>I</given-names></name><name><surname>Valsecchi</surname><given-names>F</given-names></name><name><surname>Primiano</surname><given-names>G</given-names></name><name><surname>Calder</surname><given-names>EL</given-names></name><name><surname>Carelli</surname><given-names>V</given-names></name><name><surname>Denton</surname><given-names>TT</given-names></name><name><surname>Beal</surname><given-names>MF</given-names></name><name><surname>Gross</surname><given-names>SS</given-names></name><name><surname>Manfredi</surname><given-names>G</given-names></name><name><surname>D’Aurelio</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Rewiring of glutamine metabolism is a bioenergetic adaptation of human cells with mitochondrial DNA mutations</article-title><source>Cell Metabolism</source><volume>27</volume><fpage>1007</fpage><lpage>1025</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2018.03.002</pub-id><pub-id pub-id-type="pmid">29657030</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Rong</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>ω-Alkynyl arachidonic acid promotes anti-inflammatory macrophage M2 polarization against acute myocardial infarction via regulating the cross-talk between PKM2, HIF-1α and iNOS</article-title><source>Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids</source><volume>1862</volume><fpage>1595</fpage><lpage>1605</lpage><pub-id pub-id-type="doi">10.1016/j.bbalip.2017.09.009</pub-id><pub-id pub-id-type="pmid">28964797</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheon</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Son</surname><given-names>JY</given-names></name><name><surname>Kang</surname><given-names>YR</given-names></name><name><surname>An</surname><given-names>JH</given-names></name><name><surname>Kwon</surname><given-names>JH</given-names></name><name><surname>Song</surname><given-names>HS</given-names></name><name><surname>Moon</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>BM</given-names></name><name><surname>Kim</surname><given-names>HS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Pyruvate Kinase M2: A novel biomarker for the early detection of acute kidney injury</article-title><source>Toxicological Research</source><volume>32</volume><fpage>47</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.5487/TR.2016.32.1.047</pub-id><pub-id pub-id-type="pmid">26977258</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costanzo</surname><given-names>MC</given-names></name><name><surname>Roselli</surname><given-names>C</given-names></name><name><surname>Brandes</surname><given-names>M</given-names></name><name><surname>Duby</surname><given-names>M</given-names></name><name><surname>Hoang</surname><given-names>Q</given-names></name><name><surname>Jang</surname><given-names>D</given-names></name><name><surname>Koesterer</surname><given-names>R</given-names></name><name><surname>Kudtarkar</surname><given-names>P</given-names></name><name><surname>Moriondo</surname><given-names>A</given-names></name><name><surname>Nguyen</surname><given-names>T</given-names></name><name><surname>Ruebenacker</surname><given-names>O</given-names></name><name><surname>Smadbeck</surname><given-names>P</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Butterworth</surname><given-names>AS</given-names></name><name><surname>Aragam</surname><given-names>KG</given-names></name><name><surname>Lumbers</surname><given-names>RT</given-names></name><name><surname>Khera</surname><given-names>AV</given-names></name><name><surname>Lubitz</surname><given-names>SA</given-names></name><name><surname>Ellinor</surname><given-names>PT</given-names></name><name><surname>Gaulton</surname><given-names>KJ</given-names></name><name><surname>Flannick</surname><given-names>J</given-names></name><name><surname>Burtt</surname><given-names>NP</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Cardiovascular disease knowledge portal: a community resource for cardiovascular disease research</article-title><source>Circulation. Genomic and Precision Medicine</source><volume>16</volume><elocation-id>e004181</elocation-id><pub-id pub-id-type="doi">10.1161/CIRCGEN.123.004181</pub-id><pub-id pub-id-type="pmid">37814896</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cotter</surname><given-names>DG</given-names></name><name><surname>Schugar</surname><given-names>RC</given-names></name><name><surname>Crawford</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Ketone body metabolism and cardiovascular disease</article-title><source>American Journal of Physiology. Heart and Circulatory Physiology</source><volume>304</volume><fpage>H1060</fpage><lpage>H1076</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00646.2012</pub-id><pub-id pub-id-type="pmid">23396451</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danesh</surname><given-names>FR</given-names></name><name><surname>Wada</surname><given-names>J</given-names></name><name><surname>Wallner</surname><given-names>EI</given-names></name><name><surname>Sahai</surname><given-names>A</given-names></name><name><surname>Srivastava</surname><given-names>SK</given-names></name><name><surname>Kanwar</surname><given-names>YS</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Gene regulation of aldose-, aldehyde- and a renal specific oxido reductase (RSOR) in the pathobiology of diabetes mellitus</article-title><source>Current Medicinal Chemistry</source><volume>10</volume><fpage>1399</fpage><lpage>1406</lpage><pub-id pub-id-type="doi">10.2174/0929867033457368</pub-id><pub-id pub-id-type="pmid">12871137</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dezfulian</surname><given-names>C</given-names></name><name><surname>Shiva</surname><given-names>S</given-names></name><name><surname>Alekseyenko</surname><given-names>A</given-names></name><name><surname>Pendyal</surname><given-names>A</given-names></name><name><surname>Beiser</surname><given-names>DG</given-names></name><name><surname>Munasinghe</surname><given-names>JP</given-names></name><name><surname>Anderson</surname><given-names>SA</given-names></name><name><surname>Chesley</surname><given-names>CF</given-names></name><name><surname>Vanden Hoek</surname><given-names>TL</given-names></name><name><surname>Gladwin</surname><given-names>MT</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Nitrite therapy after cardiac arrest reduces reactive oxygen species generation, improves cardiac and neurological function, and enhances survival via reversible inhibition of mitochondrial complex I</article-title><source>Circulation</source><volume>120</volume><fpage>897</fpage><lpage>905</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.109.853267</pub-id><pub-id pub-id-type="pmid">19704094</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duranski</surname><given-names>MR</given-names></name><name><surname>Greer</surname><given-names>JJM</given-names></name><name><surname>Dejam</surname><given-names>A</given-names></name><name><surname>Jaganmohan</surname><given-names>S</given-names></name><name><surname>Hogg</surname><given-names>N</given-names></name><name><surname>Langston</surname><given-names>W</given-names></name><name><surname>Patel</surname><given-names>RP</given-names></name><name><surname>Yet</surname><given-names>SF</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Kevil</surname><given-names>CG</given-names></name><name><surname>Gladwin</surname><given-names>MT</given-names></name><name><surname>Lefer</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Cytoprotective effects of nitrite during in vivo ischemia-reperfusion of the heart and liver</article-title><source>The Journal of Clinical Investigation</source><volume>115</volume><fpage>1232</fpage><lpage>1240</lpage><pub-id pub-id-type="doi">10.1172/JCI22493</pub-id><pub-id pub-id-type="pmid">15841216</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elias</surname><given-names>JE</given-names></name><name><surname>Gygi</surname><given-names>SP</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry</article-title><source>Nature Methods</source><volume>4</volume><fpage>207</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1038/nmeth1019</pub-id><pub-id pub-id-type="pmid">17327847</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eng</surname><given-names>JK</given-names></name><name><surname>McCormack</surname><given-names>AL</given-names></name><name><surname>Yates</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database</article-title><source>Journal of the American Society for Mass Spectrometry</source><volume>5</volume><fpage>976</fpage><lpage>989</lpage><pub-id pub-id-type="pmid">24226387</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forrester</surname><given-names>MT</given-names></name><name><surname>Thompson</surname><given-names>JW</given-names></name><name><surname>Foster</surname><given-names>MW</given-names></name><name><surname>Nogueira</surname><given-names>L</given-names></name><name><surname>Moseley</surname><given-names>MA</given-names></name><name><surname>Stamler</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Proteomic analysis of S-nitrosylation and denitrosylation by resin-assisted capture</article-title><source>Nature Biotechnology</source><volume>27</volume><fpage>557</fpage><lpage>559</lpage><pub-id pub-id-type="pmid">19483679</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujii</surname><given-names>J</given-names></name><name><surname>Homma</surname><given-names>T</given-names></name><name><surname>Miyata</surname><given-names>S</given-names></name><name><surname>Takahashi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Pleiotropic actions of aldehyde reductase (AKR1A)</article-title><source>Metabolites</source><volume>11</volume><elocation-id>343</elocation-id><pub-id pub-id-type="doi">10.3390/metabo11060343</pub-id><pub-id pub-id-type="pmid">34073440</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garg</surname><given-names>SS</given-names></name><name><surname>Gupta</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Polyol pathway and redox balance in diabetes</article-title><source>Pharmacological Research</source><volume>182</volume><elocation-id>106326</elocation-id><pub-id pub-id-type="doi">10.1016/j.phrs.2022.106326</pub-id><pub-id pub-id-type="pmid">35752357</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez</surname><given-names>FM</given-names></name><name><surname>Shiva</surname><given-names>S</given-names></name><name><surname>Vincent</surname><given-names>PS</given-names></name><name><surname>Ringwood</surname><given-names>LA</given-names></name><name><surname>Hsu</surname><given-names>LY</given-names></name><name><surname>Hon</surname><given-names>YY</given-names></name><name><surname>Aletras</surname><given-names>AH</given-names></name><name><surname>Cannon</surname><given-names>RO</given-names><suffix>III</suffix></name><name><surname>Gladwin</surname><given-names>MT</given-names></name><name><surname>Arai</surname><given-names>AE</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Nitrite anion provides potent cytoprotective and antiapoptotic effects as adjunctive therapy to reperfusion for acute myocardial infarction</article-title><source>Circulation</source><volume>117</volume><fpage>2986</fpage><lpage>2994</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.107.748814</pub-id><pub-id pub-id-type="pmid">18519850</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grimmett</surname><given-names>ZW</given-names></name><name><surname>Venetos</surname><given-names>NM</given-names></name><name><surname>Premont</surname><given-names>RT</given-names></name><name><surname>Stamler</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>GSNOR regulates cardiomyocyte differentiation and maturation through protein S-nitrosylation</article-title><source>The Journal of Cardiovascular Aging</source><volume>1</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.20517/jca.2021.25</pub-id><pub-id pub-id-type="pmid">34790976</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupte</surname><given-names>SA</given-names></name><name><surname>Levine</surname><given-names>RJ</given-names></name><name><surname>Gupte</surname><given-names>RS</given-names></name><name><surname>Young</surname><given-names>ME</given-names></name><name><surname>Lionetti</surname><given-names>V</given-names></name><name><surname>Labinskyy</surname><given-names>V</given-names></name><name><surname>Floyd</surname><given-names>BC</given-names></name><name><surname>Ojaimi</surname><given-names>C</given-names></name><name><surname>Bellomo</surname><given-names>M</given-names></name><name><surname>Wolin</surname><given-names>MS</given-names></name><name><surname>Recchia</surname><given-names>FA</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Glucose-6-phosphate dehydrogenase-derived NADPH fuels superoxide production in the failing heart</article-title><source>Journal of Molecular and Cellular Cardiology</source><volume>41</volume><fpage>340</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2006.05.003</pub-id><pub-id pub-id-type="pmid">16828794</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamada</surname><given-names>Y</given-names></name><name><surname>Kitoh</surname><given-names>R</given-names></name><name><surname>Raskin</surname><given-names>P</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Crucial role of aldose reductase activity and plasma glucose level in sorbitol accumulation in erythrocytes from diabetic patients</article-title><source>Diabetes</source><volume>40</volume><fpage>1233</fpage><lpage>1240</lpage><pub-id pub-id-type="doi">10.2337/diab.40.10.1233</pub-id><pub-id pub-id-type="pmid">1936586</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatzistergos</surname><given-names>KE</given-names></name><name><surname>Paulino</surname><given-names>EC</given-names></name><name><surname>Dulce</surname><given-names>RA</given-names></name><name><surname>Takeuchi</surname><given-names>LM</given-names></name><name><surname>Bellio</surname><given-names>MA</given-names></name><name><surname>Kulandavelu</surname><given-names>S</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Balkan</surname><given-names>W</given-names></name><name><surname>Kanashiro-Takeuchi</surname><given-names>RM</given-names></name><name><surname>Hare</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>S-Nitrosoglutathione reductase deficiency enhances the proliferative expansion of adult heart progenitors and myocytes post myocardial infarction</article-title><source>Journal of the American Heart Association</source><volume>4</volume><elocation-id>e001974</elocation-id><pub-id pub-id-type="doi">10.1161/JAHA.115.001974</pub-id><pub-id pub-id-type="pmid">26178404</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hauck</surname><given-names>L</given-names></name><name><surname>Dadson</surname><given-names>K</given-names></name><name><surname>Chauhan</surname><given-names>S</given-names></name><name><surname>Grothe</surname><given-names>D</given-names></name><name><surname>Billia</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Inhibiting the Pkm2/b-catenin axis drives in vivo replication of adult cardiomyocytes following experimental MI</article-title><source>Cell Death &amp; Differentiation</source><volume>28</volume><fpage>1398</fpage><lpage>1417</lpage><pub-id pub-id-type="doi">10.1038/s41418-020-00669-9</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hausenloy</surname><given-names>DJ</given-names></name><name><surname>Yellon</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Myocardial ischemia-reperfusion injury: a neglected therapeutic target</article-title><source>The Journal of Clinical Investigation</source><volume>123</volume><fpage>92</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1172/JCI62874</pub-id><pub-id pub-id-type="pmid">23281415</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayashida</surname><given-names>K</given-names></name><name><surname>Bagchi</surname><given-names>A</given-names></name><name><surname>Miyazaki</surname><given-names>Y</given-names></name><name><surname>Hirai</surname><given-names>S</given-names></name><name><surname>Seth</surname><given-names>D</given-names></name><name><surname>Silverman</surname><given-names>MG</given-names></name><name><surname>Rezoagli</surname><given-names>E</given-names></name><name><surname>Marutani</surname><given-names>E</given-names></name><name><surname>Mori</surname><given-names>N</given-names></name><name><surname>Magliocca</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Berra</surname><given-names>L</given-names></name><name><surname>Hindle</surname><given-names>AG</given-names></name><name><surname>Donnino</surname><given-names>MW</given-names></name><name><surname>Malhotra</surname><given-names>R</given-names></name><name><surname>Bradley</surname><given-names>MO</given-names></name><name><surname>Stamler</surname><given-names>JS</given-names></name><name><surname>Ichinose</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Improvement in outcomes after cardiac arrest and resuscitation by inhibition of S-Nitrosoglutathione reductase</article-title><source>Circulation</source><volume>139</volume><fpage>815</fpage><lpage>827</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.117.032488</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hendgen-Cotta</surname><given-names>UB</given-names></name><name><surname>Merx</surname><given-names>MW</given-names></name><name><surname>Shiva</surname><given-names>S</given-names></name><name><surname>Schmitz</surname><given-names>J</given-names></name><name><surname>Becher</surname><given-names>S</given-names></name><name><surname>Klare</surname><given-names>JP</given-names></name><name><surname>Steinhoff</surname><given-names>HJ</given-names></name><name><surname>Goedecke</surname><given-names>A</given-names></name><name><surname>Schrader</surname><given-names>J</given-names></name><name><surname>Gladwin</surname><given-names>MT</given-names></name><name><surname>Kelm</surname><given-names>M</given-names></name><name><surname>Rassaf</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Nitrite reductase activity of myoglobin regulates respiration and cellular viability in myocardial ischemia-reperfusion injury</article-title><source>PNAS</source><volume>105</volume><fpage>10256</fpage><lpage>10261</lpage><pub-id pub-id-type="doi">10.1073/pnas.0801336105</pub-id><pub-id pub-id-type="pmid">18632562</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heusch</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Critical issues for the translation of cardioprotection</article-title><source>Circulation Research</source><volume>120</volume><fpage>1477</fpage><lpage>1486</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.117.310820</pub-id><pub-id pub-id-type="pmid">28450365</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hicks</surname><given-names>KG</given-names></name><name><surname>Cluntun</surname><given-names>AA</given-names></name><name><surname>Schubert</surname><given-names>HL</given-names></name><name><surname>Hackett</surname><given-names>SR</given-names></name><name><surname>Berg</surname><given-names>JA</given-names></name><name><surname>Leonard</surname><given-names>PG</given-names></name><name><surname>Ajalla Aleixo</surname><given-names>MA</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Bott</surname><given-names>AJ</given-names></name><name><surname>Salvatore</surname><given-names>SR</given-names></name><name><surname>Chang</surname><given-names>F</given-names></name><name><surname>Blevins</surname><given-names>A</given-names></name><name><surname>Barta</surname><given-names>P</given-names></name><name><surname>Tilley</surname><given-names>S</given-names></name><name><surname>Leifer</surname><given-names>A</given-names></name><name><surname>Guzman</surname><given-names>A</given-names></name><name><surname>Arok</surname><given-names>A</given-names></name><name><surname>Fogarty</surname><given-names>S</given-names></name><name><surname>Winter</surname><given-names>JM</given-names></name><name><surname>Ahn</surname><given-names>HC</given-names></name><name><surname>Allen</surname><given-names>KN</given-names></name><name><surname>Block</surname><given-names>S</given-names></name><name><surname>Cardoso</surname><given-names>IA</given-names></name><name><surname>Ding</surname><given-names>J</given-names></name><name><surname>Dreveny</surname><given-names>I</given-names></name><name><surname>Gasper</surname><given-names>WC</given-names></name><name><surname>Ho</surname><given-names>Q</given-names></name><name><surname>Matsuura</surname><given-names>A</given-names></name><name><surname>Palladino</surname><given-names>MJ</given-names></name><name><surname>Prajapati</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>P</given-names></name><name><surname>Tittmann</surname><given-names>K</given-names></name><name><surname>Tolan</surname><given-names>DR</given-names></name><name><surname>Unterlass</surname><given-names>J</given-names></name><name><surname>VanDemark</surname><given-names>AP</given-names></name><name><surname>Vander Heiden</surname><given-names>MG</given-names></name><name><surname>Webb</surname><given-names>BA</given-names></name><name><surname>Yun</surname><given-names>CH</given-names></name><name><surname>Zhao</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Schopfer</surname><given-names>FJ</given-names></name><name><surname>Hill</surname><given-names>CP</given-names></name><name><surname>Nonato</surname><given-names>MC</given-names></name><name><surname>Muller</surname><given-names>FL</given-names></name><name><surname>Cox</surname><given-names>JE</given-names></name><name><surname>Rutter</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Protein-metabolite interactomics of carbohydrate metabolism reveal regulation of lactate dehydrogenase</article-title><source>Science</source><volume>379</volume><fpage>996</fpage><lpage>1003</lpage><pub-id pub-id-type="doi">10.1126/science.abm3452</pub-id><pub-id pub-id-type="pmid">36893255</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hiele</surname><given-names>M</given-names></name><name><surname>Ghoos</surname><given-names>Y</given-names></name><name><surname>Rutgeerts</surname><given-names>P</given-names></name><name><surname>Vantrappen</surname><given-names>G</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Metabolism of erythritol in humans: comparison with glucose and lactitol</article-title><source>The British Journal of Nutrition</source><volume>69</volume><fpage>169</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1079/bjn19930019</pub-id><pub-id pub-id-type="pmid">8457525</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Homilius</surname><given-names>C</given-names></name><name><surname>Seefeldt</surname><given-names>JM</given-names></name><name><surname>Axelsen</surname><given-names>JS</given-names></name><name><surname>Pedersen</surname><given-names>TM</given-names></name><name><surname>Sørensen</surname><given-names>TM</given-names></name><name><surname>Nielsen</surname><given-names>R</given-names></name><name><surname>Wiggers</surname><given-names>H</given-names></name><name><surname>Hansen</surname><given-names>J</given-names></name><name><surname>Matchkov</surname><given-names>VV</given-names></name><name><surname>Bøtker</surname><given-names>HE</given-names></name><name><surname>Boedtkjer</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Ketone body 3-hydroxybutyrate elevates cardiac output through peripheral vasorelaxation and enhanced cardiac contractility</article-title><source>Basic Research in Cardiology</source><volume>118</volume><elocation-id>37</elocation-id><pub-id pub-id-type="doi">10.1007/s00395-023-01008-y</pub-id><pub-id pub-id-type="pmid">37688627</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hootman</surname><given-names>KC</given-names></name><name><surname>Trezzi</surname><given-names>JP</given-names></name><name><surname>Kraemer</surname><given-names>L</given-names></name><name><surname>Burwell</surname><given-names>LS</given-names></name><name><surname>Dong</surname><given-names>X</given-names></name><name><surname>Guertin</surname><given-names>KA</given-names></name><name><surname>Jaeger</surname><given-names>C</given-names></name><name><surname>Stover</surname><given-names>PJ</given-names></name><name><surname>Hiller</surname><given-names>K</given-names></name><name><surname>Cassano</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Erythritol is a pentose-phosphate pathway metabolite and associated with adiposity gain in young adults</article-title><source>PNAS</source><volume>114</volume><fpage>E4233</fpage><lpage>E4240</lpage><pub-id pub-id-type="doi">10.1073/pnas.1620079114</pub-id><pub-id pub-id-type="pmid">28484010</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horton</surname><given-names>JL</given-names></name><name><surname>Davidson</surname><given-names>MT</given-names></name><name><surname>Kurishima</surname><given-names>C</given-names></name><name><surname>Vega</surname><given-names>RB</given-names></name><name><surname>Powers</surname><given-names>JC</given-names></name><name><surname>Matsuura</surname><given-names>TR</given-names></name><name><surname>Petucci</surname><given-names>C</given-names></name><name><surname>Lewandowski</surname><given-names>ED</given-names></name><name><surname>Crawford</surname><given-names>PA</given-names></name><name><surname>Muoio</surname><given-names>DM</given-names></name><name><surname>Recchia</surname><given-names>FA</given-names></name><name><surname>Kelly</surname><given-names>DP</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The failing heart utilizes 3-hydroxybutyrate as a metabolic stress defense</article-title><source>JCI Insight</source><volume>4</volume><fpage>1</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1172/jci.insight.124079</pub-id><pub-id pub-id-type="pmid">30668551</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoshino</surname><given-names>S</given-names></name><name><surname>Manya</surname><given-names>H</given-names></name><name><surname>Imae</surname><given-names>R</given-names></name><name><surname>Kobayashi</surname><given-names>K</given-names></name><name><surname>Kanagawa</surname><given-names>M</given-names></name><name><surname>Endo</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Endogenous reductase activities for the generation of ribitol-phosphate, a CDP-ribitol precursor, in mammals</article-title><source>Journal of Biochemistry</source><volume>175</volume><fpage>418</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1093/jb/mvad115</pub-id><pub-id pub-id-type="pmid">38140954</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hron</surname><given-names>WT</given-names></name><name><surname>Menahan</surname><given-names>LA</given-names></name><name><surname>Lech</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="1978">1978</year><article-title>Inhibition of hormonal stimulation of lipolysis in perfused rat heart by ketone bodies</article-title><source>Journal of Molecular and Cellular Cardiology</source><volume>10</volume><fpage>161</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1016/0022-2828(78)90040-8</pub-id><pub-id pub-id-type="pmid">204794</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>ZM</given-names></name><name><surname>Gao</surname><given-names>E</given-names></name><name><surname>Fonseca</surname><given-names>FV</given-names></name><name><surname>Hayashi</surname><given-names>H</given-names></name><name><surname>Shang</surname><given-names>X</given-names></name><name><surname>Hoffman</surname><given-names>NE</given-names></name><name><surname>Chuprun</surname><given-names>JK</given-names></name><name><surname>Tian</surname><given-names>X</given-names></name><name><surname>Tilley</surname><given-names>DG</given-names></name><name><surname>Madesh</surname><given-names>M</given-names></name><name><surname>Lefer</surname><given-names>DJ</given-names></name><name><surname>Stamler</surname><given-names>JS</given-names></name><name><surname>Koch</surname><given-names>WJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Convergence of G Protein–Coupled Receptor and S-Nitrosylation signaling determines the outcome to cardiac ischemic injury</article-title><source>Science Signaling</source><volume>6</volume><elocation-id>ra95</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.2004225</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huck</surname><given-names>JHJ</given-names></name><name><surname>Verhoeven</surname><given-names>NM</given-names></name><name><surname>Struys</surname><given-names>EA</given-names></name><name><surname>Salomons</surname><given-names>GS</given-names></name><name><surname>Jakobs</surname><given-names>C</given-names></name><name><surname>van der Knaap</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Ribose-5-phosphate isomerase deficiency: new inborn error in the pentose phosphate pathway associated with a slowly progressive leukoencephalopathy</article-title><source>American Journal of Human Genetics</source><volume>74</volume><fpage>745</fpage><lpage>751</lpage><pub-id pub-id-type="doi">10.1086/383204</pub-id><pub-id pub-id-type="pmid">14988808</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hutcheson</surname><given-names>RM</given-names></name><name><surname>Reynolds</surname><given-names>VH</given-names></name><name><surname>Touster</surname><given-names>O</given-names></name></person-group><year iso-8601-date="1956">1956</year><article-title>The reduction of L-xylulose to xylitol by guinea pig liver mitochondria</article-title><source>The Journal of Biological Chemistry</source><volume>221</volume><fpage>697</fpage><lpage>709</lpage><pub-id pub-id-type="pmid">13357463</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huttlin</surname><given-names>EL</given-names></name><name><surname>Jedrychowski</surname><given-names>MP</given-names></name><name><surname>Elias</surname><given-names>JE</given-names></name><name><surname>Goswami</surname><given-names>T</given-names></name><name><surname>Rad</surname><given-names>R</given-names></name><name><surname>Beausoleil</surname><given-names>SA</given-names></name><name><surname>Villén</surname><given-names>J</given-names></name><name><surname>Haas</surname><given-names>W</given-names></name><name><surname>Sowa</surname><given-names>ME</given-names></name><name><surname>Gygi</surname><given-names>SP</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A tissue-specific atlas of mouse protein phosphorylation and expression</article-title><source>Cell</source><volume>143</volume><fpage>1174</fpage><lpage>1189</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2010.12.001</pub-id><pub-id pub-id-type="pmid">21183079</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janssens</surname><given-names>S</given-names></name><name><surname>Pokreisz</surname><given-names>P</given-names></name><name><surname>Schoonjans</surname><given-names>L</given-names></name><name><surname>Pellens</surname><given-names>M</given-names></name><name><surname>Vermeersch</surname><given-names>P</given-names></name><name><surname>Tjwa</surname><given-names>M</given-names></name><name><surname>Jans</surname><given-names>P</given-names></name><name><surname>Scherrer-Crosbie</surname><given-names>M</given-names></name><name><surname>Picard</surname><given-names>MH</given-names></name><name><surname>Szelid</surname><given-names>Z</given-names></name><name><surname>Gillijns</surname><given-names>H</given-names></name><name><surname>Van de Werf</surname><given-names>F</given-names></name><name><surname>Collen</surname><given-names>D</given-names></name><name><surname>Bloch</surname><given-names>KD</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction</article-title><source>Circulation Research</source><volume>94</volume><fpage>1256</fpage><lpage>1262</lpage><pub-id pub-id-type="doi">10.1161/01.RES.0000126497.38281.23</pub-id><pub-id pub-id-type="pmid">15044322</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johansson</surname><given-names>S</given-names></name><name><surname>Rosengren</surname><given-names>A</given-names></name><name><surname>Young</surname><given-names>K</given-names></name><name><surname>Jennings</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Mortality and morbidity trends after the first year in survivors of acute myocardial infarction: a systematic review</article-title><source>BMC Cardiovascular Disorders</source><volume>17</volume><elocation-id>53</elocation-id><pub-id pub-id-type="doi">10.1186/s12872-017-0482-9</pub-id><pub-id pub-id-type="pmid">28173750</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>DA</given-names></name><name><surname>Pellaton</surname><given-names>C</given-names></name><name><surname>Velmurugan</surname><given-names>S</given-names></name><name><surname>Rathod</surname><given-names>KS</given-names></name><name><surname>Andiapen</surname><given-names>M</given-names></name><name><surname>Antoniou</surname><given-names>S</given-names></name><name><surname>van Eijl</surname><given-names>S</given-names></name><name><surname>Webb</surname><given-names>AJ</given-names></name><name><surname>Westwood</surname><given-names>MA</given-names></name><name><surname>Parmar</surname><given-names>MK</given-names></name><name><surname>Mathur</surname><given-names>A</given-names></name><name><surname>Ahluwalia</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Randomized phase 2 trial of intracoronary nitrite during acute myocardial infarction</article-title><source>Circulation Research</source><volume>116</volume><fpage>437</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.305082</pub-id><pub-id pub-id-type="pmid">25512434</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kam</surname><given-names>KWL</given-names></name><name><surname>Qi</surname><given-names>JS</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Wong</surname><given-names>TM</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Estrogen reduces cardiac injury and expression of beta1-adrenoceptor upon ischemic insult in the rat heart</article-title><source>The Journal of Pharmacology and Experimental Therapeutics</source><volume>309</volume><fpage>8</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1124/jpet.103.058339</pub-id><pub-id pub-id-type="pmid">14718598</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korte</surname><given-names>T</given-names></name><name><surname>Fuchs</surname><given-names>M</given-names></name><name><surname>Arkudas</surname><given-names>A</given-names></name><name><surname>Geertz</surname><given-names>S</given-names></name><name><surname>Meyer</surname><given-names>R</given-names></name><name><surname>Gardiwal</surname><given-names>A</given-names></name><name><surname>Klein</surname><given-names>G</given-names></name><name><surname>Niehaus</surname><given-names>M</given-names></name><name><surname>Krust</surname><given-names>A</given-names></name><name><surname>Chambon</surname><given-names>P</given-names></name><name><surname>Drexler</surname><given-names>H</given-names></name><name><surname>Fink</surname><given-names>K</given-names></name><name><surname>Grohé</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Female mice lacking estrogen receptor beta display prolonged ventricular repolarization and reduced ventricular automaticity after myocardial infarction</article-title><source>Circulation</source><volume>111</volume><fpage>2282</fpage><lpage>2290</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.0000164262.08004.BB</pub-id><pub-id pub-id-type="pmid">15867180</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kukreja</surname><given-names>RC</given-names></name><name><surname>Salloum</surname><given-names>FN</given-names></name><name><surname>Das</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Role of cGMP Signaling and Phosphodiesterase-5 inhibitors in Cardioprotection</article-title><source>Journal of the American College of Cardiology</source><volume>59</volume><fpage>1921</fpage><lpage>1927</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2011.09.086</pub-id><pub-id pub-id-type="pmid">22624832</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>CW</given-names></name><name><surname>Chen</surname><given-names>HL</given-names></name><name><surname>Tu</surname><given-names>MY</given-names></name><name><surname>Lin</surname><given-names>WY</given-names></name><name><surname>Röhrig</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>SH</given-names></name><name><surname>Lan</surname><given-names>YW</given-names></name><name><surname>Chong</surname><given-names>KY</given-names></name><name><surname>Chen</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A novel osteoporosis model with ascorbic acid deficiency in Akr1A1 gene knockout mice</article-title><source>Oncotarget</source><volume>8</volume><fpage>7357</fpage><lpage>7369</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.14458</pub-id><pub-id pub-id-type="pmid">28060768</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landoni</surname><given-names>G</given-names></name><name><surname>Zangrillo</surname><given-names>A</given-names></name><name><surname>Lomivorotov</surname><given-names>VV</given-names></name><name><surname>Likhvantsev</surname><given-names>V</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>De Simone</surname><given-names>F</given-names></name><name><surname>Fominskiy</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Cardiac protection with phosphocreatine: a meta-analysis</article-title><source>Interactive CardioVascular and Thoracic Surgery</source><volume>23</volume><fpage>637</fpage><lpage>646</lpage><pub-id pub-id-type="doi">10.1093/icvts/ivw171</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>B</given-names></name><name><surname>Fazelinia</surname><given-names>H</given-names></name><name><surname>Mohanty</surname><given-names>I</given-names></name><name><surname>Raimo</surname><given-names>S</given-names></name><name><surname>Tenopoulou</surname><given-names>M</given-names></name><name><surname>Doulias</surname><given-names>PT</given-names></name><name><surname>Ischiropoulos</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Endogenous S-nitrosocysteine proteomic inventories identify a core of proteins in heart metabolic pathways</article-title><source>Redox Biology</source><volume>47</volume><elocation-id>102153</elocation-id><pub-id pub-id-type="doi">10.1016/j.redox.2021.102153</pub-id><pub-id pub-id-type="pmid">34610554</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lazzeri</surname><given-names>C</given-names></name><name><surname>Valente</surname><given-names>S</given-names></name><name><surname>Chiostri</surname><given-names>M</given-names></name><name><surname>Gensini</surname><given-names>GF</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Clinical significance of lactate in acute cardiac patients</article-title><source>World Journal of Cardiology</source><volume>7</volume><fpage>483</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.4330/wjc.v7.i8.483</pub-id><pub-id pub-id-type="pmid">26322188</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lefer</surname><given-names>DJ</given-names></name><name><surname>Marbán</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Is cardioprotection dead?</article-title><source>Circulation</source><volume>136</volume><fpage>98</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.116.027039</pub-id><pub-id pub-id-type="pmid">28674094</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lima</surname><given-names>B</given-names></name><name><surname>Lam</surname><given-names>GKW</given-names></name><name><surname>Xie</surname><given-names>L</given-names></name><name><surname>Diesen</surname><given-names>DL</given-names></name><name><surname>Villamizar</surname><given-names>N</given-names></name><name><surname>Nienaber</surname><given-names>J</given-names></name><name><surname>Messina</surname><given-names>E</given-names></name><name><surname>Bowles</surname><given-names>D</given-names></name><name><surname>Kontos</surname><given-names>CD</given-names></name><name><surname>Hare</surname><given-names>JM</given-names></name><name><surname>Stamler</surname><given-names>JS</given-names></name><name><surname>Rockman</surname><given-names>HA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Endogenous <italic>S</italic> -nitrosothiols protect against myocardial injury</article-title><source>PNAS</source><volume>106</volume><fpage>6297</fpage><lpage>6302</lpage><pub-id pub-id-type="doi">10.1073/pnas.0901043106</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lommi</surname><given-names>J</given-names></name><name><surname>Kupari</surname><given-names>M</given-names></name><name><surname>Koskinen</surname><given-names>P</given-names></name><name><surname>Näveri</surname><given-names>H</given-names></name><name><surname>Leinonen</surname><given-names>H</given-names></name><name><surname>Pulkki</surname><given-names>K</given-names></name><name><surname>Härkönen</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Blood ketone bodies in congestive heart failure</article-title><source>Journal of the American College of Cardiology</source><volume>28</volume><fpage>665</fpage><lpage>672</lpage><pub-id pub-id-type="doi">10.1016/0735-1097(96)00214-8</pub-id><pub-id pub-id-type="pmid">8772754</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marina Prendes</surname><given-names>MG</given-names></name><name><surname>García</surname><given-names>JV</given-names></name><name><surname>Fernández</surname><given-names>MA</given-names></name><name><surname>Pérez</surname><given-names>MJ</given-names></name><name><surname>Perazzo</surname><given-names>JC</given-names></name><name><surname>Savino</surname><given-names>EA</given-names></name><name><surname>Varela</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Effects of 5-hydroxydecanoate and ischemic preconditioning on the ischemic-reperfused heart of fed and fasted rats</article-title><source>Journal of Physiology and Biochemistry</source><volume>61</volume><fpage>447</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.1007/BF03168451</pub-id><pub-id pub-id-type="pmid">16440599</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitchell</surname><given-names>GA</given-names></name><name><surname>Kassovska-Bratinova</surname><given-names>S</given-names></name><name><surname>Boukaftane</surname><given-names>Y</given-names></name><name><surname>Robert</surname><given-names>MF</given-names></name><name><surname>Wang</surname><given-names>SP</given-names></name><name><surname>Ashmarina</surname><given-names>L</given-names></name><name><surname>Lambert</surname><given-names>M</given-names></name><name><surname>Lapierre</surname><given-names>P</given-names></name><name><surname>Potier</surname><given-names>E</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Medical aspects of ketone body metabolism</article-title><source>Clinical and Investigative Medicine. Medecine Clinique et Experimentale</source><volume>18</volume><fpage>193</fpage><lpage>216</lpage><pub-id pub-id-type="pmid">7554586</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mnatsakanyan</surname><given-names>R</given-names></name><name><surname>Markoutsa</surname><given-names>S</given-names></name><name><surname>Walbrunn</surname><given-names>K</given-names></name><name><surname>Roos</surname><given-names>A</given-names></name><name><surname>Verhelst</surname><given-names>SHL</given-names></name><name><surname>Zahedi</surname><given-names>RP</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Proteome-wide detection of S-nitrosylation targets and motifs using bioorthogonal cleavable-linker-based enrichment and switch technique</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>2195</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-10182-4</pub-id><pub-id pub-id-type="pmid">31097712</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monedero</surname><given-names>V</given-names></name><name><surname>Pérez-Martínez</surname><given-names>G</given-names></name><name><surname>Yebra</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Perspectives of engineering lactic acid bacteria for biotechnological polyol production</article-title><source>Applied Microbiology and Biotechnology</source><volume>86</volume><fpage>1003</fpage><lpage>1015</lpage><pub-id pub-id-type="doi">10.1007/s00253-010-2494-6</pub-id><pub-id pub-id-type="pmid">20180114</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>R</given-names></name><name><surname>Møller</surname><given-names>N</given-names></name><name><surname>Gormsen</surname><given-names>LC</given-names></name><name><surname>Tolbod</surname><given-names>LP</given-names></name><name><surname>Hansson</surname><given-names>NH</given-names></name><name><surname>Sorensen</surname><given-names>J</given-names></name><name><surname>Harms</surname><given-names>HJ</given-names></name><name><surname>Frøkiær</surname><given-names>J</given-names></name><name><surname>Eiskjaer</surname><given-names>H</given-names></name><name><surname>Jespersen</surname><given-names>NR</given-names></name><name><surname>Mellemkjaer</surname><given-names>S</given-names></name><name><surname>Lassen</surname><given-names>TR</given-names></name><name><surname>Pryds</surname><given-names>K</given-names></name><name><surname>Bøtker</surname><given-names>HE</given-names></name><name><surname>Wiggers</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cardiovascular effects of treatment with the ketone body 3-hydroxybutyrate in chronic heart failure patients</article-title><source>Circulation</source><volume>139</volume><fpage>2129</fpage><lpage>2141</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.118.036459</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perone</surname><given-names>F</given-names></name><name><surname>Lembo</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Thioredoxin-1: a cardioprotector against stress</article-title><source>Cardiovascular Research</source><volume>116</volume><fpage>1654</fpage><lpage>1655</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvaa113</pub-id><pub-id pub-id-type="pmid">32346725</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prabhakar</surname><given-names>G</given-names></name><name><surname>Vona-Davis</surname><given-names>L</given-names></name><name><surname>Murray</surname><given-names>D</given-names></name><name><surname>Lakhani</surname><given-names>P</given-names></name><name><surname>Murray</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Phosphocreatine restores high-energy phosphates in ischemic myocardium: implication for off-pump cardiac revascularization</article-title><source>Journal of the American College of Surgeons</source><volume>197</volume><fpage>786</fpage><lpage>791</lpage><pub-id pub-id-type="doi">10.1016/j.jamcollsurg.2003.05.001</pub-id><pub-id pub-id-type="pmid">14585415</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pullen</surname><given-names>AB</given-names></name><name><surname>Kain</surname><given-names>V</given-names></name><name><surname>Serhan</surname><given-names>CN</given-names></name><name><surname>Halade</surname><given-names>GV</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Molecular and cellular differences in cardiac repair of male and female mice</article-title><source>Journal of the American Heart Association</source><volume>9</volume><elocation-id>e015672</elocation-id><pub-id pub-id-type="doi">10.1161/JAHA.119.015672</pub-id><pub-id pub-id-type="pmid">32295449</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qaed</surname><given-names>E</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Almoiliqy</surname><given-names>M</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Chu</surname><given-names>P</given-names></name><name><surname>Alademi</surname><given-names>S</given-names></name><name><surname>Alademi</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Alshwmi</surname><given-names>M</given-names></name><name><surname>Al-Azab</surname><given-names>M</given-names></name><name><surname>Ahsan</surname><given-names>A</given-names></name><name><surname>Mahdi</surname><given-names>S</given-names></name><name><surname>Han</surname><given-names>G</given-names></name><name><surname>Niu</surname><given-names>M</given-names></name><name><surname>Ali</surname><given-names>A</given-names></name><name><surname>Shopit</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Qaid</surname><given-names>A</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Peng</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Phosphocreatine improves cardiac dysfunction by normalizing mitochondrial respiratory function through JAK2/STAT3 signaling pathway in vivo and in vitro</article-title><source>Oxidative Medicine and Cellular Longevity</source><volume>2019</volume><elocation-id>6521218</elocation-id><pub-id pub-id-type="doi">10.1155/2019/6521218</pub-id><pub-id pub-id-type="pmid">31885809</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rice</surname><given-names>T</given-names></name><name><surname>Zannini</surname><given-names>E</given-names></name><name><surname>K Arendt</surname><given-names>E</given-names></name><name><surname>Coffey</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A review of polyols - biotechnological production, food applications, regulation, labeling and health effects</article-title><source>Critical Reviews in Food Science and Nutrition</source><volume>60</volume><fpage>2034</fpage><lpage>2051</lpage><pub-id pub-id-type="doi">10.1080/10408398.2019.1625859</pub-id><pub-id pub-id-type="pmid">31210053</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>J</given-names></name><name><surname>Kinoshita</surname><given-names>K</given-names></name><name><surname>Sakurai</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Elevated blood acetoacetate levels reduce major adverse cardiac and cerebrovascular events risk in acute myocardial infarction</article-title><source>Open Medicine</source><volume>18</volume><elocation-id>20230793</elocation-id><pub-id pub-id-type="doi">10.1515/med-2023-0793</pub-id><pub-id pub-id-type="pmid">37693839</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schlicker</surname><given-names>L</given-names></name><name><surname>Szebenyi</surname><given-names>DME</given-names></name><name><surname>Ortiz</surname><given-names>SR</given-names></name><name><surname>Heinz</surname><given-names>A</given-names></name><name><surname>Hiller</surname><given-names>K</given-names></name><name><surname>Field</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Unexpected roles for ADH1 and SORD in catalyzing the final step of erythritol biosynthesis</article-title><source>The Journal of Biological Chemistry</source><volume>294</volume><fpage>16095</fpage><lpage>16108</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA119.009049</pub-id><pub-id pub-id-type="pmid">31511322</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname><given-names>R</given-names></name><name><surname>Kelm</surname><given-names>M</given-names></name><name><surname>Heusch</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Nitric oxide in myocardial ischemia/reperfusion injury</article-title><source>Cardiovascular Research</source><volume>61</volume><fpage>402</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1016/j.cardiores.2003.09.019</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selvaraj</surname><given-names>S</given-names></name><name><surname>Kelly</surname><given-names>DP</given-names></name><name><surname>Margulies</surname><given-names>KB</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Implications of altered ketone metabolism and therapeutic ketosis in heart failure</article-title><source>Circulation</source><volume>141</volume><fpage>1800</fpage><lpage>1812</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.119.045033</pub-id><pub-id pub-id-type="pmid">32479196</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seth</surname><given-names>D</given-names></name><name><surname>Hess</surname><given-names>DT</given-names></name><name><surname>Hausladen</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Y-J</given-names></name><name><surname>Stamler</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A multiplex enzymatic machinery for cellular protein S-nitrosylation</article-title><source>Molecular Cell</source><volume>69</volume><fpage>451</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2017.12.025</pub-id><pub-id pub-id-type="pmid">29358078</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seth</surname><given-names>P</given-names></name><name><surname>Hausladen</surname><given-names>A</given-names></name><name><surname>Premont</surname><given-names>RT</given-names></name><name><surname>Stamler</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Protocol for preparing Thiopropyl Sepharose resin used for capturing S-nitrosylated proteins</article-title><source>STAR Protocols</source><volume>4</volume><elocation-id>102430</elocation-id><pub-id pub-id-type="doi">10.1016/j.xpro.2023.102430</pub-id><pub-id pub-id-type="pmid">37925633</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharov</surname><given-names>VG</given-names></name><name><surname>Afonskaya</surname><given-names>NI</given-names></name><name><surname>Ruda</surname><given-names>MY</given-names></name><name><surname>Cherpachenko</surname><given-names>NM</given-names></name><name><surname>Markosyan</surname><given-names>RA</given-names></name><name><surname>Shepeleva</surname><given-names>II</given-names></name><name><surname>Samarenko</surname><given-names>MB</given-names></name><name><surname>Saks</surname><given-names>VA</given-names></name></person-group><year iso-8601-date="1986">1986</year><article-title>Protection of ischemic myocardium by exogenous phosphocreatine (neoton): pharmacokinetics of phosphocreatine, reduction of infarct size, stabilization of sarcolemma of ischemic cardiomyocytes, and antithrombotic action</article-title><source>Biochemical Medicine and Metabolic Biology</source><volume>35</volume><fpage>101</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1016/0885-4505(86)90064-2</pub-id><pub-id pub-id-type="pmid">3778674</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shioura</surname><given-names>KM</given-names></name><name><surname>Geenen</surname><given-names>DL</given-names></name><name><surname>Goldspink</surname><given-names>PH</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Sex-related changes in cardiac function following myocardial infarction in mice</article-title><source>American Journal of Physiology. Regulatory, Integrative and Comparative Physiology</source><volume>295</volume><fpage>R528</fpage><lpage>R534</lpage><pub-id pub-id-type="doi">10.1152/ajpregu.90342.2008</pub-id><pub-id pub-id-type="pmid">18550865</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siddiqi</surname><given-names>N</given-names></name><name><surname>Neil</surname><given-names>C</given-names></name><name><surname>Bruce</surname><given-names>M</given-names></name><name><surname>MacLennan</surname><given-names>G</given-names></name><name><surname>Cotton</surname><given-names>S</given-names></name><name><surname>Papadopoulou</surname><given-names>S</given-names></name><name><surname>Feelisch</surname><given-names>M</given-names></name><name><surname>Bunce</surname><given-names>N</given-names></name><name><surname>Lim</surname><given-names>PO</given-names></name><name><surname>Hildick-Smith</surname><given-names>D</given-names></name><name><surname>Horowitz</surname><given-names>J</given-names></name><name><surname>Madhani</surname><given-names>M</given-names></name><name><surname>Boon</surname><given-names>N</given-names></name><name><surname>Dawson</surname><given-names>D</given-names></name><name><surname>Kaski</surname><given-names>JC</given-names></name><name><surname>Frenneaux</surname><given-names>M</given-names></name><collab>NIAMI investigators</collab></person-group><year iso-8601-date="2014">2014</year><article-title>Intravenous sodium nitrite in acute ST-elevation myocardial infarction: a randomized controlled trial (NIAMI)</article-title><source>European Heart Journal</source><volume>35</volume><fpage>1255</fpage><lpage>1262</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehu096</pub-id><pub-id pub-id-type="pmid">24639423</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siragusa</surname><given-names>M</given-names></name><name><surname>Thöle</surname><given-names>J</given-names></name><name><surname>Bibli</surname><given-names>S-I</given-names></name><name><surname>Luck</surname><given-names>B</given-names></name><name><surname>Loot</surname><given-names>AE</given-names></name><name><surname>de Silva</surname><given-names>K</given-names></name><name><surname>Wittig</surname><given-names>I</given-names></name><name><surname>Heidler</surname><given-names>J</given-names></name><name><surname>Stingl</surname><given-names>H</given-names></name><name><surname>Randriamboavonjy</surname><given-names>V</given-names></name><name><surname>Kohlstedt</surname><given-names>K</given-names></name><name><surname>Brüne</surname><given-names>B</given-names></name><name><surname>Weigert</surname><given-names>A</given-names></name><name><surname>Fisslthaler</surname><given-names>B</given-names></name><name><surname>Fleming</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Nitric oxide maintains endothelial redox homeostasis through PKM2 inhibition</article-title><source>The EMBO Journal</source><volume>38</volume><elocation-id>e100938</elocation-id><pub-id pub-id-type="doi">10.15252/embj.2018100938</pub-id><pub-id pub-id-type="pmid">31328803</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snorek</surname><given-names>M</given-names></name><name><surname>Hodyc</surname><given-names>D</given-names></name><name><surname>Sedivý</surname><given-names>V</given-names></name><name><surname>Durišová</surname><given-names>J</given-names></name><name><surname>Skoumalová</surname><given-names>A</given-names></name><name><surname>Wilhelm</surname><given-names>J</given-names></name><name><surname>Neckář</surname><given-names>J</given-names></name><name><surname>Kolář</surname><given-names>F</given-names></name><name><surname>Herget</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Short-term fasting reduces the extent of myocardial infarction and incidence of reperfusion arrhythmias in rats</article-title><source>Physiological Research</source><volume>61</volume><fpage>567</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.33549/physiolres.932338</pub-id><pub-id pub-id-type="pmid">23098657</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stomberski</surname><given-names>CT</given-names></name><name><surname>Zhou</surname><given-names>HL</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>van den Akker</surname><given-names>F</given-names></name><name><surname>Stamler</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Molecular recognition of <italic>S</italic>-nitrosothiol substrate by its cognate protein denitrosylase</article-title><source>The Journal of Biological Chemistry</source><volume>294</volume><fpage>1568</fpage><lpage>1578</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA118.004947</pub-id><pub-id pub-id-type="pmid">30538128</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stomberski</surname><given-names>CT</given-names></name><name><surname>Venetos</surname><given-names>NM</given-names></name><name><surname>Zhou</surname><given-names>HL</given-names></name><name><surname>Qian</surname><given-names>Z</given-names></name><name><surname>Collison</surname><given-names>BR</given-names></name><name><surname>Field</surname><given-names>SJ</given-names></name><name><surname>Premont</surname><given-names>RT</given-names></name><name><surname>Stamler</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>A multienzyme S-nitrosylation cascade regulates cholesterol homeostasis</article-title><source>Cell Reports</source><volume>41</volume><elocation-id>111538</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2022.111538</pub-id><pub-id pub-id-type="pmid">36288700</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>GW</given-names></name><name><surname>Selker</surname><given-names>HP</given-names></name><name><surname>Thiele</surname><given-names>H</given-names></name><name><surname>Patel</surname><given-names>MR</given-names></name><name><surname>Udelson</surname><given-names>JE</given-names></name><name><surname>Ohman</surname><given-names>EM</given-names></name><name><surname>Maehara</surname><given-names>A</given-names></name><name><surname>Eitel</surname><given-names>I</given-names></name><name><surname>Granger</surname><given-names>CB</given-names></name><name><surname>Jenkins</surname><given-names>PL</given-names></name><name><surname>Nichols</surname><given-names>M</given-names></name><name><surname>Ben-Yehuda</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Relationship between infarct size and outcomes following primary PCI: patient-level analysis from 10 randomized trials</article-title><source>Journal of the American College of Cardiology</source><volume>67</volume><fpage>1674</fpage><lpage>1683</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2016.01.069</pub-id><pub-id pub-id-type="pmid">27056772</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Morgan</surname><given-names>M</given-names></name><name><surname>Shen</surname><given-names>RF</given-names></name><name><surname>Steenbergen</surname><given-names>C</given-names></name><name><surname>Murphy</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Preconditioning results in S-nitrosylation of proteins involved in regulation of mitochondrial energetics and calcium transport</article-title><source>Circulation Research</source><volume>101</volume><fpage>1155</fpage><lpage>1163</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.107.155879</pub-id><pub-id pub-id-type="pmid">17916778</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Sha</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Hu</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>S</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Gu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Gu</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Pu</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>B</given-names></name><name><surname>Xie</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Ji</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Mitochondrial GSNOR alleviates cardiac dysfunction via ANT1 denitrosylation</article-title><source>Circulation Research</source><volume>133</volume><fpage>220</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.123.322654</pub-id><pub-id pub-id-type="pmid">37377022</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tao</surname><given-names>L</given-names></name><name><surname>Gao</surname><given-names>E</given-names></name><name><surname>Bryan</surname><given-names>NS</given-names></name><name><surname>Qu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>HR</given-names></name><name><surname>Hu</surname><given-names>A</given-names></name><name><surname>Christopher</surname><given-names>TA</given-names></name><name><surname>Lopez</surname><given-names>BL</given-names></name><name><surname>Yodoi</surname><given-names>J</given-names></name><name><surname>Koch</surname><given-names>WJ</given-names></name><name><surname>Feelisch</surname><given-names>M</given-names></name><name><surname>Ma</surname><given-names>XL</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Cardioprotective effects of thioredoxin in myocardial ischemia and the reperfusion role of S-nitrosation</article-title><source>PNAS</source><volume>101</volume><fpage>11471</fpage><lpage>11476</lpage><pub-id pub-id-type="doi">10.1073/pnas.0402941101</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>TeSlaa</surname><given-names>T</given-names></name><name><surname>Ralser</surname><given-names>M</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Rabinowitz</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>The pentose phosphate pathway in health and disease</article-title><source>Nature Metabolism</source><volume>5</volume><fpage>1275</fpage><lpage>1289</lpage><pub-id pub-id-type="doi">10.1038/s42255-023-00863-2</pub-id><pub-id pub-id-type="pmid">37612403</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Touster</surname><given-names>O</given-names></name><name><surname>Harwell</surname><given-names>SO</given-names></name></person-group><year iso-8601-date="1958">1958</year><article-title>The isolation of L-arabitol from pentosuric urine</article-title><source>The Journal of Biological Chemistry</source><volume>230</volume><fpage>1031</fpage><lpage>1041</lpage><pub-id pub-id-type="pmid">13525419</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsao</surname><given-names>CW</given-names></name><name><surname>Aday</surname><given-names>AW</given-names></name><name><surname>Almarzooq</surname><given-names>ZI</given-names></name><name><surname>Anderson</surname><given-names>CAM</given-names></name><name><surname>Arora</surname><given-names>P</given-names></name><name><surname>Avery</surname><given-names>CL</given-names></name><name><surname>Baker-Smith</surname><given-names>CM</given-names></name><name><surname>Beaton</surname><given-names>AZ</given-names></name><name><surname>Boehme</surname><given-names>AK</given-names></name><name><surname>Buxton</surname><given-names>AE</given-names></name><name><surname>Commodore-Mensah</surname><given-names>Y</given-names></name><name><surname>Elkind</surname><given-names>MSV</given-names></name><name><surname>Evenson</surname><given-names>KR</given-names></name><name><surname>Eze-Nliam</surname><given-names>C</given-names></name><name><surname>Fugar</surname><given-names>S</given-names></name><name><surname>Generoso</surname><given-names>G</given-names></name><name><surname>Heard</surname><given-names>DG</given-names></name><name><surname>Hiremath</surname><given-names>S</given-names></name><name><surname>Ho</surname><given-names>JE</given-names></name><name><surname>Kalani</surname><given-names>R</given-names></name><name><surname>Kazi</surname><given-names>DS</given-names></name><name><surname>Ko</surname><given-names>D</given-names></name><name><surname>Levine</surname><given-names>DA</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Magnani</surname><given-names>JW</given-names></name><name><surname>Michos</surname><given-names>ED</given-names></name><name><surname>Mussolino</surname><given-names>ME</given-names></name><name><surname>Navaneethan</surname><given-names>SD</given-names></name><name><surname>Parikh</surname><given-names>NI</given-names></name><name><surname>Poudel</surname><given-names>R</given-names></name><name><surname>Rezk-Hanna</surname><given-names>M</given-names></name><name><surname>Roth</surname><given-names>GA</given-names></name><name><surname>Shah</surname><given-names>NS</given-names></name><name><surname>St-Onge</surname><given-names>MP</given-names></name><name><surname>Thacker</surname><given-names>EL</given-names></name><name><surname>Virani</surname><given-names>SS</given-names></name><name><surname>Voeks</surname><given-names>JH</given-names></name><name><surname>Wang</surname><given-names>NY</given-names></name><name><surname>Wong</surname><given-names>ND</given-names></name><name><surname>Wong</surname><given-names>SS</given-names></name><name><surname>Yaffe</surname><given-names>K</given-names></name><name><surname>Martin</surname><given-names>SS</given-names></name><collab>American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee</collab></person-group><year iso-8601-date="2023">2023</year><article-title>Heart disease and stroke statistics-2023 update: a report from the american heart association</article-title><source>Circulation</source><volume>147</volume><fpage>e93</fpage><lpage>e621</lpage><pub-id pub-id-type="doi">10.1161/CIR.0000000000001123</pub-id><pub-id pub-id-type="pmid">36695182</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uchihashi</surname><given-names>M</given-names></name><name><surname>Hoshino</surname><given-names>A</given-names></name><name><surname>Okawa</surname><given-names>Y</given-names></name><name><surname>Ariyoshi</surname><given-names>M</given-names></name><name><surname>Kaimoto</surname><given-names>S</given-names></name><name><surname>Tateishi</surname><given-names>S</given-names></name><name><surname>Ono</surname><given-names>K</given-names></name><name><surname>Yamanaka</surname><given-names>R</given-names></name><name><surname>Hato</surname><given-names>D</given-names></name><name><surname>Fushimura</surname><given-names>Y</given-names></name><name><surname>Honda</surname><given-names>S</given-names></name><name><surname>Fukai</surname><given-names>K</given-names></name><name><surname>Higuchi</surname><given-names>Y</given-names></name><name><surname>Ogata</surname><given-names>T</given-names></name><name><surname>Iwai-Kanai</surname><given-names>E</given-names></name><name><surname>Matoba</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Cardiac-Specific Bdh1 overexpression ameliorates oxidative stress and cardiac remodeling in pressure overload-induced heart failure</article-title><source>Circulation. Heart Failure</source><volume>10</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1161/CIRCHEARTFAILURE.117.004417</pub-id><pub-id pub-id-type="pmid">29242353</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verhoeven</surname><given-names>NM</given-names></name><name><surname>Huck</surname><given-names>JHJ</given-names></name><name><surname>Roos</surname><given-names>B</given-names></name><name><surname>Struys</surname><given-names>EA</given-names></name><name><surname>Salomons</surname><given-names>GS</given-names></name><name><surname>Douwes</surname><given-names>AC</given-names></name><name><surname>van der Knaap</surname><given-names>MS</given-names></name><name><surname>Jakobs</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Transaldolase deficiency: liver cirrhosis associated with a new inborn error in the pentose phosphate pathway</article-title><source>American Journal of Human Genetics</source><volume>68</volume><fpage>1086</fpage><lpage>1092</lpage><pub-id pub-id-type="doi">10.1086/320108</pub-id><pub-id pub-id-type="pmid">11283793</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wamelink</surname><given-names>MMC</given-names></name><name><surname>Williams</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><source>In Physician’s Guide to the Diagnosis, Treatment, and Follow-Up of Inherited Metabolic Diseases</source><publisher-name>Springer International Publishing</publisher-name><pub-id pub-id-type="doi">10.1007/978-3-030-67727-5_40</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Chatterjee</surname><given-names>D</given-names></name><name><surname>Jeon</surname><given-names>HY</given-names></name><name><surname>Akerman</surname><given-names>M</given-names></name><name><surname>Vander Heiden</surname><given-names>MG</given-names></name><name><surname>Cantley</surname><given-names>LC</given-names></name><name><surname>Krainer</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Exon-centric regulation of pyruvate kinase M alternative splicing via mutually exclusive exons</article-title><source>Journal of Molecular Cell Biology</source><volume>4</volume><fpage>79</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1093/jmcb/mjr030</pub-id><pub-id pub-id-type="pmid">22044881</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C-X</given-names></name><name><surname>Guo</surname><given-names>J-J</given-names></name><name><surname>Di</surname><given-names>A-J</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>W-M</given-names></name><name><surname>Cheng</surname><given-names>A-R</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Si</surname><given-names>R-C</given-names></name><name><surname>Lan</surname><given-names>T-S</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>H-L</given-names></name><name><surname>Yan</surname><given-names>G-L</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The Protective Effect of Cx43 protein-mediated phosphocreatine on myocardial ischemia/reperfusion injury</article-title><source>Cardiology Research and Practice</source><volume>2021</volume><elocation-id>8838151</elocation-id><pub-id pub-id-type="doi">10.1155/2021/8838151</pub-id><pub-id pub-id-type="pmid">33552599</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Dasgupta</surname><given-names>S</given-names></name><name><surname>Niewold</surname><given-names>EL</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Tan</surname><given-names>L</given-names></name><name><surname>Ferdous</surname><given-names>A</given-names></name><name><surname>Lorenzi</surname><given-names>PL</given-names></name><name><surname>Rothermel</surname><given-names>BA</given-names></name><name><surname>Gillette</surname><given-names>TG</given-names></name><name><surname>Adams</surname><given-names>CM</given-names></name><name><surname>Scherer</surname><given-names>PE</given-names></name><name><surname>Hill</surname><given-names>JA</given-names></name><name><surname>Wang</surname><given-names>ZV</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>ATF4 protects the heart from failure by antagonizing oxidative stress</article-title><source>Circulation Research</source><volume>131</volume><fpage>91</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.122.321050</pub-id><pub-id pub-id-type="pmid">35574856</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2019">2019a</year><article-title>GWAS Atlas PheWAS</article-title><ext-link ext-link-type="uri" xlink:href="https://atlas.ctglab.nl/PheWAS">https://atlas.ctglab.nl/PheWAS</ext-link><date-in-citation iso-8601-date="2024-11-20">November 20, 2024</date-in-citation></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>K</given-names></name><name><surname>Stringer</surname><given-names>S</given-names></name><name><surname>Frei</surname><given-names>O</given-names></name><name><surname>Umićević Mirkov</surname><given-names>M</given-names></name><name><surname>de Leeuw</surname><given-names>C</given-names></name><name><surname>Polderman</surname><given-names>TJC</given-names></name><name><surname>van der Sluis</surname><given-names>S</given-names></name><name><surname>Andreassen</surname><given-names>OA</given-names></name><name><surname>Neale</surname><given-names>BM</given-names></name><name><surname>Posthuma</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2019">2019b</year><article-title>A global overview of pleiotropy and genetic architecture in complex traits</article-title><source>Nature Genetics</source><volume>51</volume><fpage>1339</fpage><lpage>1348</lpage><pub-id pub-id-type="doi">10.1038/s41588-019-0481-0</pub-id><pub-id pub-id-type="pmid">31427789</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whalen</surname><given-names>EJ</given-names></name><name><surname>Foster</surname><given-names>MW</given-names></name><name><surname>Matsumoto</surname><given-names>A</given-names></name><name><surname>Ozawa</surname><given-names>K</given-names></name><name><surname>Violin</surname><given-names>JD</given-names></name><name><surname>Que</surname><given-names>LG</given-names></name><name><surname>Nelson</surname><given-names>CD</given-names></name><name><surname>Benhar</surname><given-names>M</given-names></name><name><surname>Keys</surname><given-names>JR</given-names></name><name><surname>Rockman</surname><given-names>HA</given-names></name><name><surname>Koch</surname><given-names>WJ</given-names></name><name><surname>Daaka</surname><given-names>Y</given-names></name><name><surname>Lefkowitz</surname><given-names>RJ</given-names></name><name><surname>Stamler</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Regulation of beta-adrenergic receptor signaling by S-nitrosylation of G-protein-coupled receptor kinase 2</article-title><source>Cell</source><volume>129</volume><fpage>511</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.02.046</pub-id><pub-id pub-id-type="pmid">17482545</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Witkowski</surname><given-names>M</given-names></name><name><surname>Nemet</surname><given-names>I</given-names></name><name><surname>Alamri</surname><given-names>H</given-names></name><name><surname>Wilcox</surname><given-names>J</given-names></name><name><surname>Gupta</surname><given-names>N</given-names></name><name><surname>Nimer</surname><given-names>N</given-names></name><name><surname>Haghikia</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>XS</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Saha</surname><given-names>PP</given-names></name><name><surname>Demuth</surname><given-names>I</given-names></name><name><surname>König</surname><given-names>M</given-names></name><name><surname>Steinhagen-Thiessen</surname><given-names>E</given-names></name><name><surname>Cajka</surname><given-names>T</given-names></name><name><surname>Fiehn</surname><given-names>O</given-names></name><name><surname>Landmesser</surname><given-names>U</given-names></name><name><surname>Tang</surname><given-names>WHW</given-names></name><name><surname>Hazen</surname><given-names>SL</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>The artificial sweetener erythritol and cardiovascular event risk</article-title><source>Nature Medicine</source><volume>29</volume><fpage>710</fpage><lpage>718</lpage><pub-id pub-id-type="doi">10.1038/s41591-023-02223-9</pub-id><pub-id pub-id-type="pmid">36849732</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Witkowski</surname><given-names>M</given-names></name><name><surname>Nemet</surname><given-names>I</given-names></name><name><surname>Li</surname><given-names>XS</given-names></name><name><surname>Wilcox</surname><given-names>J</given-names></name><name><surname>Ferrell</surname><given-names>M</given-names></name><name><surname>Alamri</surname><given-names>H</given-names></name><name><surname>Gupta</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Tang</surname><given-names>WHW</given-names></name><name><surname>Hazen</surname><given-names>SL</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Xylitol is prothrombotic and associated with cardiovascular risk</article-title><source>European Heart Journal</source><volume>45</volume><fpage>2439</fpage><lpage>2452</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehae244</pub-id><pub-id pub-id-type="pmid">38842092</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>An</surname><given-names>W</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Treatment with D-β-hydroxybutyrate protects heart from ischemia/reperfusion injury in mice</article-title><source>European Journal of Pharmacology</source><volume>829</volume><fpage>121</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2018.04.019</pub-id><pub-id pub-id-type="pmid">29679541</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Xing</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Protective effects of phosphocreatine administered post-treatment combined with ischemic post-conditioning on rat hearts with myocardial ischemia/reperfusion injury</article-title><source>Journal of Clinical Medicine Research</source><volume>7</volume><fpage>242</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.14740/jocmr2087w</pub-id><pub-id pub-id-type="pmid">25699120</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Hess</surname><given-names>DT</given-names></name><name><surname>Reynolds</surname><given-names>JD</given-names></name><name><surname>Stamler</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Hemoglobin S-nitrosylation plays an essential role in cardioprotection</article-title><source>The Journal of Clinical Investigation</source><volume>126</volume><fpage>4654</fpage><lpage>4658</lpage><pub-id pub-id-type="doi">10.1172/JCI90425</pub-id><pub-id pub-id-type="pmid">27841756</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>HL</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Anand</surname><given-names>P</given-names></name><name><surname>Stomberski</surname><given-names>CT</given-names></name><name><surname>Qian</surname><given-names>Z</given-names></name><name><surname>Hausladen</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Rhee</surname><given-names>EP</given-names></name><name><surname>Parikh</surname><given-names>SM</given-names></name><name><surname>Karumanchi</surname><given-names>SA</given-names></name><name><surname>Stamler</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Metabolic reprogramming by the S-nitroso-CoA reductase system protects against kidney injury</article-title><source>Nature</source><volume>565</volume><fpage>96</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0749-z</pub-id><pub-id pub-id-type="pmid">30487609</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>HL</given-names></name><name><surname>Grimmett</surname><given-names>ZW</given-names></name><name><surname>Venetos</surname><given-names>NM</given-names></name><name><surname>Stomberski</surname><given-names>CT</given-names></name><name><surname>Qian</surname><given-names>Z</given-names></name><name><surname>McLaughlin</surname><given-names>PJ</given-names></name><name><surname>Bansal</surname><given-names>PK</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Reynolds</surname><given-names>JD</given-names></name><name><surname>Premont</surname><given-names>RT</given-names></name><name><surname>Stamler</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2023">2023a</year><article-title>An enzyme that selectively S-nitrosylates proteins to regulate insulin signaling</article-title><source>Cell</source><volume>186</volume><fpage>5812</fpage><lpage>5825</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2023.11.009</pub-id><pub-id pub-id-type="pmid">38056462</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>H-L</given-names></name><name><surname>Hausladen</surname><given-names>A</given-names></name><name><surname>Anand</surname><given-names>P</given-names></name><name><surname>Rajavel</surname><given-names>M</given-names></name><name><surname>Stomberski</surname><given-names>CT</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Premont</surname><given-names>RT</given-names></name><name><surname>Greenlee</surname><given-names>WJ</given-names></name><name><surname>van den Akker</surname><given-names>F</given-names></name><name><surname>Stamler</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2023">2023b</year><article-title>Identification of a selective SCoR2 inhibitor that protects against acute kidney injury</article-title><source>Journal of Medicinal Chemistry</source><volume>66</volume><fpage>5657</fpage><lpage>5668</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.2c02089</pub-id><pub-id pub-id-type="pmid">37027003</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Zoccarato</surname><given-names>A</given-names></name><name><surname>Smyrnias</surname><given-names>I</given-names></name><name><surname>Reumiller</surname><given-names>CM</given-names></name><name><surname>Hafstad</surname><given-names>AD</given-names></name><name><surname>Chong</surname><given-names>M</given-names></name><name><surname>Richards</surname><given-names>DA</given-names></name><name><surname>Santos</surname><given-names>CXC</given-names></name><name><surname>Visnagri</surname><given-names>A</given-names></name><name><surname>Bromage</surname><given-names>DI</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Sawyer</surname><given-names>G</given-names></name><name><surname>Thompson</surname><given-names>R</given-names></name><name><surname>Shah</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>NRF2 Activation in the Heart Induces Glucose Metabolic Reprogramming and Mediates Cardioprotection via Upregulation of the Pentose Phosphate Pathway</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2023.05.12.540342</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>Z</given-names></name><name><surname>Sasaguri</surname><given-names>S</given-names></name><name><surname>Rajesh</surname><given-names>KG</given-names></name><name><surname>Suzuki</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>dl-3-Hydroxybutyrate administration prevents myocardial damage after coronary occlusion in rat hearts</article-title><source>American Journal of Physiology. Heart and Circulatory Physiology</source><volume>283</volume><fpage>H1968</fpage><lpage>H1974</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00250.2002</pub-id><pub-id pub-id-type="pmid">12384475</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuurbier</surname><given-names>CJ</given-names></name><name><surname>Bertrand</surname><given-names>L</given-names></name><name><surname>Beauloye</surname><given-names>CR</given-names></name><name><surname>Andreadou</surname><given-names>I</given-names></name><name><surname>Ruiz-Meana</surname><given-names>M</given-names></name><name><surname>Jespersen</surname><given-names>NR</given-names></name><name><surname>Kula-Alwar</surname><given-names>D</given-names></name><name><surname>Prag</surname><given-names>HA</given-names></name><name><surname>Eric Botker</surname><given-names>H</given-names></name><name><surname>Dambrova</surname><given-names>M</given-names></name><name><surname>Montessuit</surname><given-names>C</given-names></name><name><surname>Kaambre</surname><given-names>T</given-names></name><name><surname>Liepinsh</surname><given-names>E</given-names></name><name><surname>Brookes</surname><given-names>PS</given-names></name><name><surname>Krieg</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cardiac metabolism as a driver and therapeutic target of myocardial infarction</article-title><source>Journal of Cellular and Molecular Medicine</source><volume>24</volume><fpage>5937</fpage><lpage>5954</lpage><pub-id pub-id-type="doi">10.1111/jcmm.15180</pub-id><pub-id pub-id-type="pmid">32384583</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><table-wrap id="app1keyresource" position="anchor"><label>Appendix 1—key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Strain, strain background (mouse, male and female)</td><td align="left" valign="bottom">Akr1a1<sup>tm1Dgen</sup>, mixed 129x C57BL/6</td><td align="left" valign="bottom">Deltagen;<break/><xref ref-type="bibr" rid="bib102">Zhou et al., 2019</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Referred to as SCoR2-KO</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>E. coli</italic>)</td><td align="left" valign="bottom">OneShot Omnima competent cells</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">C8540-03</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>E. coli</italic>)</td><td align="left" valign="bottom">BL21-CodonPlus competent cells</td><td align="left" valign="bottom">Agilent</td><td align="char" char="." valign="bottom">230240</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (human)</td><td align="left" valign="bottom">HEK293</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">CRL-1573</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Transfected construct (human)</td><td align="left" valign="bottom">BDH1 cDNA in pDONR223</td><td align="left" valign="bottom">DNAsu</td><td align="left" valign="bottom">Clone: HsCD00352477</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Transfected construct (human)</td><td align="left" valign="bottom">BDH1 cDNA in pcDNA-DEST40</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Mammalian expression, V5 epitope tag</td></tr><tr><td align="left" valign="bottom">Transfected construct (human)</td><td align="left" valign="bottom">BDH1 C115S cDNA in pcDNA-DEST40</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Mammalian expression, C115S mutant, V5 epitope tag</td></tr><tr><td align="left" valign="bottom">Biological sample (human)</td><td align="left" valign="bottom">Post-mortem myocardium</td><td align="left" valign="bottom">Duke Human Heart Repository</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-AKR1A1/SCoR2 (rabbit polyclonal)</td><td align="left" valign="bottom">Proteintech</td><td align="char" char="ndash" valign="bottom">15054-1-AP</td><td align="left" valign="bottom">10 µg for IP; 1:1000 for blotting</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-PKM2 (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">D78A4</td><td align="left" valign="bottom">1:1000 for blotting</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-p97 (mouse monoclonal)</td><td align="left" valign="bottom">Fitzgerald</td><td align="char" char="." valign="bottom">10R-P104A</td><td align="left" valign="bottom">1:1000 for blotting</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-BDH1 (rabbit polyclonal)</td><td align="left" valign="bottom">Proteintech</td><td align="char" char="ndash" valign="bottom">15417-1-AP</td><td align="left" valign="bottom">1:1000 for blotting</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">AKR1A1 cDNA in pET21b</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib1">Anand et al., 2014</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Bacterial expression, CT 6xHis tag for purification</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">forward: 5′-<named-content content-type="sequence">CGTCCAGCTCAATGTCTCCAGCAGCGAAGAGG</named-content>reverse: 5′-<named-content content-type="sequence">CCTCTTCGCTGCTGGAGACATTGAGCTGGACG</named-content></td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom"/><td align="left" valign="bottom">PCR primers for human SCoR2 C115S mutagenesis</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">forward: 5′-<named-content content-type="sequence">GCAGAGATTCAACAAGTCTCCCCTC</named-content>mutant reverse: 5′-<named-content content-type="sequence">GGGCCAGCTCATTCCTCCCACTCAT</named-content>wild-type reverse: 5′-<named-content content-type="sequence">AGCTAAGGCTCCGAGCAGTGCTAAC</named-content></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib102">Zhou et al., 2019</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">PCR primers for mouse SCoR2 (Akr1a1) genotyping</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">SCoR2/AKR1A1-6xHis</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib1">Anand et al., 2014</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Bacterial expression, CT 6xHis tag for purification</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">QuikChange II site-directed mutagenesis kit</td><td align="left" valign="bottom">Agilent</td><td align="char" char="." valign="bottom">200523</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Troponin-1 ELISA kit</td><td align="left" valign="bottom">Kamiya</td><td align="left" valign="bottom">KT-470</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">LDH activity assay</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">MAK066-1KT</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">NADP/NADPH-Glo assay</td><td align="left" valign="bottom">Promega</td><td align="left" valign="bottom">G9071</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Cyclic GMP Complete ELISA kit</td><td align="left" valign="bottom">Enzo</td><td align="left" valign="bottom">ADI-900-164</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Thiopropyl-Sepharose</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib73">Seth et al., 2023</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">GraphPad Prism statistics software (v9)</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com/">https://www.graphpad.com/</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr></tbody></table></table-wrap></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.106601.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Emoto</surname><given-names>Noriaki</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Kobe Pharmaceutical University</institution><country>Japan</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Compelling</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Valuable</kwd></kwd-group></front-stub><body><p>This study provides new and interesting findings that SCoR2 acts as a denitrosylase to control cardioprotective metabolic reprogramming and prevent injury following ischemia/reperfusion. The <bold>compelling</bold> evidence is supported by a novel multi-omics approach, but questions remain regarding the stability and human relevance of BDH1 as well as the sufficiency of SCoR2. Overall, the work will be of interest to cardiovascular researchers and provides <bold>valuable</bold> information to the field, though some mechanistic aspects require further clarification.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.106601.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>This study shows a novel role for SCoR2 in regulating metabolic pathways in the heart to prevent injury following ischemia/reperfusion. It combines a new multi-omics method to determine SCoR2 mediated metabolic pathways in the heart. This paper would be of interest to cardiovascular researchers working on cardioprotective strategies following ischemic injury in the heart.</p><p>Strengths:</p><p>(1) Use of SCoR2KO mice subjected to I/R injury.</p><p>(2) Identification of multiple metabolic pathways in the heart by a novel multi-omics approach.</p><p>Comments on revisions:</p><p>Authors have addressed all concerns raised in the previous round of review. Substantial modifications have been made in response to those concerns. There are no further comments.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.106601.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>This manuscript addresses the gap in knowledge related to the cardiac function of the S-denitrosylase SNO-CoA Reductase 2 (SCoR2; product of the Akr1a1 gene). Genetic variants in SCoR2 have been linked to cardiovascular disease, yet its exact role in heart remains unclear. This paper demonstrates that mice deficient in SCoR2 show significant protection in a myocardial infarction (MI) model. SCoR2 influenced ketolytic energy production, antioxidant levels, and polyol balance through the S-nitrosylation of crucial metabolic regulators.</p><p>Strengths:</p><p>Addresses a well-defined gap in knowledge related to the cardiac function of SNO-CoA Reductase 2. Besides the in-depth case for this specific player, the manuscripts sheds more light on the links between S-nytrosylation and metabolic reprogramming in heart.</p><p>Rigorous proof of requirement through the combination of gene knockout and in vivo myocardial ischemia/reperfusion</p><p>Identification of precise Cys residue for SNO-modification of BDH1 as SCoR2 target in cardiac ketolysis</p><p>Weaknesses:</p><p>The experiments with BDH1 stability were performed in mutant 293 cells. Was there a difference in BDH1 stability in myocardial tissue or primary cardiomyocytes from SCoR2-null vs -WT mice? Same question extends to PKM2.</p><p>In the absence of tracing experiments, the cross-sectional changes in ketolysis, glycolysis or polyol intermediates presented in Figures 4 and 5 are suggestive at best. This needs to be stressed while describing and interpreting these results.</p><p>The findings from human samples with ischemic and non-ischemic cardiomyopathy do not seem immediately or linearly in line with each other and with the model proposed from the KO mice. While the correlation holds up in the non-ischemic cardiomyopathy (increased SNO-BDH1, SNO-PKM2 with decreased SCoR2 expression), how do the Authors explain the decreased SNO-BDH1 with preserved SCoR2 expression in ischemic cardiomyopathy? This seems counterintuitive as activation of ketolysis is a quite established myocardial response to the ischemic stress. It may help the overall message clarity to focus the human data part on only NICM patients.</p><p>(partially linked to the point above) an important proof that is lacking at present is the proof of sufficiency for SCoR2 in S-Nytrosylation of targets and cardiac remodeling. Does SCoR2 overexpression in heart or isolated cardiomyocytes reduce S-nitrosylation of BDH1 and other targets, undermining heart function at baseline or under stress?</p><p>Comments on revisions:</p><p>Some of my points have been addressed. However, the points related to (1) BDH1 stability effect in cardiomyocytes; (2) human relevance of SNO-BDH1; (3) SCoR2 sufficiency remain unclear. That said, this manuscript will provide useful information to the field as such.</p></body></sub-article><sub-article article-type="referee-report" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.106601.3.sa3</article-id><title-group><article-title>Reviewer #3 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>This manuscript demonstrates that mice lacking the denitrosylase enzyme SCoR2/AKR1A1 demonstrate a robust cardioprotection resulting from reprogramming of multiple metabolic pathways, revealing</p><p>widespread, coordinated metabolic regulation by SCoR2.</p><p>Strengths:</p><p>The extensive experimental evidence provided the use of the knockout model</p><p>Weaknesses:</p><p>No direct evidence for the underlying mechanism.</p><p>The mouse model used is not a tissue-specific knock-out.</p></body></sub-article><sub-article article-type="author-comment" id="sa4"><front-stub><article-id pub-id-type="doi">10.7554/eLife.106601.3.sa4</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Grimmett</surname><given-names>Zachary W</given-names></name><role specific-use="author">Author</role><aff><institution>Case Western Reserve University</institution><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Rongli</given-names></name><role specific-use="author">Author</role><aff><institution>Case Western Reserve University</institution><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Hua-Lin</given-names></name><role specific-use="author">Author</role><aff><institution>Case Western Reserve University</institution><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Qiuying</given-names></name><role specific-use="author">Author</role><aff><institution>Weill Cornell Medicine</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Miller</surname><given-names>Dawson</given-names></name><role specific-use="author">Author</role><aff><institution>Weill Cornell Medical Center</institution><addr-line><named-content content-type="city">New York City</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Qian</surname><given-names>Zhaoxia</given-names></name><role specific-use="author">Author</role><aff><institution>Case Western Reserve University</institution><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Justin</given-names></name><role specific-use="author">Author</role><aff><institution>Case Western Reserve University</institution><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Kalra</surname><given-names>Riti</given-names></name><role specific-use="author">Author</role><aff><institution>Case Western Reserve University</institution><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Gross</surname><given-names>Steven</given-names></name><role specific-use="author">Author</role><aff><institution>Weill Cornell Medicine</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Koch</surname><given-names>Walter J</given-names></name><role specific-use="author">Author</role><aff><institution>Duke University</institution><addr-line><named-content content-type="city">Durham</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Premont</surname><given-names>Richard T</given-names></name><role specific-use="author">Author</role><aff><institution>Case Western Reserve University</institution><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Stamler</surname><given-names>Jonathan S</given-names></name><role specific-use="author">Author</role><aff><institution>Case Western Reserve University</institution><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Public review):</bold></p><p>Summary:</p><p>This study shows a novel role for SCoR2 in regulating metabolic pathways in the heart to prevent injury following ischemia/reperfusion. It combines a new multi-omics method to determine SCoR2 mediated metabolic pathways in the heart. This paper would be of interest to cardiovascular researchers working on cardioprotective strategies following ischemic injury in the heart.</p><p>Strengths:</p><p>(1) Use of SCoR2KO mice subjected to I/R injury.</p><p>(2) Identification of multiple metabolic pathways in the heart by a novel multi-omics approach.</p><p>We thank the Reviewer for the positive review of our manuscript.</p><p>Weaknesses:</p><p>(1) Use of a global SCoR2KO mice is a limitation since the effects in the heart can be a combination of global loss of SCoR2.</p><p>(2) Lack of a cell type specific effect.</p></disp-quote><p>We agree that global KOs limit the cell type-specific mechanistic conclusions that can be drawn. Global knockouts are nonetheless informative in their own right and serve to identify phenotypes worthy of further study.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public review):</bold></p><p>Summary:</p><p>This manuscript addresses the gap in knowledge related to the cardiac function of the S-denitrosylase SNOCoA Reductase 2 (SCoR2; product of the Akr1a1 gene). Genetic variants in SCoR2 have been linked to cardiovascular disease, yet their exact role in the heart remains unclear. This paper demonstrates that mice deficient in SCoR2 show significant protection in a myocardial infarction (MI) model. SCoR2 influenced ketolytic energy production, antioxidant levels, and polyol balance through the S-nitrosylation of crucial metabolic regulators.</p><p>Strengths:</p><p>(1) Addresses a well-defined gap in knowledge related to the cardiac function of SNO-CoA Reductase 2. Besides the in-depth case for this specific player, the manuscript sheds more light on the links between Snitrosylation and metabolic reprogramming in the heart.</p><p>(2) Rigorous proof of requirement through the combination of gene knockout and in vivo myocardial ischemia/reperfusion.</p><p>(3) Identification of precise Cys residue for SNO-modification of BDH1 as SCoR2 target in cardiac ketolysis</p></disp-quote><p>We thank the Reviewer for their kind words.</p><disp-quote content-type="editor-comment"><p>Weaknesses:</p><p>(1) The experiments with BDH1 stability were performed in mutant 293 cells. Was there a difference in BDH1 stability in myocardial tissue or primary cardiomyocytes from SCoR2-null vs -WT mice? The same question extends to PKM2.</p></disp-quote><p>We have not assessed BDH1 stability directly in cardiomyocytes. However, S-nitrosylation increased BDH1 stability in HEK293 cells, and BDH1 expression was increased in (injured) hearts of SCoR2KO mice, together with increased SNO-BDH1.</p><p>For PKM2, there is a wealth of published evidence from us and others that S-nitrosylation does not regulate protein stability but rather inhibits tetramerization required for full activity.</p><disp-quote content-type="editor-comment"><p>(2) In the absence of tracing experiments, the cross-sectional changes in ketolysis, glycolysis, or polyol intermediates presented in Figures 4 and 5 are suggestive at best. This needs to be stressed while describing and interpreting these results.</p></disp-quote><p>We now acknowledge this limitation in the ‘Limitations’ section of the manuscript and in edits made to the text.</p><disp-quote content-type="editor-comment"><p>(3) The findings from human samples with ischemic and non-ischemic cardiomyopathy do not seem immediately or linearly in line with each other and with the model proposed from the KO mice. While the correlation holds up in the non-ischemic cardiomyopathy (increased SNO-BDH1, SNO-PKM2 with decreased SCoR2 expression), how do the authors explain the decreased SNO-BDH1 with preserved SCoR2 expression in ischemic cardiomyopathy? This seems counterintuitive as activation of ketolysis is a quite established myocardial response to ischemic stress. It may help the overall message clarity to focus the human data part on only NICM patients.</p></disp-quote><p>We find it interesting and important that SNO-BDH1 is readily detected in human heart tissue and its level is correlated to disease state. Our findings suggest conservation of this mechanism in human heart failure. However, we caution against drawing further conclusions related to NICM or ICM. Our animal model (based on a single time point) cannot faithfully recapitulate patients with chronic heart disease or differences between NICM and ICM.</p><disp-quote content-type="editor-comment"><p>(4) This is partially linked to the point above. An important proof that is lacking at present is the proof of sufficiency for SCoR2 in S-nitrosylation of targets and cardiac remodeling. Does SCoR2 overexpression in the heart or isolated cardiomyocytes reduce S-nitrosylation of BDH1 and other targets, undermining heart function at baseline or under stress?</p></disp-quote><p>The Reviewer proposes to test the effect of SCoR2 overexpression on cardioprotection. This is an interesting experiment for future study with the following caveats. First, it presupposes that native expression of SCoR2 is insufficient to control basal steady state S-nitrosylation of SNO-BDH1 and SNO-PKM2 (this does not seem to be the case). Second, overexpressed SCoR2 may be mislocalized within cells or associated with unnatural targets. Thank you.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Public review):</bold></p><p>Summary:</p><p>This manuscript demonstrates that mice lacking the denitrosylase enzyme SCoR2/AKR1A1 demonstrate a robust cardioprotection resulting from reprogramming of multiple metabolic pathways, revealing widespread, coordinated metabolic regulation by SCoR2.</p><p>Strengths:</p><p>(1) The extensive experimental evidence.</p><p>(2) The use of the knockout model.</p></disp-quote><p>We thank the Reviewer for identifying strengths in our work.</p><disp-quote content-type="editor-comment"><p>Weaknesses:</p><p>(1) The connection of direct evidence for the mechanism.</p></disp-quote><p>We believe we have identified a novel mechanism for cardioprotection entailing coordinate reprogramming of multiple metabolic pathways and suggesting a widescale role for SCoR2 in metabolic regulation. This is the key message we convey. While genetic dissection of individual pathways may be worthwhile, these investigations will have their own limitations.</p><disp-quote content-type="editor-comment"><p>(2) The mouse model used is not tissue-specific.</p></disp-quote><p>Please see our response to Reviewer 1, above.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Recommendations for the authors):</bold></p><p>In the study, titled &quot;The denitrosylase SCoR2 controls cardioprotective metabolic reprogramming&quot;, Grimmett ZW et al., describe a role for SNO-CoA Reductase 2 (SCoR2) in promoting cardioprotection via metabolic reprogramming in the heart after I/R injury. Authors show that loss SCoR2 coordinates multiple metabolic pathways to limit infarct size. Overall, the hypothesis is interesting, however there are some limitations as described below:</p><p>(1) It is unclear whether SCoR2 mice are global or cardiomyocyte specific.</p></disp-quote><p>We apologize for any confusion. These are global SCoR2<sup>-/-</sup> mice. This is now stated in the Results when first identifying the strain, as well as in the Methods.</p><disp-quote content-type="editor-comment"><p>(2) Can the authors clarify how divergent metabolic pathways such as Ketone oxidation, glycolysis, PPP and polyol metabolism work downstream of SCoR2 to impact cardioprotection in mice with I/R.</p></disp-quote><p>The metabolic pathways of ketone oxidation, glycolysis, PPP and polyols appear to converge to support ischemic cardioprotection in SCoR2<sup>-/-</sup> mice, as depicted in the model shown in Fig. 5L. Subsequent to SNO-PKM2 blockade of flux through glycolysis (detailed in this manuscript and in Zhou et al, 2019, PMID: 30487609, as well as by others), substrates of ketolysis and glycolysis are funneled into the PPP, producing the antioxidant NADPH and energy precursor phosphocreatine, which are well-known to be cardioprotective. This occurs more readily in SCoR2<sup>-/-</sup> mice due to elevated SNO-BDH1 (detailed in this manuscript).</p><p>Polyols, thought to be products of the PPP carbohydrate intermediates arabinose, ribulose, xylulose (among others), have recently been shown to be harmful to cardiovascular health in humans. These polyols are uniformly downregulated in SCoR2<sup>-/-</sup> mice. We suggest this is likely the result of S-nitrosylation of SCoR2-substrate enzymes that form polyols (SCoR2/Akr1a1 is unable to directly reduce carbohydrates to their corresponding polyols). Regulation of endogenous polyol production in humans is a new concept and the mechanisms whereby these compounds increase risk of cardiac events are a subject of active investigation. This is detailed in the final paragraph of both the Results and Discussion sections, and in Fig. 5L.</p><disp-quote content-type="editor-comment"><p>(3) The only functional outcome of SCoR2 loss in echocardiography and measurements for apoptosis. However, it would be important to determine whether the cardioprotective effect persists. It seems cardiac function was recorded 24hours post injury and whether the benefit remains till later time point such as 2 or 4 weeks is not shown. Without this time point, loss of SCoR2 only leads to an acute increment in function.</p></disp-quote><p>Loss of SCoR2 reduced post-MI mortality at 4 hr; cardiac functional changes (plus troponin, LDH, and apoptosis) were studied in surviving animals at 24 hr post-MI. Cardiac response to acute injury and to chronic injury (weeks post-MI) are not the same metabolically. This is well elucidated in the literature and exemplified by the role of PKM2, which is protective in the chronic response to MI (28 days post-MI; PMID: 32078387), but implicated in injury at shorter timepoints post-MI (PMID: 33288902, 28964797). All that said, functional changes at 2-4 weeks will be important to determine in the future, as the Reviewer indicates.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations for the authors):</bold></p><p>(1) The last paragraph of the Results section should be divided into the statement related to Table S2 in the Results section, and the rest of the paragraph should be put somewhere in the Discussion.</p></disp-quote><p>Thank you for this suggestion, which we have taken.</p><disp-quote content-type="editor-comment"><p>(2) The number of mice alive/dead should be reported in the histogram in Figure 1G.</p></disp-quote><p>Done.</p><disp-quote content-type="editor-comment"><p>(3) A concise Graphical Abstract will be useful to grasp the overall logic and message of the manuscript from the beginning.</p></disp-quote><p>We thank you for this suggestion and have added a graphical abstract to the manuscript.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Recommendations for the authors):</bold></p><p>I would suggest having more evidence on the effect of metabolic reprogramming on which cell type. The use of a global knockout is a major limitation, and probably some in vitro experiments with shRNA knockdown in endothelial cells and fibroblasts would provide more insights.</p></disp-quote><p>The reviewer suggests one direction for future study. We identify a novel mechanism for cardioprotection entailing coordinate reprogramming of multiple metabolic pathways and suggesting a widescale role for SCoR2 in metabolic regulation. This is the message we wish to convey. The role of cardiomyocytes vs contributing cell types is a thoughtful direction for future study. Thank you.</p><disp-quote content-type="editor-comment"><p><bold>Editor's additional comment:</bold></p><p>The editors wish to highlight a critical issue concerning the characterization of the SCoR2−/− mice employed in this study.</p><p>In the Methods section (page 20), the manuscript states that &quot;SCoR2+/− mice were made by Deltagen, Inc as described previously (33).&quot; However, reference 33 does not describe SCoR2−/− mice; instead, it refers to other genetically modified strains, including Akr1a1+/−, eNOS−/−, and PKM2−/− mice, with no mention of a SCoR2-targeted model.</p><p>The editors fully acknowledge that the authors may be using the term &quot;SCoR2&quot; as a functional synonym for Akr1a1, based on its described role as a mammalian homologue of yeast SCoR. If this is the case, such equivalence should be explicitly stated in the manuscript to prevent potential confusion. Moreover, considering that the genetic deletion of Akr1a1 (i.e., SCoR2) underlies the key mechanistic findings presented, it is essential that the manuscript include a clear and comprehensive description of the generation and validation of the mouse model used.</p><p>We therefore ask the authors to (1) clarify the nomenclature and relationship between &quot;SCoR2&quot; and Akr1a1, and (2) provide full details on the generation of the knockout mice, including the targeting strategy and the genotyping procedures. This information is necessary not only to ensure transparency and reproducibility but also to allow readers to fully appreciate the biological relevance of the findings.</p></disp-quote><p>Thank you for identifying this inconsistency. We have adjusted the manuscript text accordingly to clearly state that SCoR2 is a functional name for the product of the Akr1a1 gene and that these SCoR2<sup>-/-</sup> mice are the same as Akr1a1<sup>-/-</sup> mice described in Ref 33. We have augmented the Methods text to describe the generation and genotyping of these SCoR2/Akr1a1 knockout mice.</p></body></sub-article></article>